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 3 List of Abbreviations 
1. List of Abbreviations 
bFGF basic fibroblast growth factor 
B-Raf v-raf murine sarcoma viral oncogene homolog B1 
BTSC brain tumor stem cells 
cDNA complementary DNA 
CEA carcinoembryonic antigen 
CGH comparative genomic hybridization 
CIN chromosomal instability 
CMV cytomegalovirus 
CSC cancer stem cells  
DC dendritic cells 
DMEM Dulbecco´s Modified Eagle Medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
EGF epithelial growth factor 
EGFR epithelial growth factor receptor 
EGFRvIII epithelial growth factor receptor variant III 
ELISA enzyme-linked immunosorbent assay  
FCS fetal calf serum 
GBM glioblastoma multiforme 
GFAP glial fibrillary acidic protein  
HER2/neu human epidermal growth factor receptor 2 
HIP 1 huntingtin interacting protein 1 
HLA human leukocyte antigen 
IDH isocitrate dehydrogenase 
IDO indoleamine-2,3-dioxygenase 
IFNγ interferon gamma 
IL interleukin 
IL-13Rα interleukin-13 receptor alpha 
K-Ras Kirsten rat sarcoma viral oncogene homolog 
MGMT O-6-methylguanine-DNA methyltransferase 
MMP metallopeptidase 
MMR mismatch repair 
MRI magnetic resonance imaging 
 4 List of Abbreviations 
MSI microsatellite instability 
mTOR mammalian target of rapamycin 
NF1 neurofibromin 1 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDGF platelet-derived growth factor 
PDGFβR platelet-derived growth factor beta receptor 
PTEN phosphatase and tensin homolog 
RB retinoblastoma 
RGD R=arginine, G= glycine, D=aspartic acid 
RNA ribonucleic acid 
SNP single nucleotide polymorphism 
T reg regulatory T cells 
TAA tumor associated antigen 
TBP TATA box binding protein 
TGF-β transforming growth factor-beta 
TMZ Temozolomide 
TNFα tumor necrosis factor alpha 
TP53 tumor protein p53 
TSA tumor specific antigen 
VEGF vascular endothelial growth factor 
WHO world health organization 
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2. Introduction 
2.1 Glioblastoma multiforme 
2.1.1 Definition 
Glioblastoma multiforme (GBM) is defined as a “malignant, invasive, rapidly growing 
pulpy or cystic tumor of the cerebrum (or the spinal cord). The lesion spreads with 
pseudopod-like projections. It is composed of a mixture of monocytes, pyriform cells, 
immature and mature astrocytes, and neural ectodermal cells with fibrous or 
protoplasmic processes; also called anaplastic astrocytoma or glioma multiforme” 
[Mosby's Medical Dictionary, 8th edition 2009, Elsevier]. 
The world health organization (WHO) classifies tumors of the central nervous system 
according to their histology, morphology and malignancy into four grades I - IV1. 
Grade I is assigned to low proliferative lesions which may be cured by surgical 
resection alone. Neoplasms with low-level proliferative activity but a generally 
infiltrative nature are designated grade II; in these cases recurrence is frequent. 
WHO grade III is generally reserved for lesions with histological evidence of 
malignancy, including nuclear atypia and brisk mitotic activity. The designation grade 
IV is assigned to cytologically malignant, mitotically (highly) active, necrosis-prone 
neoplasms with typically rapid pre- and postoperative disease progression and a fatal 
outcome2,3. Although therapeutically not relevant these tumors are divided into 
primary (arise de novo as grade IV tumors) and secondary (progress from low grade 
to grade IV tumors) GBM4. 
 
2.1.2 Epidemiology 
GBM is the most common malignancy of the brain in adults; it accounts for 12 - 15% 
of all brain tumors [Pschyrembel] and makes up for half of the gliomas5. The yearly 
incidence is 7 newly diagnosed cases per 100 000 adults and only 0.1 per 100 000 in 
children6. Although the disease may be present at any age, the incidence of primary 
GBM peaks at 50 - 70 years [Pschyrembel], with a median age of 64 years at 
diagnosis6. In contrast, secondary GBM, which develop from relapses of lower-grade 
precursor malignancies, more frequently appear in younger patients at a median age 
of 45 years7. 
There is a slight preponderance of GBM in male, with a male to female ratio of 
1.5 to 18. Interestingly the incidence is twice as high in European descendants as 
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compared to African American or Asian descendants9. These types of studies 
(comparing large ethnic populations under the “same” living conditions) are only 
feasible in larger populations where different ethnicities are domiciled, e.g. the United 
States. 
 
2.1.3 Etiology 
Although most GBM appear to be sporadic, several genetic disorders are associated 
with an increased incidence: tuberous sclerosis, neurofibromatosis 1 and 2, von 
Hippel Lindau disease, Turcot and Li-Fraumeni syndrome8 [Pschyrembel]. The only 
well-established risk factors for GBM are exposure to ionizing radiation and a genetic 
predisposition9. More recently, the contribution of several common low-penetrance 
susceptibility alleles to the development of gliomas was discovered10,11. In contrast to 
many other tumor entities, no connection between GBM and smoking, a particular 
diet or the use of mobile phones could be made8,12. Only very inconclusive evidence 
for a potential association with occupational risk factors (such as working as 
physician, fire fighter or farmer), the exposure to electromagnetic fields and brain 
traumas was obtained9. 
 
2.1.4 Clinical presentation and diagnosis 
The initial clinical presentation is highly variable and depends primarily on the 
localization (cerebrum, frontal lobe, corpus callosum) and size of the tumor5. Very 
occasionally, a tumor is asymptomatic until it reaches an enormous size8. Common 
symptoms include neurological symptoms (aphasia, paresthesia, hemiparesis and 
visual as well as sensory disturbances), mood and personality changes, seizures or 
symptoms of increased intracranial pressure such as nausea, vomiting or 
headache5,8. For diagnosis, magnetic resonance imaging (MRI) is the imaging 
technique of first choice. In selected cases positron-emission tomography or 
advanced MRI modalities (e.g. perfusion imaging, diffusion imaging magnetic 
resonance spectroscopy) may be useful (e.g. for selection of biopsy targets or 
differentiation of recurrent tumor from treatment-related changes)5,8. 
 
2.1.5 Prognosis 
The prognosis for patients presenting with a GBM is dismal, given the fact that up to 
date no curative therapy could be established5,13. The two year survival rate is 10% 
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when irradiation is the sole treatment; for combined radio-chemotherapy with 
Temozolomide (TMZ) the two year survival rate can be augmented to 14% for 
patients with an active (unmethylated) O-6-methylguanine-deoxyribonucleic acid 
(DNA) methyltransferase (MGMT) promoter or even to 46% for patients with 
inactivation (methylation) of this promoter14,15. 
Despite aggressive irradiation and chemo-treatment, the median overall survival 
remains low: 15 months for newly-diagnosed GBM and 5-7 months for recurrent or 
relapsed GBM13. 
 
2.1.6 Pathobiology and molecular biomarkers 
Cell of origin 
For the most part, it remains unclear what initiates gliomagenesis and in which cell 
type malignant transformation is initiated. Several studies, especially those using 
murine models, addressed this question and revealed that any cell in the hierarchy 
with proliferative capacity can serve as cell of origin16. Hence, not only neuronal stem 
cells and the eponymous (glia) cells of the disease but also mature neurons, 
astrocytes and oligodendrocyte precursors may initiate GBM tumors16-18. 
Cancer stem cells (brain tumor stem cells) 
Most cancers comprise a heterogeneous population of cells with different proliferative 
potential19. There is increasing evidence that the tumor bulk mass contains a 
population of cells with stem-like characteristics, so called cancer stem cells (CSC). 
These CSC are defined as cells with the ability for self-renewal, extensive 
proliferative capacity, the potential for multilineage differentiation and tumor 
initiation3,20,21. CSC are not only responsible for tumor maintenance but are also 
thought to be the key players in recurrence and therapy resistance22.  
Tumor entities recently described as having CSC populations include malignancies of 
the hematological system, breast, brain, pancreas, neck, prostate and colon23-29. In 
glioblastoma, brain tumor stem cells (BTSC), also often referred to as 
glioma-initiating or glioma-propagating cells, are thought to represent a small 
subpopulation of cells giving rise to all types of GBM cells and seem exquisitely 
resistant to conventional therapeutic interventions3,20,30. The lack of robust markers 
allowing the identification of BTSC is an obstacle in the development of specific 
treatments. Frequently proposed cell surface markers for BTSC (alone or in 
combination) include CD133, CD15, Nestin, CD34 and CD4422,30-32. 
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Hallmarks of GBM tumors (angiogenesis, invasion and heterogeneity) 
The dismal prognosis of GBM is largely due to a highly invasive phenotype, the 
extensive (neo-) angiogenesis and great heterogeneity of these tumors. These 
hallmarks have very frequently been analyzed and described by the scientific 
community1,3,33-36. Angiogenesis facilitates tumor progression35. Therapy failure often is 
pinned to the heterogeneous composition of the tumors22. Finally, extensive invasion 
into the surrounding brain tissue regularly accounts for recurrence or relapse of the 
tumors3. In contrast to most other malignancies, GBM tumors very rarely 
metastasize37. 
Mutations 
Common mutations in GBM comprise general tumor mutations (e.g. tumor protein 
p53 (TP53) and phosphatase and tensin homolog (PTEN)) as well as GBM specific 
alterations (e.g. epidermal growth factor receptor (EGFR), isocitrate dehydrogenase 
(IDH) 1 and 2)1,38,39. The most frequently mutated genes are TP53 (35-42%), PTEN 
(24-37%), neurofibromin 1 (NF1) (15-21%), EGFR (14-45%), retinoblastoma (RB) 1 
(8-13%), phosphoinositide-3-kinase, regulatory subunit 1 (8-10%), phosphatidyl-
inositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (7-10%) and IDH 1 
(11-20%)40-43. Notably mutations in the genes IDH 1 and 2 are GBM specific 
mutations; often taken into consideration to distinguish between primary and 
secondary GBM in especially the most common mutation R132H for IDH 14. Further 
a GBM specific mutation of the EGFR is the variant III (EGFRvIII). This mutation 
comprises the deletion of exons 2-7, encoding for the extracellular domain of the 
receptor and thus leading to a weak but constitutively active receptor signaling44,45. 
The EGFRvIII is frequently present in primary GBM and only scarcely found in 
secondary GBM46,47. 
Chromosomal changes 
Genomic instability is one key characteristic of malignancies48. Generally two types 
are discerned; chromosomal instability (CIN) and microsatellite instability (MSI). MSI 
is rare in non-hereditary newly diagnosed GBM49,50. However, after long term 
chemotherapy inactivating mutations in mismatch repair (MMR) genes may be 
observed more frequently and the frequency of MSI in relapsed GBM tumors is 
increased49. Also the loss of the MMR system leads to mutations especially in 
repetitive sequences, so called microsatellites, and specifically in the alteration of 
their length51. 
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Evolving new techniques have set a market for detailed chromosomal alteration 
analyses. Popular methods include single nucleotide polymorphism (SNP) arrays and 
comparative genomic hybridization (CGH), which allow not only detecting copy 
number alterations but also structural changes43. A broad spectrum of copy number 
alterations and gene abnormalities have been discovered for GBM tumors. 
Frequently amplified gene loci include 1q32, 1q44, 3q26, 4q12, 7p11-12, 7q21-22, 
7q31, 12q13-15 and 12p13; whereas often deleted loci are 1p32-36, 2q21-22, 
6q26-27, 9p (complete or at least 21-23), 10p and q, 13q14, 17p13, 17q11 and 
19q43,52. Loss of heterozygosity or loss of chromosome 10 is the most common 
genetic alteration in GBM tumors and is associated with poor survival53. In contrast 
the co-deletion of 1p and 19q is associated with a prolonged survival39. 
Epigenetics (methylation) 
The most prominent epigenetic marker in GBM tumors is the methylation status of 
the MGMT promoter. The MGMT gene encodes for a DNA repair protein, which can 
reverse the DNA-damage of alkylation by chemotherapeutic agents such as TMZ. 
The methylation status is thus a predictive marker for success of chemotherapy with 
alkylating agents. A methylated (inactive) promoter correlates with a better response 
to TMZ, whereas an unmethylated (active) promoter is associated with a weaker 
response15. The methylation status of the MGMT promoter is not only a predictive 
marker but also has prognostic value. Patients with MGMT promoter methylation in 
the tumors have a better prognosis15; so their clinical outcome is better independent 
of the treatment they receive. 
Beside methylation of the MGMT promoter other gene loci have been described to 
frequently be hypermethylated in GBM tumors: fms-related tyrosine kinase 3, frizzled 
family receptor 9, GATA binding protein 6, homeobox A11, homeobox A3, homeobox 
A5, homeobox A9, 5-hydroxytryptamine (serotonin) receptor 1B, Moloney murine 
sarcoma viral oncogene homolog, neurofilament light polypeptide Ras association 
(RalGDS/AF-6) domain family member 1, retinol binding protein 1, slit homolog 2, T-
cell acute lymphocytic leukemia 1, transcription factor AP-2 alpha, transcription factor 
AP-2 beta, transcription factor AP-2 gamma, tumor suppressor candidate 3 and zinc 
finger protein 215. Other gene loci are often hypomethylated in GBM: chemokine 
(C-X-C motif) ligand 3, interleukin (IL) 8, matrix metallopeptidase (MMP) 9, protease 
serine, 1, prostate stem cell antigen, S-100 calcium binding protein A2 and tumor 
necrosis factor (ligand) superfamily member 1054-56. 
 10 Introduction 
Aberrant signaling pathways 
Mutations, chromosomal and epigenetic alterations ultimately lead to altered 
signaling processes in GBM cells. The main pathways affected hereof are the RB 
pathway, the p53 pathway, the phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha / mitogen activated kinase-like protein pathway, the EGFR 
pathway, the PTEN / serine/threonine protein kinase pathway and the platelet-
derived growth factor (PDGF) pathway5. All of these pathways are involved in major 
cell processes such as cell growth, proliferation, replication and cell cycle control. 
Molecular sub-classification 
Different approaches have been undertaken to classify and thus better stratify these 
tumors - i.e. to design optimal treatment strategies. The most prominent and 
established classification by the WHO differentiates tumors (WHO grade I - IV) 
according to their histology, morphology and degree of malignancy (as described 
above). Further, these tumors are divided into primary and secondary GBM4. Primary 
tumors are characterized by amplification and/or mutation of the EGFR, whereas 
secondary tumors are associated with mutations in the genes IDH 1 and 24.  
The most recent approach classifies these tumors by the origin of the tumor initiating 
cell type and specific molecular markers: pro-neural (oligodendrocytic cells), neural 
(neurons), mesenchymal (astroglia, microglia) and classical (astrocytic cells) 
GBM39,40,57. Especially for the latter classification a variety of molecular characteristics 
is taken into account; characteristic for the proneural subtype are mutations in the 
genes TP53 and IDH 1, in the neural subtype no representative mutations have been 
identified so far, characteristic mutations for the mesenchymal subtype are found in 
NF1 and PTEN and the classical subtype is associated with EGFR amplification and 
mutation39,40,57. The importance of molecularly defining the tumors is affirmed by the 
increasingly extensive molecular pathological profiling. 
 
2.1.7 Therapy 
Conventional (standard) Therapy 
Since the seminal work by Stupp et al. was published in 2005, the standard therapy 
for patients with newly diagnosed GBM consists of (sub-) total resection followed by 
radio-chemotherapy. This consists of fractionated focal irradiation that is given e.g. at 
2Gy per cycle. The treatment is administered five days per week over a period of six 
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weeks adding up to a total dose of 60Gy with concomitant TMZ of 75mg/square 
meter per day from the first to the last day of irradiation but no longer than 49 days. 
After a four week break adjuvant TMZ treatment consists of a five day schedule 
every 28 days with a 150-200mg/square meter dose which is given in addition14. In 
case of relapse surgery is repeated in 30% of cases. Alternatively, hypofractionated 
stereotactic irradiation or chemotherapy is applied; Fotemustine or Nimustine 
(alkylating substances) are alternative second-line agents after TMZ failure58-60. 
Despite optimal combination therapy, the poor prognosis remains. This enduring 
dismal prognosis clearly underlines the necessity for new therapeutic interventions. 
The wide field of immunotherapy represents one major novel approach. In common 
with another emerging strategy, the so called targeted therapies, is defining (tumor 
specific) molecular structures for such therapeutic interventions. 
Immunotherapy 
Tumors develop when the immune system cannot recognize or eliminate malignant 
cells; many different influences often render a tumor either invisible to the immune 
system or resistant to its cytolytic functions61. The ultimate goal of immunotherapy is 
to make these malignant cells visible to the immune system and overcome that 
resistance. 
In 2011 Ralph M. Steinman (together with Bruce A. Beutler and Jules A. Hoffmann) 
was awarded The Nobel Prize in Medicine "For his discovery of the dendritic cell and 
its role in adaptive immunity" [“Ralph M. Steinman - Biographical" Nobelprize.org.20 
Jan2013]. Dendritic cells (DC) are professional antigen presenting cells, capable of 
stimulating CD4+ and CD8+ T cells62. The principle of a DC vaccination is to load the 
DC with tumor antigen(s), have them present the antigen(s) to T cells and thus 
stimulate tumor-specific cytotoxic T cells, which can eliminate residual tumor cells in 
the patients62. A common strategy to generate such antigen-specific DC is to isolate 
monocytes from patient blood, differentiate them with the help of cytokines to 
immature DC and finally load and mature the DC with a cocktail of cytokines and 
antigens (in form of peptides, tumor lysate or nucleic acid)62. Using tumor lysate as 
the source of antigens is one very promising approach and already under 
investigation in clinical trials. The success in patients with recurrent GBM but also in 
patients with newly diagnosed brain tumor is enormous63-65. Tumor-derived 
ribonucleic acid (RNA) is another successful source of antigens66. Finally, a variety of 
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tumor-antigen derived peptides selected for highest immunogenicity are analyzed in 
clinical studies as well67,68. 
Cytomegalovirus (CMV) proteins confer both oncogenic and tumor-modulating 
mechanisms and numerous entities have been described to be CMV positive69. 
Recent reports have demonstrated the presence of CMV also in GBM tumors. CMV 
may promote the malignant phenotype of GBM cells by enhancing cell invasiveness, 
activating telomerase and inducing tumor-suppressive monocytes70,71. CMV is a 
common immunological target after conditioning, stem cell transplantation and 
subsequent CMV reactivation. A direct T cell transfer is only rarely performed in GBM 
patients, however there are few case reports on autologous ex vivo expanded CMV 
specific or γδ T cells prolonging survival of GBM patients72.  
Targeted therapy 
The aim of targeted therapy is defining molecular structures for drug applications. 
Therapeutic antibodies bind to molecules or receptors that are involved in key 
signaling processes of tumor cells 73. The monoclonal antibody Bevacizumab inhibits 
angiogenesis by depriving the cells of vascular endothelial growth factor (VEGF)73. 
Cetuximab, also a monoclonal antibody, binds to the EGFR and prevents binding of 
the ligand epidermal growth factor (EGF) to the receptor and disrupts the pathway73. 
Beside monoclonal antibodies, small molecules are capable of interrupting cell 
signaling. In GBM therapy, tyrosine kinase inhibitors are popular. They can inhibit 
specific kinases or tyrosine kinases in general. Erlotinib and Gefitinib inhibit the 
EGFR, Cediranib inhibits VEGF, Sorafinib and Sunitinib inhibit the VEGFR and 
PDGFR and Imatinib is a general tyrosine kinase inhibitor74-78. Enzastaurin inhibits the 
protein kinase C and Etoposide is an inhibitor of the topoisomerase79,80. Frequently 
targeted is the mammalian target of rapamycin (mTOR) pathway by inhibiting mTOR 
through substances as Temsirolimus, Everolimus and Rapamycin81. Celecoxib 
reduces GBM cell viability in vitro and combined with irradiation increases tumor 
necrosis and reduces tumor microvascular density82. 
Cilengitide (CGT), a cyclic RGD pentapeptide (R=arginine, G= glycine, D=aspartic 
acid) antagonist of the integrins αvβ3 and αvβ5, which are over expressed both on 
GBM and on tumor invasive endothelial cells83, is a novel promising compound for the 
treatment of solid cancers, and various clinical trials have been performed or are still 
on-going84-86. Integrins are dimeric membrane proteins composed of alpha and beta 
subunits87,88. The classic role of integrins is anchoring cells to the extra cellular matrix 
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but they also participate in a variety of signaling processes. They are involved in 
malignant transformation, migration, and metastasis89. The integrins αvβ3 and αvβ5 
play key roles in different angiogenic pathways. The αvβ3 integrins are involved in 
the basic fibroblast growth factor/tumor necrosis factor alpha (TNFα) induced 
pathway while αvβ5 integrins regulate the VEGF/transforming growth factor alpha 
dependent one90. In addition to anti-angiogenesis, CGT displays a broad anti-
neoplastic effect which is not yet fully understood, but likely involves both integrin-
expressing tumor cells and the surrounding stroma. In vitro, CGT treated GBM cells 
detach from the surface and undergo cell death by anoikis (or a similar 
mechanism)91,92, and in vivo CGT has strong anti-GBM activity as monotherapy93. 
Recent studies showed beneficial effects of CGT in treatment of GBM either as 
monotherapy94 or as add-on to standard irradiation plus TMZ treatment85,86. 
Novel / rediscovered therapeutic approaches 
DNA alkylating agents, apart from TMZ, were neglected after the ground breaking 
results by Stupp and colleagues with TMZ. More recently, the substance class of 
nitrosourea agents (Nitrosourea and Fotemustine) has had a renaissance and was 
reestablished as alternative therapy for GBM. At surgery Carmustine may be 
implanted as wafers directly into the tumor bed95. 
Agents originally used to treat other complaints such as Disulfiram to treat alcoholism 
and Thalidomide as a sedative have proven efficacy in treating GBM tumors96,97. 
Transforming growth factor-beta (TGF-β) plays a role in all major tumor processes. It 
retains stemness of BTSC, contributes to aberrant vascularization, functions as an 
important player in invasion, is a potent immunosuppressant cytokine secreted by 
GBM tumors and is also involved in chemo- and radio-resistance98-100. Therefore, 
TGF-β is an ideal target for GBM therapy. The TGF-β2 inhibitor Trabedersen is as 
effective or even slightly more potent compared to standard therapy101. A TGF-β 
receptor I inhibitor (LY2109761) is under current investigation in clinical trials. A 
safety study in Glioma has just been completed and the data should be published 
soon (NCT01472731); while the trial investigating the combination of LY2109761 with 
TMZ-based radio-chemotherapy in patients with newly diagnosed malignant Glioma 
is still recruiting (NCT01220271). 
Closely related to immunotherapy is the oncolytic virus therapy which is based on 
using live viruses to selectively infect and subsequently replicate in cancer cells, with 
minimal destruction of non-neoplastic tissue102. The idea of using oncolytic viruses 
 14 Introduction 
goes back to the early 1900s, when an Italian physician could demonstrate 
spontaneous regression of cervical carcinoma after injection with a live rabies 
vaccine103. Since then many clinical trials have been performed demonstrating safety 
and efficacy102,103. Just recently a phase I/IIa study administering Parvovirus H-1 
(ParvOryx) in patients with progressive primary or recurrent GBM has started and the 
study design was published104.  
 
In summary of the above, it seems likely that a combination of conventional and 
novel therapy forms is most likely the way to go und numerous strategies are 
currently under investigation105. 
 
2.2 Glioblastoma models 
2.2.1 Definition 
A model is a “thing used as an example to follow or imitate” [Oxford dictionary: 
http://oxforddictionaries.com]. 
The main purpose for generating models of brain tumors is to identify mechanisms 
contributing to oncogenesis or tumor maintenance, uncovering distinct molecular 
patterns and defining or evaluating potential therapeutic strategies. “Targeted” 
therapies “only” need molecular testing but for functional analyses, such as response 
prediction, vital and proliferating malignant cells are indispensable106,107. 
Consequently, the wide heterogeneous spectrum must be considered in drug 
development and preclinical testing. Patient individual tumor models provide ideal 
material for such studies. There are two types of patient individual tumor models: 
in vitro (primary cell cultures) and in vivo (patient derived xenografts in 
immunodeficient animals)108,109. These models should be passaged as little as 
possible preventing epigenetic or genetic alterations and thus keeping them close to 
the original tumor110,111. Moreover, it is important to establish models from individual 
tumors in order to cover a broad spectrum and to ensure that the genetic 
heterogeneity of a given tumor entity is fully represented. These individual models 
allow the most accurate response and resistance prediction outside the patient. The 
high precision of therapy prediction with such individual models in carcinomas could 
be demonstrated by Voskoglou-Nomikos and colleagues as well as by Fiebig and co-
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workers with 90% and even 97% accuracy rates for prediction of response and 
resistance, respectively112,113. 
 
2.2.2 In vitro models 
Monolayer culture 
Establishing cell cultures from GBM tumors was popular in the 1970s to 1990s (this 
becomes apparent when performing a pub med search: 1973 – 1998: 16 publications 
describing the establishment and characterization of glioma cell lines)114. Tumor 
tissue is minced and single cell suspension transferred to culture dishes; outgrowing 
cells grow in monolayers115,116. This method of modeling is easily feasible, crowned 
with success and provides models for highly reproducible analyses114. Frequently, the 
cell lines are according to their highly malignant nature immortal and readily 
expandable to a vast number of cells for experimental approaches114. However, 
limitations lie in genotypic and phenotypic drift or even clonal selection over time of 
culturing117. An over proportionally high frequency of the mesenchymal subtype is 
observed in vitro57 and not all molecular characteristics are maintained under 
standard culture conditions118-121. 
Neurosphere culture 
To overcome the limitations of monolayer culture, new strategies have been 
developed. For so called spheroid cultures, single cell suspensions are transferred to 
culture dishes made of ultralow adhesion plastic122; outgrowing cells cluster as 
spheroids. The aggregates are multicellular and maintain DNA ploidy, a similar 
percentage of proliferating cells as in situ, clonal sub-populations and thus the 
heterogeneity of the patient tumor123,124. On the down side the level of apoptosis is 
increased (compared to monolayer cultures), the expression of differentiation 
markers is up-regulated (compared to stem cell cultures), the spheroids are hard to 
disaggregate and finally it is difficult to obtain a sufficient number of cells for 
experimental analysis125. 
Stem cell culture 
Establishing tumor cell lines that retain cancer-initiating stem cell properties would 
provide a valuable and accurate model of the human disease and give insight into 
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the origin of tumor heterogeneity as well as enable detailed analysis of molecular 
mechanisms regulating transformation, self-renewal and differentiation125.  
Neurosphere cultures enable isolation and identification of BTSC from human adult 
GBM, which possess the capacity to establish, sustain, and expand these tumors 
in vitro and in vivo24,126. Also, more recently specific monolayer culture conditions 
have been identified which allow propagation of BTSC117,125. The cells are grown in 
serum free media (as opposed to the classical monolayer cell culture) but key growth 
factors EGF and basic fibroblast growth factor (bFGF) are supplemented125. The 
advantage of monolayer BTSC culture, as opposed to the spheroid version, is an 
increased efficacy of establishing and propagating GBM cells. Lower apoptosis rates 
and decreased differentiation may be the attributes leading to the advantage125. 
 
2.2.3 In vivo models 
Chemically induced tumors 
Since the 1970s several chemically induced brain tumor models have been 
developed127. Murine, canine and feline models exist but are less popular114. These 
experimental tumors may be induced by local, oral, intravenous or transplacental 
exposure to N-nitroso compounds of adult or pregnant animals128,129. Chemically 
induced brain tumors appear to differ largely from human gliomas and are frequently 
referred to as “gliosarcomas” or “gliomas-like tumors”114. The histological 
characteristics are mainly lost; infiltrative growth may be observed but no single cell 
infiltration114. 
Genetically engineered mice 
Increased understanding of genomic alterations in human brain tumors has led to the 
development of highly defined and well characterized genetically engineered mouse 
models114. Multiple gene gains and losses are possible as well as a cell type and 
developmental specific manipulation130-133. Conditional strategies include tet-regulation 
(on- off switch: by adding tetracyclines to the water the expression or inhibition of a 
gene cloned behind a tet-regulated promoter can be induced) and cre-inducible 
alleles (the cre recombinase is expressed in a promoter specific manner and thus 
induces exclusively in cells with activated promoter the excision of a gene between 
two lox sequences)71,134. Genetically engineered models allow addressing specific 
molecular events responsible for tumor initiation and progression114. Further modeling 
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of tumor stroma interaction is possible e.g. analyzing (neo-) angiogenesis processes 
in tumors114. Since these models include immune competent animals, influences of 
the immune system may be determined114; not only in therapy settings. The major 
drawback of the system is the loss of heterogeneity since the experimental tumor is 
composed of cells with a number of specific homogenous genetic changes114. These 
models cannot properly reflect the complete intratumoral genomic and phenotypic 
variations of a natural human GBM. 
Xenograft models 
The in vivo model representing patient individual tumors are so called xenografts. 
The strategy is based on implanting fresh (brain) tumor cells or pieces into 
immunodeficient animals135. The engraftment can be in an orthotopic manner (into the 
organ of which the patient tumor originated from) or a heterotopic one (mostly 
subcutaneous implantation into the flanks). The latter often is a subcutaneous 
implantation into the flanks of mice. This method is easily feasible since it does not 
require great surgical skills and the procedure is fast to perform136. However, the take 
rate is rather low and if tumors grow it is outside of their normal environment136. For 
the orthotopic GBM model, tumor cells are implanted into the brain of mice. The 
success rate is nearly 100% and the tumor growth takes place in a more familiar 
micromilieu. Moreover, the invasive phenotype is preserved (as opposed to the 
heterotopic model) and the tumors show histological features similar to the patients´ 
tumors137. However, the tumors depend on the host vasculature for oxygen and 
nutrition114. As a major drawback, orthotopic modeling of brain tumors is technically 
challenging. 
 
2.3 The aim of the study 
GBM tumors are associated with a very poor prognosis despite optimal aggressive 
combinational therapy regimens; thus highlighting the urgency of developing novel 
most optimally effective therapies. Here tumor models may enter the picture either as 
in vitro (cell lines) or in vivo models (engraftment into immunodeficient mice). Their 
crucial role would lie in the ability of drug testing on a cellular functional level and the 
identification of novel prognostic and predictive markers. A feasible solution might be 
the establishment of patient-individual tumor models out of a small resection 
specimen sample of each patient and thus not interfering with the necessity to obtain 
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complete pathological diagnosis. These patient-derived cell lines would definitely 
provide a nearly unlimited and readily available source of antigens for 
immunotherapeutic interventions and allow basic and translational research at the 
same time.  
In this study, preferably a tumor sample of every resection specimen of GBM patients 
that had been operated on in Rostock should be collected, a proportion stored in a 
GBM biobank and model establishment attempted. Any established models should 
then be added to the biobank. 
The biobank, envisioned in this project, should not only store tumor samples but 
include patients´ peripheral lymphocytes and sera as well as all established 
patient-derived models. All samples (patient tumors and models) should undergo 
molecular pathological characterization. 
The morphology of outgrowing in vitro models should be documented. The cell lines 
should be analyzed for their expression of GBM and neuronal markers by flow 
cytometry and the proportion of BTSC-like cells in the cultures should be determined. 
With regard to immunological approaches the presence of human leukocyte antigen 
(HLA) class I and II molecules is to be assessed and the specific alleles (two-digits 
encompassing) are to be identified by HLA typing. Because the presence of tumor 
antigens is of great interest, their expression should also be analyzed by flow 
cytometry. The molecular composition of GBM tumors is of great relevance. Thus, 
molecular pathological analyses such as assessing MGMT promoter methylation, 
mutations in typical tumor suppressor genes and (EGFR) amplifications are to be 
performed and compared to the patients´ tumors. The secretion of cytokines, relevant 
for tumor growth and immunosuppression, should be quantified by enzyme-linked 
immunosorbent assay (ELISA). In a first step towards individualized therapy and 
response prediction an extensive drug sensitivity screening is planned. Finally, CGH 
arrays of the models shall complete the characterization and allow for the 
identification of novel tumor suppressor candidate genes which shall be validated in 
subsequent analyses. 
For in vivo models (xenografts) tumor pieces should be implanted subcutaneous into 
the flanks of immunodeficient mice. Successful outgrowth should be documented, the 
mice sacrificed and xenograft models added to the biobank. 
The cell lines shall be analyzed concerning their in vitro sensitivity to a broad panel of 
drugs (used in standard or experimental GBM therapies) and drug screening 
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potential should be assessed. These findings might be subsequently verified in the in 
vivo models. 
Given the time consuming, and not seldom complex logistic of patient-individual 
tumor modeling the aim of this study is to establish a broad variety of these 
patient-derived tumor models, both, in vitro and in vivo and most possibly 
representing the full clinical repertoire. This way, establishment of in vitro and in vivo 
models from fresh and frozen vital tumor material could be compared. The goal is to 
improve the take rates and simplify logistics to ultimately provide an easily feasible 
method and thus also enable decentralized sample collection. 
This work should substantially support the attempt of providing an individual, 
tumor-specific therapy for every GBM patient. 
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3. Material and Methods 
3.1 Material 
Disposable material 
Cell strainer (100µM) BD Falcon 
CryoPure tube (1.6ml) Sarstedt 
Culture flasks (T25, T75, T175) Greiner bio-one 
PP-tubes (1.3ml) Greiner bio-one  
PP-tubes sterile (15ml, 50ml) Greiner bio-one 
FACS tubes (5ml) Sarstedt  
Insulin Syringes U-100 BD Diabetes 
Microtiter plates (6-Well, 24-Well, 96-Well) Greiner bio-one 
Reaction tube (0.5ml, 1.5ml, 2.0ml) Sarstedt 
Scalpels sterile (Figure 10) Dahlhausen  
Serological pipette (5ml, 10ml, 25ml) Greiner bio-one 
Serum monovette (7.5ml) Sarstedt  
Surgical thread Vicryl 6.0 Ethicon  
Syringe (20ml) BD Plastipak 
 
Reagents 
Agarose Biozym 
Betaisodona solution Mundipharma GmbH 
Calcein AM eBioscience 
Collagen secret composition 
Co-trimoxazol Ratiopharm 
Dimethyl sulfoxide (DMSO) AppliChem  
DMEM/Ham´s F-12 PAA 
Ethanol AppliChem 
Eye and nose ointment Bayer Vital GmbH 
Exonuclease I Fermentas 
FastAP alkaline phosphatase Frementas 
Fetal calf serum (FCS) PAA 
Formafix 4% Grimm med. Logistik GmbH 
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Glutamin PAA 
Heparin Roche 
Hepes Sigma-Aldrich 
Ketamin 10% Belapharm 
Lymphocyte PAA 
MyTaq HS DNA polymerase Bioline 
Phosphate buffered saline (PBS) PAA 
Penicillin Jenapharm 
Rompun 2% Bayer Vital GmbH 
Saponin Sigma-Alrich 
Streptomycin InfectoPharm 
SssI enzyme Fermentas 
SYBR Green master mix Applied Biosystems 
Trypan blue Fluka 
Trypsin PAA 
 
Therapeutic agents 
BCNU Bristol-Myers Squibb 
Bevacizumab Roche 
CCNU Sigma-Aldrich 
Celecoxib Molekula  
Cetuximab GlaxoSmithKline 
Cilengitide Merck KGaA 
Cisplatin Teva GmbH 
Cytarabine Cell Pharm GmbH 
Imatinib Novartis 
Irinotecan Pfizer 
Methotrexate Teva GmbH 
Nilotinib Novartis 
Procarbazine Sigma-tau 
Rapamycin Pfizer 
Thalidomide Sigma-Aldrich 
Temozolomide Sigma-Aldrich 
Topotecan GlaxoSmithKline 
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Vincristine Hexal 
 
Kits 
Wizard Genomic DNA Purification Kit Promega 
GeneMATRIX universal RNA purification Kit EURx 
High Capacity cDNA Reverse Transcription Kit Applied Biosystems 
EpiTect Bisulfite Kit Qiagen 
SensiFAST Probe Kit Bioline 
BigDye Terminator v1.1 Cycle Sequencing Kit Applied Biosystems 
BigDye XTerminator Purification Kit Applied Biosystems 
SNP Array 6.0 Affymetrix 
 
IL-6 ELISA (matched pair) Immunotools 
IL-8 ELISA (matched pair) Immunotools 
TNFα ELISA (set pair) Immunotools 
AssayMax Human TGF-β1 ELISA Kit Assaypro 
Human CEA ELISA Kit RayBio 
 
Antibodies 
Isotype controls for flow cytometry 
All isotype controls were obtained from Immunotools. 
Specific antibodies for flow cytometry 
Species Target Clone Isotype Label Manufacturer 
Rat pan αv RMV-7 IgG1 PE eBioscience 
Mouse αvβ3 LM609 IgG1 none Merck Millipore 
Rabbit αvβ5 EM09902 IgG none Merck KGaA 
Mouse CD15 MEM-158 IgM PE Immunotools 
Mouse CD24 SN3 IgG1 PE Immunotools 
Mouse CD34 -581- IgG1 PE Immunotools 
Mouse CD44 MEM-85 IgG2b APC Immunotools 
Mouse CD90 AS02 IgG1 FITC Dianova 
Mouse CD133 AC133 IgG1 PE Miltenyi 
Mouse CEA IH4Fc IgG1 PE Immunotools 
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Mouse HIP 1 1B11 IgG1 none Abcam 
Rabbit IL-13Rα polyclonal IgG none Assay bio Tech 
Rabbit TGF-β polyclonal IgG none Abcam 
Mouse GFAP GA5 IgG1 FITC eBioscience 
Mouse Nestin 10C2 IgG1 FITC eBioscience 
Mouse S-100 B32.1 IgG1 None Abcam 
Mouse Vimentin V9 IgG1 None Abcam 
 
Secondary antibodies for flow cytometry 
Species Target Label Manufacturer 
Goat Mouse PE Dako Cytomation 
Swine Rabbit FITC Dako Cytomation 
 
Primer 
Target 
Primer Sequence 
forward reverse 
IDH 1 (Exon 4) 5’-GCACGGTCTTCAGAGAAGCC-3’ 5’-CACATTATTGCCAACATGAC-3’ 
IDH 2 (Exon 4) 5’-GCCCACACATTTGCACTCTA-3’ 5’-CAGAGACAAGAGGATGGCTAGG-3’ 
B-Raf (Exon 15) 5’-TCATAATGCTTGCTCTGATAGGA-3’ 5’-CTTTCTAGTAACTCAGCAGC-3’ 
K-Ras (Exon 2) 5’-GTACTGGTGGAGTATTTGATAGTGTATTAA-3’ 5’-TCAAAGAATGGTCCTGCACC-3’ 
K-Ras (Exon 3) 5’-CTTTGGAGCAGGAACAATGTCT-3’ 5’-TACACAAAGAAAGCCCTCCCC-3’ 
TP53 (Exon 5) 5’-(GC40)TTCCTCTTCCTACAGTACTC-3’ 5’-CTGGGCAACCAGCCCTGTCGT-3’ 
TP53 (Exon 6) 5’-(GC40)GACGACAGGGCTGGTTGCCCA-3’ 5’-AGTTGCAAACCAGACCTCAG-3’ 
TP53 (Exon 7) 5’-(GC40)TCTCCTAGGTTGGCTCT-3’ 5’-GCAAGTGGCTCCTGACCTGG-3’ 
TP53 (Exon 8) 5’-CCTATCCTGAGTAGTGGTAATC-3’ 5’-(GC40)CCGCTTCTTGTCCTGCTTGCTT-3’ 
PTEN (segment 1) 5’-TTCCATCCTGCAGAAGAAGC-3’ 5’-GCTGTGGTGGGTTATGGTCT-3’ 
PTEN (segment 2) 5’-ACCGCCAAATTTAATTGCAG-3’ 5’-CGCCACTGAACATTGGAATA-3’ 
PTEN (segment 3) 5’-GTGGCACTGTTGTTTCACAAG-3’ 5’-CTGCACGCTCTATACTGCAAA-3’ 
PTEN (segment 4) 5’-ACCAGGACCAGAGGAAACCT-3’ 5’-AAGGTCCATTTTCAGTTTATTCAAG-3’ 
EGFR 5’-TCCCATGATGATCTGTCCCTCACA-3’ 5’-CAGGAAAATGCTGGCTGACCTAAG-3’ 
LINE1 5’-TGCTTTGAATGCGTCCCAGAG-3’ 5’-AAAGCCGCTCAACTACATGG-3’ 
MGMT 
methylation 5’-GCGTTTCGACGTTCGTAGGT-3’ 5’-CACTCTTCCGAAAACGAAACG-3’ 
Probe (MGMT) 5’-6FAM-CGCAAACGATACGCACCGCGA-TMR-3’ 
MGMT 
expression 5’-CCGAGGCTATCGAAGAGTTC-3’ 5’-TCCGAATTTCACAACCTTCA-3’ 
COL2A1 5’-TCTAACAATTATAAACTCCAACCACCAA-3’ 5’-GGGAAGATGGGATAGAAGGGAATAT-3’ 
Probe (COL2A1) 5’-6FAM-CCTTCATTCTAACCCAATACCTATCCCACCTCTAAA-TMR-3’ 
PTEN expression 5’-ACCAGGACCAGAGGAAACCT-3’ 5’-CTGCACGCTCTATACTGCAAA-3’ 
TBP 5’-TCGGAGAGTTCTGGGATTGT-3’ 5’-CACGAAGTGCAATGGTCTTT-3’ 
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Buffer 
Buffer P: PBS with 1% FCS, 0.03% Saponin and 0.01M Hepes 
 
Instruments 
Accu pipet  Integra 
Centrifuges Eppendorf (5415 D) 
 Hettich (Rotina 38) 
CO2 Incubator Memmert 
FACS Calibur BD 
Freezer (-20°C) Bosch 
Freezer (-80°C) Kryotech  
Freezing container Nalgene 
Laminaflow bench Nunc  
NanoDrop Thermo-Scientific 
Microplate reader Infinite M200 Tecan 
Microscope (Primo Vert) Zeiss 
Mikro-Dismembrator S Sartorius 
Neubauer chamber Marienfeld 
Nitrogen tank (Espace 661) Air Liquide 
Polymerase chain reaction (PCR) Cycler BioRad 
Pipette Eppendorf 
Refrigerator Liebherr  
Sliding rule Asculap 
StepOne™ Real-Time PCR System Applied Biosystems 
USB Camera (AxioCam) Zeiss 
Water bath VEB MLW Prüfgerätewerk 
3500 Series Genetic Analyzer Applied Biosystems 
 
Animals 
NMRI nu/nu 
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Software and Programs 
Office 2010 Microsoft 
SigmaStat 3.5 Systat 
SigmaPlot 10.0 Systat 
SeqScape Software v2.7 Applied Biosystems  
AxioVision 4.8.2 Carl Zeiss 
Photoshope CS3 Adobe 
Papers Mekentosj 
Genotyping Console 4.1.2 Affymetrix 
 
3.2 Methods 
Tumor specimen collection and cryopreservation 
Between August 2009 and October 2012, clinical samples from patients with WHO 
grade I - IV GBM tumors were collected from the Neurosurgery department at the 
University hospital Rostock. Prior informed consent was obtained in written form from 
all patients, and all procedures were approved by the institutions’ Ethics Committee 
(reference number: A 2009/34) in accordance with general accepted guidelines for 
the use of human material. Resection specimens of GBM tumors were received 
sterile and freshly from surgery. Tumor tissue samples were snap frozen in liquid 
nitrogen and stored in the gas phase above liquid nitrogen. Additionally, tumor tissue 
cubes (3 x 3 x 3 mm) were frozen vitally. For this procedure, tumor pieces were cut 
with a sterile scalpel blade, and 4 tumor pieces were transferred into one sterile cryo-
tube in 1.5ml freezing medium (FCS containing 10% DMSO), sealed in a freezing 
container, and placed immediately at -80°C. Until unthawing, tubes were kept at -
80°C (for a maximum of 6 weeks) or, after overnight cooling, transferred into a 
nitrogen tank (for longer storage periods). For subsequent modeling procedures, 
cryo-preserved tumor pieces were thawed at 37°C. 
 
Xenografting into immunodeficient mice 
Tumor xenograftings were done by one of the following approaches: (I) xenografting 
of primaries on the day of surgery; (II) xenografting of primaries after 
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cryo-preservation; and (III) re-transplantation of xenografts. Tumor pieces were 
implanted subcutaneously bilaterally into the flanks of six to eight week old female 
NMRI nu/nu mice under anesthesia consisting of Ketamin/Xylazin (90/25 mg/kg body 
weight) injected intraperitoneal. Mice were kept in the animal facilities of the medical 
faculty of the University of Rostock and maintained in specified pathogen-free 
conditions. Animals were exposed to 12-h light/12-h darkness cycles and standard 
food and water including antibiotics (Co-trimoxazol) ad libitum. Their care and 
housing were in accordance with guidelines as put forth by the German Ethical 
Committee and the Guide for the Care and Use of Laboratory Animals (Institute of 
Laboratory Animal Resources, National Research Council; NIH Guide, vol.25, no.28, 
1996). Growth of tumors to volumes of 1 - 1.5 cm3 was taken as evidence of 
successful xenografting, and the animals were then sacrificed for collection of tumor 
tissues for further studies. 
 
Tissue culture and cell line establishment 
Tumor tissue was minced (by crossed scalpels) in DMEM/Ham´s F-12 cell culture 
media supplemented with 10% FCS, 2mM L-glutamine and penicillin-streptomycin 
and passed through a cell strainer to obtain a single cell suspension. Cells were 
washed with PBS and seeded in 6 well plates coated with collagen. Outgrowing cells 
were detached with trypsin and transferred to T25 cell culture flasks. Cells passaged 
2-3 times in this manner were transferred to T175 culture flasks and expanded for 
subsequent analyses.  
In general, all cell culture processes were performed under a sterile lamina flow 
bench. The cell lines were cultured in DMEM/Ham´s F-12 media supplemented with 
10% FCS and 2mM L-glutamin (penicillin-streptomycin was only added to fresh 
cultures). All cells were kept in an incubator at 37°C and 5% CO2. Cells were 
detached by incubation with trypsin for 5min at 37°C. Cell number and viability was 
assessed by trypan blue staining and counting using a Neubauer chamber. For 
cryo-storage cells were washed with PBS and 1 x 106 cells were frozen in 1.5ml 
freezing media (FCS containing 10% DMSO) per aliquot. Cryo-tubes were placed in 
a freezing container and frozen down at -80°C. 
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Phenotypic characterization (microphotography) 
Cells were cultured in T25 flasks to a confluence of 60 – 80% and photographed 
using the AxioVision 4.8.2 software. Photographs were edited subsequently with 
Photoshop CS3. 
 
Growth kinetics 
Cells (5 x 105 cells) were plated in 5ml media in quintuplicate T25 culture flasks per 
cell line and allowed to attach and grow for 48h. Cells were detached by 
trypsinization and the amount of vital cells was assessed by trypan blue staining 
using a Neubauer chamber. One flask was counted every 24h for five consecutive 
days.  
 
Isolation of nucleic acids 
Genomic DNA (gDNA) from snap frozen tumor tissue and cell culture cell pellets 
(3 x 106 cells) was isolated using the Wizard Genomic DNA Purification kit according 
to the manufacturer’s instructions. Total RNA from cell culture pellets (3 x 106 cells) 
was isolated using the GeneMATRIX universal RNA purification kit also according to 
the manufacturer´s instructions. Concentration of isolated nucleic acids was 
determined with the NanoDrop1000. 
 
Complementary DNA (cDNA) synthesis 
10µl total RNA was used for reverse transcription applying the High Capacity cDNA 
Reverse Transcription Kit according to the manufacturer´s instructions. 
 
Molecular characterization 
MGMT promoter methylation 
For analyzing the MGMT promoter methylation, the MethyLight method was applied. 
Briefly, gDNA was subject to bisulfite conversion using the Epitect Bisulfite Kit 
according to the manufacturer’s recommendations. A primer / probe combination 
specific for methylated MGMT promoter sequence was used, with the SensiFast 
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Probe Kit. CpG Methylase (SssI) treated DNA served as calibrator, since it is 
considered to be fully methylated. The collagenase gene 2A1 (COL2A1), was used 
as endogenous control. The percentage of methylated reference (PMR) value was 
calculated by dividing the MGMT / COL2A1 ratio of the sample by the MGMT / 
COL2A1 ratio of the SssI-treated DNA, and multiplying by 100. Samples with a PMR 
value > 4 were considered as methylated138. All reactions were performed in 
triplicates. 
cDNA expression 
The relative expression of MGMT and PTEN cDNA was assessed by real time PCR. 
The desired regions were amplified by PCR using the specific primers for either 
MGMT or PTEN and TATA box binding protein (TBP; housekeeping gene) and the 
Fast SYBR Green master mix on a StepOne Realtime PCR system. The amount of 
incorporated SYBER Green was assessed at the end of each cycle by measuring the 
absorbance at 260nm. Quantitative values (Ct value = threshold cycle number at 
which the increase in the signal associated with an exponential growth of PCR 
products starts to be detected) were expressed as x-fold differences in target gene 
expression relative to the reference gene TBP and were determined as follows: 
2 -ΔCt [ΔCt = Ct-value (TBP) - Ct-value (target gene)] 
 
Mutations (TP53, IDH1 & 2, K-Ras, B-Raf, PTEN) 
Samples underwent analyses for the following loci: IDH 1 R132 (exon 4), IDH 2 R172 
(exon 4), v-raf murine sarcoma viral oncogene homolog B1 (B-Raf) V600 (exon 15), 
Kirsten rat sarcoma viral oncogene homolog (K-Ras) G12, G13 (exon 2) and Q61 
(exon 3), TP53 (exons 5 to 8) and full length PTEN (cDNA). The desired regions 
were amplified by PCR using the specific primers. The PCR was performed using 
MyTaqHS polymerase according to the manufacturer’s recommendations. The PCR 
reaction was controlled by agarose gel electrophoresis and 15µl of the products were 
purified using 3 units of FAST AP Alkaline Phosphatase and 30 units of 
Exonuclease I by incubation at 37°C for 15min and subsequent heat inactivation at 
85°C for 15min. 
One microliter of the PCR product was used as template for Sanger sequencing 
using BigDye Terminator v1.1 Cycle Sequencing kit and the primers used for PCR 
according to the manufacturer’s protocol. The sequencing products were purified 
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using the BigDye XTerminator Purification kit. The sequence was analyzed using the 
3500 genetic analyzer system and the SeqScape Software v2.7. 
 
EGFR amplification 
For determination of EGFR copy number, quantitative PCR was performed. 30 ng 
gDNA were used as template. The run was performed on a StepOne Realtime PCR 
system using Fast SYBR Green Mastermix. Commercial normal human gDNA was 
used as calibrator and the repetitive element LINE1 as endogenous control. The 
calculation of the EGFR copy number was performed using the ΔΔCt-algorithm. All 
reactions were performed in triplicates.  
CIN was assessed using SNP Array 6.0 from Affymetrix according to manufacturer’s 
instructions. The analyses were performed by the core facility of the Department for 
Immunology under supervision of Dr. Koczan. 
 
HLA typing 
A 2-digit resolution typing of the following HLA loci was performed by the Transfusion 
Medicine at the University Medicine in Rostock: HLA-A, -B and -C and HLA-DR 
and -DQ. 
 
Flow cytometry 
Cells were harvested by incubation with trypsin; the enzymatic reaction was stopped 
by adding cell culture media. Cells were washed with PBS, counted and 5 x 105 cells 
were stained with respective antibodies or isotype controls for an extra-cellular 
staining. Cells were washed with PBS and resuspended in final volume of 200µl 
PBS. In case of unlabeled primary antibodies, excess antibody was washed out with 
PBS and respective secondary antibodies were added and final wash step was 
performed as above. 
Similarly, 5 x 105 cells were treated with buffer P for 10min to permeabilize the cell 
membrane for an intra-cellular staining. Cells were incubated with the antibodies and 
washed with buffer P. After a second 10min incubation period respective secondary 
antibodies were added in buffer P. Cells were washed and resuspended in Formafix 
at a final volume of 200µl.  
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For the staining method with unlabeled primary antibodies, cells handled the same 
way with no primary antibody served as negative controls. All incubations were 
performed on ice for 30min. 
 
Cytokine secretion (ELISA) 
Cells (5 x 104 cells) were plated in 5ml media per well in duplicates in 6 well culture 
plates and allowed to attach for 24h. The media was replaced by fresh media or 
media without FCS (for TGF-β secretion). 1ml samples of supernatant were collected 
on days 3 and 5 and stored at -80°C. For detection of cytokine production samples 
were unthawed on ice and 100µl supernatant was used for each ELISA assay. The 
ELISA assays were performed according to the manufacturer’s instructions. 
 
Drug response 
Cells (5 x 103 cells) were plated in 150µl media per well in triplicate in 96well flat 
bottom culture plates and allowed to attach for 24h. The following concentration 
ranges of drugs were tested (given are final concentrations in the experimental 
wells):  
BCNU: 500µM – 32nM 
Bevacizumab: 2.5mg/ml – 39ng/ml 
CCNU: 500µM – 32nM  
Celecoxib: 1mM – 64nM  
Cetuximab: 20µg/ml – 313ng/ml 
Cilengitide: 40µM – 10nM 
Cisplatin: 30µM – 30nM  
Cytarabine: 500µM – 125nM  
Imatinib: 250µM – 60nM 
Irinotecan: 1mM – 244nM  
Methotrexate: 1mM – 1µM  
Nilotinib: 10µM – 2.5nM 
Procarbazine: 50µM – 3.2 nM  
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Rapamycin: 30µM – 30nM  
Thalidomide: 40µM – 10nM 
Temozolomide: 2mM – 128nM 
Topotecan: 5µM – 320pM  
Vincristine: 244nM – 300pM  
Equal volumes DMSO (for cells treated with BCNU, CCNU, Celecoxib, Procarbazine, 
Thalidomide and Temozolomide) were added to cells serving as live control. Cells 
were incubated with the substances for 72h, and media was replaced together with 
substances in the same concentrations as before. After another 72 hour incubation 
period cells serving as dead control were incubated with 70% ethanol for 30min and 
viability was assessed by using the viability dye calcein AM in a final concentration of 
0.7µM in fresh medium:PBS (2:1). Cells were incubated at 37°C in the dark for 
20min; fluorescence intensity was assessed using the microplate reader Infinite 
M200 with 485nm excitation, 535nm emission and a constant gain of 160. Values 
were normalized (1= value live control; 0= value dead control). 
 
Statistics 
All statistical analyses were performed using the software program SigmaPlot. 
Success rates of model establishment from newly diagnosed tumors and relapses 
were compared by performing a Chi square test and a Fishers exact test. A T-test 
was performed to identify correlations between drug responses and molecular 
characteristics of the tumors. In order to analyze differences (or not) between the cell 
line pairs a paired T-test was performed. Finally, differences in the response of tow 
cell lines (in pairs) to a drug were assessed by Mann-Whitney U test. 
The IC50 values were calculated using the Standard Curves macro in SigmaPlot. 
All survival curves and box plot diagrams were generated using the SigmaPlot 
software. 
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4. Results 
4.1 Biobanking and Model Generation 
Having the big buzz words “individualized therapy”, “response-” and “resistance-
prediction” in mind, the establishment and detailed characterization of patient-derived 
models and biobanking of patient material is a logical scientific reaction. 
The assessed patient cohort was operated on in the Department of Neurosurgery at 
the University Medicine in Rostock between August 2009 and October 2012. Patient 
data were anonymized by assigning the prefix HRO (for the city of Rostock), G (for 
glioma tumor) and a consecutive number. The median age of the HROG patient 
cohort at surgery was 59 years and ranged from 13 to 80 years; 34 patients were 
male (56%) and 27 patients were female (44%), the male to female ratio was 1.3 to 
1. The majority of patients included were diagnosed with GBM grade IV tumors 
(42/61; 69%) by the Institute of Pathology. The median age here was 62 years with a 
range from 44 to 80 years; 22 (52%) patients were male and 20 (48%) patients were 
female with a male to female ratio of 1.1 to 1. Of the GBM grade IV tumors, 39 (93%) 
were primary and 3 (7%) were secondary GBM; hereof 26 (62%) were newly 
diagnosed primary tumors, 2 (5%) newly diagnosed secondary tumors, 13 (31%) 
relapses and 1 (2%) relapsed secondary tumor. Patient characteristics are 
summarized in Table 1. 
Sample ID Sex Age Diagnosis Localization Survival 
HROG02 M 68 GBM (IV) R; parietooccipital † 7 
HROG03 M 50 anaplastic Oligodendroglioma (III) R; parietal ? 9 
HROG04 F 53 relapsed GBM (IV) R; frontal † 13 
HROG05 F 60 relapsed GBM (IV) L; temporal † 3 
HROG06 M 53 GBM (IV) L; frontal † 8 
HROG07 M 55 relapsed GBM (IV) R; temporoparietal † 6 
HROG08 M 47 relapsed GBM (IV) R; frontal ? 29 
HROG09 M 66 anaplastic Astrocytoma (II-III) L; temporal 33 
HROG10 M 74 GBM (IV) R; temporal † 7 
HROG11 F 54 GBM (IV) L; frontal 30 
HROG12 M 64 GBM (IV) R; frontoparietal † 5 
HROG13 F 77 GBM (IV) L; temporal † 8 
HROG14 F 81 Subependymoma (I) IV. ventricle † 3 
HROG15 M 56 GBM (IV) R; parietal 23 
HROG16 M 53 GBM (IV) R; parietal † 26 
HROG17 M 70 relapsed GBM (IV) L; parietooccipital † 3 
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HROG18 M 71 relapsed Oligoastrocytoma (II) cerebrum ? 7 
HROG19 M 69 GBM (IV) L; temporoparietal † 15 
HROG20 M 34 diffuse Astrocytoma (II) L; temporal 24 
HROG21 M 44 secondary GBM (IV) R; parietal 21 
HROG22 M 66 relapsed GBM (IV) L; temporal † 4 
HROG23 F 60 relapsed GBM (IV) L; parietal 20 
HROG24 F 73 GBM (IV) L; occipital † 10 
HROG25 F 77 relapsed GBM (IV) L; temporal † 3 
HROG26 M 63 relapsed Astrocytoma (II) R; parietal † 8 
HROG27 M 76 Meningioma (I) cerebrum 23 
HROG28 F 76 Meningioma (I) cerebrum ? 4 
HROG29 M 39 diffuse Oligoastrocytoma (II) cerebrum 19 
HROG30 M 67 Meningioma (I) frontal ? 3 
HROG31 F 59 GBM (IV) R; occipitotemporal 21 
HROG32 F 76 GBM (IV) R; temporal 22 
HROG33 F 46 GBM (IV) L; occipitotemporal † 13 
HROG34 F 69 GBM (IV) L; frontal † 5 
HROG35 M 64 relapsed GBM (IV) R; occipital † 6 
HROG36 F 80 GBM (IV) R; parietal † 5 
HROG37 F 20 pilocytic Astrocytoma (I) L; occipital ? 2 
HROG38 F 49 GBM (IV) R; parietooccipital 19 
HROG39 F 59 Meningioma (I) cerebrum 18 
HROG41 M 71 secondary GBM (IV) L; frontal † 2 
HROG42 F 70 GBM (IV) L; frontal 16 
HROG43 M 55 Meningioma (I) L; frontal ? 8 
HROG44 M 69 Meningioma (I) L; frontal ? 8 
HROG45 M 61 relapsed Astrocytoma (II) L; parietal 13 
HROG46 F 69 GBM (IV) R; parietotemporal 15 
HROG47 M 59 GBM (IV) R; temporal † 16 
HROG48 M 13 pilocytic Astrocytoma (I) L; occipital 13 
HROG49 M 45 relapsed secondary GBM (IV) R; parietooccipital ? 6 
HROG50 F 33 diffuse Oligoastrocytoma (II) L; frontal 14 
HROG52 M 47 GBM (IV) L; temporobasal 13 
HROG53 F 50 anaplastic Astrocytoma (III) cerebrum ? 4 
HROG54 M 58 GBM (IV) R; parietal 8 
HROG55 F 74 GBM (IV) R; parietal ? 1 
HROG56 F 76 GBM (IV) trigonum ? 5 
HORG57 F 60 relapsed GBM (IV) R; parietal 8 
HROG58 F 57 GBM (IV) R; frontal 7 
HROG59 M 60 relapsed GBM (IV) R; temporal † 8 
HROG60 M 51 relapsed GBM (IV) R; temporal ? 1 
HROG61 F 50 diffuses Astrocytoma (II) L, frontal 6 
HROG62 M 71 GBM (IV) R; temporoparietal 4 
HROG63 M 48 relapsed GBM (IV) L; temporal 3 
 34 Results 
HROG64 F 57 GBM (IV) R; temporal 1 
 
Table 1: Patient characteristics 
The table summarizes patient information on sex (F = female; M = male), age at time point of resection in years, 
diagnosis by the department of pathology including WHO grading in parentheses, tumor localization 
(L = left hemisphere; R = right hemisphere) and survival († = patient died; bold = patients still alive on January 
25th 2013; ? = no information available for > 6 months) in months after resection. 
 
Attachment and outgrowth rates of the 42 consecutive WHO grade IV GBM tumor 
samples in vitro were assessed. Under standard in vitro conditions in 37/42 (88%) 
cells of the tumors attached; 25/28 (89%) newly diagnosed tumors and 12/14 (86%) 
relapses. Establishment of outgrowing cell lines was successful in 25/42 (60%) 
cases, hereof 17/28 (61%) were derived from newly diagnosed tumors and 8/14 
(57%) from relapses. Twelve (8 from newly diagnosed and 4 from relapsed tumors) 
of the cell lines divide rapidly and stable. These cell lines could be passaged over 40 
times, which implies far more than 50 cell divisions and thus exceeds the Hayflick 
limit (number of cell divisions a normal, healthy cell can undergo) and proves 
immortality139. Consequently, they were characterized in detail and subsequently 
considered as permanent cell lines. No differences in attachment (p=1.000), 
outgrowth (p=1.000) or cell line establishment (p=1.000) rates between newly 
diagnosed and relapsed tumors were observed. 
The prognosis for GBM patients is poor; it is even more devastating for patients 
diagnosed with relapsed tumors compared to those with newly diagnosed tumors 
(median survival is 15 months and 5 - 7 months respectively). The survival time of 
patients with GBM grade IV tumors after surgery correlated with the diagnosis 
(Figure 1); patients suffering from newly diagnosed tumors survived significantly 
longer than patients diagnosed with a relapse (p=0.029). The cohort of patients for 
whom cell line establishment was successful, was termed “cell line patients”; here the 
survival benefit of patients with newly diagnosed tumors might also be reached. 
However, no level of significance could be reached for the “cell line patients”; most 
likely since the cohort was too small. 
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Figure 1: Survival of patients with newly diagnosed and relapsed GBM tumors 
The Kaplan-Meier survival curves plot the survival interval (in months) of patients after the surgery of the GBM 
tumor, comparing survival intervals of patients with newly diagnosed and relapsed tumors. The graph on the left 
side (GBM patients) indicates the survival interval of the Rostock GBM patients (n=42); the graph on the right side 
(“cell line patients”) indicates the survival interval of the “cell line patients” (n=12). 
 
Engraftment of tumor pieces into immunodeficient mice was successful (tumor 
outgrowth) in 8/36 (22%) cases. Four (4/25; 16%) xenografts were derived from 
newly diagnosed tumors and four (4/11; 36%) from relapsed tumors. Engraftment 
was successful in 2/10 (20%) cases when tumor material was implanted fresh 
directly after patient surgery and six times (6/36; 17%) when the tumor material was 
vitally frozen before engraftment. Passaging of outgrowing tumors in immunodeficient 
mice was successful in the two cases assessed. No level of significance was 
reached since the sample size was too little. However, a study on a direct 
comparison of the rate of success between fresh and frozen GBM samples is 
ongoing. Small tumor pieces (3 x 3 x 3 mm) were implanted fresh (directly after 
neurosurgery) into immunodeficient mice and of the same sample tumor tissue was 
implanted into immunodeficient mice after vital cryo-preservation (1 - 12 months in 
nitrogen). 
 
4.2 Model characterization 
Morphology and doubling time 
In most cases, the morphology of monolayer GBM cell lines showed fibroblast-like or 
epithelial-like appearances, while polygonal or spindle-like cells were less frequent. 
GBM patients Cell line patients 
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In a first step, the cell lines were micro-photographed to compare their morphology 
(Figure 2); all cell lines show a fibroblast-like phenotype but differences between the 
individual cell lines are obvious, HROG10 with a larger cell body and shorter 
extensions compared to HROG06 having a smaller cell body and long extensions or 
HROG17 encompassed of long skinny cells. Furthermore, doubling times of the cell 
lines were assessed. Doubling times range from 35 hours for HROG36 to 89 hours 
for HROG07. The average doubling time is 60 hours. 
38 (± 2.7) hours  86 (± 18.7) hours 48 (± 9.4) hours  59 (± 14.0) hours  
 
89 (± 17.2) hours 62 (± 11.0) hours  74 (± 2.7) hours  52 (± 15.0) hours  
 
43 (± 9.2) hours  70 (± 16.3) hours 35 (± 4.0) hours 63 (± 3.9) hours 
 
Figure 2: Cell line morphology and doubling time 
Depicted in this figure are micro-photographed pictures (100x enlarged) and doubling times in hours (± standard 
deviation) of the cell lines. 
 
Molecular pathology 
In the era of targeted and individualized therapy unraveling molecular characteristics 
– in common or individually, for an entity and for patients – must be a prime aim; this 
obviously enables defining (novel) target structures. These targets however, may not 
only have therapeutic impact but may also serve as prognostic as well as predictive 
markers. 
HROG02 HROG04 HROG05 HROG06 
HROG07 
HROG17 
HROG10 HROG13 HROG15 
HROG38 HROG36 HROG24 
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GBM relevant molecular features such as the methylation status of the MGMT 
promoter, the amplification rate of the EGFR, as well as mutation status of the genes 
IDH 1 and 2, TP53, K-Ras, B-Raf and PTEN were assessed in comparison to the 
original tumor material (Table 2). The methylation status of the MGMT promoter was 
consistent between original tumor and cell lines. Methylation of the promoter 
occurred in 11/42 (26%) tumors and was maintained in the cell lines HROG02, 
HROG05, HROG13, HROG15 and HROG17. This coincided with no or only marginal 
(<0.001) cDNA expression. No methylation of the promoter was detectable in 27/42 
(64%) tumors; for four tumor samples the status could not be assessed. The tumors 
HROG24 and HROG36 were scored unmethylated after bisulfide sequencing; 
however cDNA expression analyses revealed only marginal expression of MGMT 
cDNA (< 0.001) for both cell lines. Further the cell lines HROG04, HROG06, 
HROG07, HROG10 and HROG38, which were also scored unmethylated after 
bisulfide sequencing, did express detectable levels of MGMT cDNA (Table 2). 
All cell lines expressed detectable levels of PTEN cDNA; however, mutations in the 
gene were very frequently (8/13; 62%) detected (HROG04, HROG05, HROG06, 
HROG15, HROG17, HROG24, HROG36 and HROG38). No mutations were 
detected in cell lines HROG02, HROG07, HROG10, HROG13 and HROG59. 
A genomic amplification of the EGFR was present in 22/42 (52%) tumors; 13 (31%) 
of these tumors had a high amplification (>10x). No amplification was detectable in 
15/42 (36%) tumors and five samples could not be analyzed. The amplification rate 
of the EGFR differed in seven (HROG02, HROG04, HROG05, HROG06, HROG07, 
HROG10, HROG17 and HROG24) out of the twelve cases when comparing the 
status of the original tumor to the one of the cell line (Table 2). Loss of the genomic 
amplification is a frequently described phenomenon in literature and explained by 
extra-chromosomal EGFR amplification (in form of mini-chromosomes) which is 
gradually lost in cell culture due to absence of selective pressure118-120. 
Of note, all mutations of the original tumors were maintained in the cell lines except 
those affecting IHD1. HROG02, HROG06 and HROG24 show a mutation in the TP53 
gene; HROG05 has a mutation in the K-Ras gene. One mutation of B-Raf was 
detected in the tumor HROG23 (no successful culture). Mutations in the gene IDH1 
were present in tumors HROG21 (still in culture – but very slowly growing) and 
HROG41; the mutation, however, was not maintained in the cell line HROG41. The 
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MGMT gene was completely deleted in HROG36 and only one allele was left in 
HROG24. No mutations in the analyzed genes were detected in tumors and cell lines 
HROG04, HROG07, HROG10, HROG13, HROG15, HROG17 or HROG38 (Table 2). 
Sample ID 
MGMT 
PTEN EGFR [x fold] Mutations promoter 
status 
cDNA 
expression 
HROG02 
tumor 
M 
  3 
TP53 R248Q 
cell line <0.001 3.68 1 
HROG04 
tumor 
U 
  36 
PTEN W274L 
cell line 1.02 12.73 1 
HROG05 
tumor 
M 
  82 K-Ras G12D 
PTEN P169S / del 212-229 cell line <0.001 1.01 1 
HROG06 
tumor 
U 
  82 TP53 R273H / R306* 
PTEN (+1 at 126) cell line 0.07 2.31 1 
HROG07 
tumor 
U 
  12 
wt 
cell line 0.34 14.92 1 
HROG10 
tumor 
U 
  2 
wt 
cell line 0.27 3.73 1 
HROG11 
tumor 
U 
  3 
wt 
cell line n.a. n.a. 1 
HROG13 
tumor 
M 
  1 
wt 
cell line <0.001 2.88 1 
HROG15 cell line M <0.001 3.70 1 TP53 R273H PTEN S170N 
HROG17 
tumor 
M 
  4 
PTEN R130* 
cell line <0.001 0.55 1 
HROG24 
tumor 
U 
  43 TP53 R273C 
MGMT CN=1 
PTEN exon 3 del / spliced  cell line <0.001 2.21 1 
HROG33 
tumor 
U 
  31 
wt 
cell line n.a. n.a. 1 
HROG36 
tumor 
U 
  1 MGMT CN=0 
PTEN I5S cell line <0.001 3.72 1 
HROG38 
tumor 
U 
  1 
PTEN I224M / R234W 
cell line 0.23 0.02 1 
HROG41 
tumor 
M 
  1 IDH1 R132H 
cell line n.a. n.a. 1  
HROG59 
tumor 
U 
  16 
wt / n.a. 
cell line 0.73 8.55 1 
 
Table 2: Molecular comparison of tumors and cell lines 
This table summarizes molecular characteristics of tumors in comparison to the corresponding cell line. Listed are 
the methylation status of the MGMT promoter (M = methylated; U = unmethylated), the relative cDNA expression 
of the MGMT gene compared to the housekeeping gene TBP, the relative cDNA expression of the PTEN gene 
compared to the housekeeping gene TBP, the genomic amplification rate of the EGFR compared to the normal 
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diploid status (1 = 2n) and detected mutations of the genes TP53, PTEN, IDH 1 and 2, K-Ras and B-Raf 
(wt = wild type, if no mutations were detected; mutations are indicated by the position with the wt amino acid in 
front and the amino acid resulting from the mutation behind or * in case of a stop codon; n.a. = not assessed; 
wt / n.a. = wild type for IDH genes, B-Raf and PTEN; TP53 and K-Ras were not assessed; CN = copy number 1, 
when one copy of the gene was lost and 0 if both copies of the gene were lost; del = deletion of amino acids; 
spliced = alternatively spliced; +1 = insertion of a base leading to a frame shift). 
 
Tumor samples of patients from whom cell line establishment was not successful 
were still molecularly analyzed (see Table 3). 
Sample ID MGMT promoter status EGFR [x fold] Mutations 
HROG12 U 37 wt 
HROG16 U 1 wt 
HROG19 U 9 wt 
HROG21 U 21 IDH1 R132H 
HROG22 M 1 wt / n.a. 
HROG23 U 2 B-Raf V600E 
HROG25 U 1 wt 
HROG31 U 2 wt 
HROG32 U 44 wt 
HROG34 U 97 wt 
HROG42 U 1 wt 
HROG46 M 125 wt 
HROG47 U 70 wt 
HROG49 U 1 wt 
HROG54 M 1 wt / n.a. 
HROG55 M 1 wt / n.a. 
HROG56 U 1 wt / n.a. 
HROG57 U 1 wt / n.a. 
HROG58 U 1 wt / n.a. 
HROG60 U 2 wt / n.a. 
HROG63 U 19 wt / n.a. 
HROG64 M 1 wt / n.a. 
 
Table 3: Molecular details of tumor samples 
This table summarizes molecular characteristics of the tumors. Listed are the methylation status of the MGMT 
promoter (M = methylated; U = unmethylated), the genomic amplification rate of the EGFR compared to the 
normal diploid status (1 = 2n) and mutations of the genes TP53, IDH 1 and 2, K-Ras and B-Raf (wt = wild type, if 
no mutations were detected; mutations are indicated by the position with the wt amino acid in front and the amino 
acid resulting from the mutation behind; wt / na = wild type for IDH genes and B-Raf, TP53 and K-Ras were not 
assessed). 
 
The methylation status of the MGMT promoter still is the only well-established 
prognostic factor for patients diagnosed with a GBM tumor. Hence, the survival 
interval of patients with methylated MGMT promoter compared to patients with no 
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such methylation was assessed. In the Rostock patient cohort survival did not 
correlate with the methylation status of the MGMT promoter, neither for all patients 
nor for the cell line patients (Figure 3). 
Figure 3: Survival of patients with methylated or unmethylated MGMT promoter 
The Kaplan-Meier survival curves plot the survival interval (in months) of patients after the surgery of the GBM 
tumor, comparing survival intervals of patients with MGMT promoter methylated tumors (mGMGT) and without 
methylation (uMGMT). The graph on the left side (GBM patients) indicates the survival interval of the Rostock 
GBM patients (n=42); the graph on the right side (“cell line patients”) indicates the survival interval of the “cell line 
patient” (n=12). 
 
An amplification of the EGFR is a prevalent feature of GBM tumors; it equips these 
tumors with a growth benefit by promoting cell division and invasion as well as 
playing a role in therapy resistance140,141. However, controversial aspects on a 
prognostic value are reported ranging from positive over neutral to negative 
prognosis142. The survival interval of patients with a high amplification of the EGFR 
(>10x) was assessed in comparison to that of patients with no or only low EGFR 
amplification (<10x). In the Rostock patient cohort survival did not correlate with the 
amplification of the EGFR, neither for all patients nor for the cell line patients 
(Figure 4). 
 
GBM patients Cell line patients 
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Figure 4: Survival of patients in regard to EGFR amplification 
The Kaplan-Meier survival curves plot the survival interval (in months) of patients after the surgery of the GBM 
tumor, comparing survival intervals of patients with highly amplified EGFR in the tumors (>10x) to tumors with no 
or only low amplification (<10x). The graph on the left side (GBM patients) indicates the survival interval of the 
Rostock GBM patients (n=42); the graph on the right side (“cell line patients”) indicates the survival interval of the 
“cell line patient” (n=12). 
 
CGH arrays 
A variety of chromosomal abnormalities are described for GBM (see above). For a 
detailed analysis addressing this issue in the GBM cell line collection (except for 
HROG38), a genomic analysis with very high resolution taking advantage of the SNP 
Array 6.0 from Affymetrix was performed. All, except for one cell line (HROG07) 
showed almost complete loss of at least one copy of chromosome 10. Chromosome 
13q was deleted in 4/11 (HROG02, HROG05, HROG24 and HROG36). The most 
frequent amplification was for chromosome 7; in 8/11 cases an amplification was 
present (HROG04, HROG05, HROG06, HROG13, HROG15, HROG17, HROG24 
and HROG36). The long arm of chromosome 9 (9q) was amplified in cell lines 
HROG02, HROG04, HROG05, HROG07, HROG17 and HROG36. Merely cell line 
HROG13 had a deletion at 1p and HROG36 at 19q; no co-deletions of the loci were 
detected (for a detailed view see supplementary material). 
 
Molecular sub-typing 
According to the molecular data and pieces of information obtained by the CGH 
arrays an attempt at sub-classifying the cell lines into the proneural, neural, 
mesenchymal and classical GBM types was undertaken (see Table 4). All but three 
GBM patients Cell line patients 
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cell lines could easily be assigned to one specific sub-type. The cell lines HROG05, 
HROG17, HROG36 and HROG38 could not be categorized definitely. Despite the 
fact that HROG05, HROG17 and HROG36 lacked the loss of 17q11.2 and for 
HROG38 no CGH data was available, they were assigned into the mesenchymal 
subtype. This is based on the fact that all four cell lines had mutated PTEN genes 
and the mesenchymal sub-type is the most common one described for GBM cell 
lines57.  
All in all, 5/12 (42%) cell lines were categorized as mesenchymal, 4/12 (33%) as 
proneural and 3/12 (25%) as classical sub-type. None of the cell lines was classified 
as neuronal sub-type, which is also due to the lack of robust markers here for. 
Sample ID GBM sub-type molecular characteristics 
HROG02 proneural TP53 mutated; 4q12 (PDGFRA) amplified 
HROG04 classical EGFR amplified; 9p21.3 (CDKN2A) deleted 
HROG05 mesenchymal* PTEN mutated 
HROG06 proneural TP53 mutated; 4q12 (PDGFRA) amplified 
HROG07 classical EGFR amplified; 9p21.3 (CDKN2A) deleted 
HROG10 proneural 4q12 (PDGFRA) amplified 
HROG13 classical Chr. 7 amplified; chr. 10 lost; 9p21.3 (CDKN2A) deleted 
HROG15 mesenchymal PTEN mutated; 17q11.2 (NF) deleted 
HROG17 mesenchymal* PTEN mutated 
HROG24 proneural TP53 mutated; 4q12 (PDGFRA) amplified 
HROG36 mesenchymal* PTEN mutated 
HROG38 mesenchymal* PTEN mutated 
 
Table 4: Molecular sub-classification of cell lines 
This table gives an overview on the sub-classification of the cell lines according to the characteristics described 
by Verhaak et al., 2010. Classifications for which only partial correlation with the molecular characteristics is 
fulfilled are marked with an asterisk. The respective molecular characteristics for each sub-type present in the cell 
line (or tumors of the patients for EGFR amplification) are indicated in the right column (chr. = chromosome). 
 
Expression of neuronal and GBM markers 
Proving neuronal origin, the expression of GBM (associated) cell surface markers 
such as CD24 and CD90 as well as neuronal markers glial fibrillary acidic protein 
(GFAP), S-100 and Vimentin was analyzed by flow cytometry (see Figure 5). In all 
twelve cell lines a high level of GBM (associated) markers, in especially CD90, was 
detectable. The expression of neuronal markers varied between the cell lines but was 
detectable in all cases (Figure 5). A population staining positive for GFAP (of at least 
10%; except for HROG13 with only 5%) and Vimentin was present in all cell lines; 
Vimentin was expressed in less than 10% of cells for cell lines HROG02, HROG04, 
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HROG07, HROG13, HROG15, HROG17 and HROG38 and cell lines HROG05; 
HROG06, HROG10, HROG24 and HROG36 stained positive for more than 10% of 
cells. No expression of S-100 was observed in cell lines HROG02, HROG07, 
HROG17 and HROG38; cell lines HROG04, HROG05, HROG06, HROG10, 
HROG13, HROG15 and HROG24 had less than 10% positively stained cells; merely 
HROG36 had a population composed of more than 20% of cells. No differences in 
expression were observed between cell lines of newly diagnosed and relapsed 
tumors. 
Figure 5: Expression of GBM and neuronal markers 
The percentage of cells expressing cell surface GBM markers CD24 and CD90 as well as intracellular expression 
of neuronal proteins GFAP, S-100 and Vimentin is depicted in the boxplot graphic. The grey box represents 
middle 50% of values; the line in the box is the median expression; whiskers indicate the range of the data set; 
outliers are plotted as dots. 
 
Expression of BTSC markers 
CSC are said to be responsible for sustaining the tumor and play a substantial role in 
therapy resistance, relapse and the metastasizing process. 
The proportion of BTSC-like cells in the twelve cultures was accessed by flow 
cytometry (see Figure 6). In all cell lines at least 80% of cells expressed CD44; not 
only a BTSC marker but also a relevant factor for EMT and characteristic for the 
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mesenchymal subtype57. The degree of expressed BTSC markers (CD15, CD34, 
CD133 and Nestin) varied from cell line to cell line, but a small positive population 
was always present. Cell lines HROG02, HROG04, HROG05, HROG10, HROG13, 
HROG15 and HROG24 had only a small population (<10%) of CD15 expressing 
cells; HROG06, HROG07, HROG17 and HROG36 had more than 10% CD15 
positive cells; only HROG38 did not stain positive for CD15. Only cell lines HROG04, 
HROG13 and HROG38 had less than 10% CD34 expressing cells; for the other nine 
cell lines more than 10% of cells stained positive for CD34. In half of the cell lines 
(HROG06, HROG10, HROG15, HROG17, HROG24 and HROG38) the population of 
CD133 positive cells was smaller than 10%. For the marker Nestin only HROG07 
and HROG13 had less than 10% positive cells. 
No differences concerning BTSC-like populations were detected between the cell 
lines from newly diagnosed and relapsed tumors. 
Figure 6: Analyses of BTSC populations 
The percentage of cells expressing BTSC markers CD15, CD34, CD44, CD133 and Nestin is depicted in the 
boxplot graphic. The grey box represents middle 50% of values; the line in the box is the median expression; 
whiskers indicate the range of the data set; outliers are plotted as dots. 
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Expression of tumor associated antigens 
Tumor specific antigens (TSA) or tumor associated antigens (TAA) qualify as prime 
target structures in therapeutic interventions. The expression (level) of TAA is of 
particular interest for immunotherapeutic interventions. Thus the presence of CEA, a 
TAA expressed by a variety of tumor entities such as melanoma, lung cancer, colon 
and gastric carcinoma143-146 and of the GBM associated / specific TAA IL-13 receptor 
alpha (IL-13Rα), TGF-β and huntingtin interacting protein 1 (HIP1) was analyzed by 
flow cytometry (see Figure 7). Surprisingly, rather high levels of CEA were detectable 
in all cell lines. No differences were observed between cell lines form newly 
diagnosed and relapsed tumors. In contrast, the degree of GBM TAA varied less 
from cell line to cell line; generally only few cells stained positive for GBM TAA, yet a 
small positive population was always present (Figure 7). Again, no differences 
between cell lines from newly diagnosed and relapsed tumors were observed. 
 
Figure 7: Expression of TAA 
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The percentage of cells expressing general and GBM specific TAA as CEA, IL-13Rα, TGF-β and HIP1 is depicted 
in the boxplot graphic. The grey box represents middle 50% of values; the line in the box is the median 
expression; whiskers indicate the range of the data set; outliers are plotted as dots. 
HLA typing 
With regard to experimental immunological analyses and for future development of 
immunotherapeutic strategies a two-digits encompassing HLA typing of the HLA loci 
HLA-A, -B, -C and HLA-DR and -DQ was performed. Of the assessed cell lines 10/12 
(83%) were HLA-A2 positive and two of those even homozygous (see Table 5). The 
average distribution in the Caucasian race is about half the population is HLA-A2 
positive147. However, since most studies, aiming at the identification of immunogenic 
epitopes from novel candidate antigens, are performed in an HLA-A2 restricted 
manner, this finding is of great academic interest. 
Sample ID 
HLA class I HLA class II 
A B C DRB1 DQB1 
HROG02 *01 *02 *08 *13 *06 *07 *03 *07 *02 - 
HROG04 *01 *02 *08 *51 *07 *15 *03 *11 *02 *03 
HROG05 *02 - *07 *40 *03 *07 *12 *13 *03 *06 
HROG06 *01 *03 *08 *35 *04 *07 *01 *13 *05 *06 
HROG07 *02 *26 *15 *27 *03 *07 *08 *15 *06 - 
HROG10 *02 *23 *15 *44 *01 *04 *07 *09 *02 *03 
HROG13 *02 - *15 *44 *03 *05 *03 *06 *04 *13 
HROG15 *02 *03 *15 *35 *03 *04 *03 *13 *02 *06 
HROG17 *11 *66 *14 *40 *01 *08 *01 *12 *03 *05 
HROG24 *02 - *40 *44 *02 *05 *07 *13 *02 *06 
HROG36 *02 *25 *40 *55 *03 - *04 *14 *03 *05 
HROG38 *02 *11 *13 *51 *03 *06 *04 *09 *03 - 
 
Table 5: HLA typing results 
The results of a 2-digits encompassing HLA typing for the loci HLA-A, -B and -C as wells as HLA-DR and -DP are 
listed. Information on both alleles is provided; in case of homozygosity the “second” allele is marked by -.  
 
Tumor cell secreted cytokines 
One frequent event in immune escape of tumors is establishing an 
immunosuppressive environment by attracting regulatory immune cells or secreting 
immunosuppressive cytokines. Tumor cells also can “communicate” with the 
surrounding tissue (the micromilieu) by cytokines. 
The secretion levels of several cytokines with immunosuppressive and/or tumor 
relevant functions were assessed (see Table 6). All but one (HROG38) GBM cell line 
secreted high levels of IL-8. High secretion of IL-6 was detectable in 6/12 (50%) cell 
lines: HROG06, HROG10, HROG15, HROG24 and HROG36. Little IL-6 was present 
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in the supernatant of HROG05; and cell lines HROG02, HROG04, HROG07, 
HROG13 and HROG38 secreted no IL-6. Merely the cell line HROG04 secreted 
TGF-β. None of the cell lines secreted CEA or TNFα (results not shown). 
Sample ID IL-6  [pg/ml] 
IL-8  
[pg/ml] 
TGF-β 
[pg/ml] 
HROG02 0.0 482.0 / 483.0 0.0 
HROG04 0.0 240.0 / 316.0 131.0 / 70.0 
HROG05 0.0 / 13.3 498.0 / 477.0 0.0 
HROG06 197.5 / 204.4 213.0 / 264.0 0.0 
HROG07 0.0 347.0 / 281.0 0.0 
HROG10 794.6 / 0.0 544.0 / 304.0 0.0 
HROG13 0.0 559.0 / 394.0 0.0 
HROG15 612.8 / 625.5 514.0 / 495.0 0.0 
HROG17 658.8 / 656.0 519.0 / 520.0 0.0 
HROG24 413.6 / 493.3 395.0 / 418.0 0.0 
HROG36 478.8 / 708.0 502.0 / 526.0 0.0 
HROG38 0.0 0.0 /11.0 0.0 
 
Table 6: Cytokine secretion 
The amount of cytokines secreted after 72 hours (value before the slash) and 120 hours (value after the slash) of 
cell culture are listed. 
 
Drug response 
A first step towards individualized therapy, response and resistance prediction may 
be establishing drug-response profiles for a variety of molecularly and phenotypically 
different patients – or more feasible from patient individual ultra-low passage cell 
lines. 
Therefore, response of the GBM cell lines to increasing doses of drugs was 
assessed. The concentrations tested were oriented according to realistically 
achievable plasma levels in treated patients. Classical chemotherapeutics such as 
alkylating agents (BCNU, CCNU, Procarbazine and TMZ), anti-metabolites 
(Cytarabine and Methotrexate), topoisomerase inhibitors (Irinotecan and Topotecan) 
and other common chemotherapeutic agents (Cisplatin and Vincristine) were 
analyzed as well as substances ascribed to the rapidly growing class of targeted 
therapeutics. These included small molecules (Celecoxib, Imatinib, Nilotinib and 
Rapamycin) and therapeutic antibodies (Bevacizumab and Cetuximab). Further, 
Thalidomide, developed as a sedative (infamous due to the Contergan scandal in the 
1950s) with detrimental consequences for the unborn of pregnant women, was found 
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to have anti-tumoral effects by inhibiting angiogenesis, was tested (IC50 values; Table 
7a, b). 
Responses to an agent varied between cell lines and sensitivity of a cell line to 
various agents differed as well. Response to CCNU, Cisplatin, Cytarabine and 
Topotecan correlated with the methylation status of the MGMT promoter or with 
cDNA expression levels. In vitro sensitivity was significantly higher in 
hypermethylated (cDNA expression <0.001) cell lines; with p=0.033 for CCNU, 
p=0.002 for Cisplatin, p=0.016 for Cytarabine and p=0.024 for Topotecan. In the case 
of the remaining alkylating substances BCNU, Procarbazine and TMZ however, no 
correlation of sensitivity towards the agents and the methylation status of the MGMT 
promoter could be observed. A general strong in vitro response to Vincristine was 
detected, yet the greatest variance between the different cell lines was observed for 
this substance (IC50 values ranged from 0.3nM to 244nM). Interestingly, in the five 
most sensitive cell lines (HROG02, HROG06, HROG15, HROG17, HROG24) to 
Irinotecan all four cell lines with mutated TP53 (HROG02, HROG06, HROG15 and 
HROG24) were found. In terms of serum level achievable amounts of Methotrexate 
had no influence on cell viability in vitro.  
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HROG02 68.0 20.0 20.0 2.0 1.0 1.0 >1.0 0.07 0.02 2.0 
HROG04 209.0 241.0 33.3 3.5 >30 >500 >1.0 2.0 3.0 4.0 
HROG05 110.0 137.0 35.7 1.2 4.0 0.5 >1.0 0.6 0.02 0.3 
HROG06 111.8 98.3 37.2 0.5 10.0 500 >1.0 0.07 0.1 18.0 
HROG07 279.0 359.0 38.7 2.0 >30 >500 >1.0 28.0 1.5 244 
HROG10 158.0 101.0 25.0 1.5 16.3 >500 >1.0 65.5 1.2 244 
HROG13 312.0 198.0 34.4 2.0 12.0 >500 >1.0 58.8 1.2 200 
HROG15 52.0 101.0 35.7 0.8 7.0 3.7 >1.0 0.07 0.02 3.6 
HROG17 21.3 61.0 3.8 0.05 3.2 0.1 >1.0 0.07 0.01 1.4 
HROG24 28.3 21.8 30.1 0.2 1.3 3.8 >1.0 0.03 0.02 9.0 
HROG36 46.0 27.5 31.6 1.2 3.2 0.5 >1.0 0.1 0.01 1.8 
HROG38 136.6 237.4 32.6 1.0 17.0 32.0 >1.0 0.8 1.0 1.8 
 
Table 7a: Response to chemotherapeutic agents 
Calculated IC50 values (from three independent assessments in triplicates) for 144 hour incubation periods with 
the therapeutic agents are provided for all cell lines.  
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None of the three cell lines most sensitive to Thalidomide had detectable MGMT 
cDNA expression (>0.001), the cell lines HROG05 and HROG17 were methylated 
and in HROG36 the MGMT gene was completely deleted. The range for the IC50 
values for Celecoxib was surprisingly narrow (48µM – 171µM). One cell line 
(HROG17) was sensitive in its response towards Imatinib (IC50 = 0.06µM) as well as 
to Nilotinib (IC50 = 0.02µM); otherwise the responses were rather heterogeneous. 
The cell lines most sensitive to Rapamycine were HROG17 and HROG24, both of 
which did not express MGMT cDNA due to methylation of the promoter in HROG17 
and loss of one MGMT copy in HROG24. In contrast, the least sensitive cell line 
HROG38 expressed MGMT cDNA, as did the three next sensitive cell lines 
(HROG06, HROG07 and HROG10). No (cytotoxic) effects of the therapeutic 
antibodies could be observed in vitro. 
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HROG02 >40 68 3.9 5.1 1.0 >2.5 >20 
HROG04 >40 48 21.3 0.3 1.0 >2.5 >20 
HROG05 40 51 149.6 5.3 1.5 >2.5 >20 
HROG06 >40 126 3.9 6.3 3.0 >2.5 >20 
HROG07 >40 171 39.1 7.5 6.0 >2.5 >20 
HROG10 >40 74 0.06 8.9 6.0 >2.5 >20 
HROG13 >40 60 39.6 9.8 2.7 >2.5 >20 
HROG15 >40 67 15.6 6.3 3.0 >2.5 >20 
HROG17 0.62 58 0.06 0.02 0.4 >2.5 >20 
HROG24 >40 68 25.3 4.4 0.9 >2.5 >20 
HROG36 10.0 60 4.2 >10.0 2.4 >2.5 >20 
HROG38 >40 68 15.3 3.6 31.0 >2.5 >20 
 
Table 7b: Response to small molecules and experimental drugs 
Calculated IC50 values (after three independent assessments in triplicates) for 144 hour incubation with the 
therapeutic agents are provided for all cell lines.  
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4.3 Technical optimization of Model Generation 
Since a feasible methodology and expedient protocols could be established, the next 
logic step seemed improving or rather optimizing these procedures with regard to 
higher efficacy and breaking down the logistics. 
Success rates 
We assessed attachment and outgrowth rates of 26 consecutive WHO grade IV GBM 
tumor samples and one relapsed astrocytoma, when prepared fresh directly after 
resection (culture #1) or after vital storage for varying periods of time in liquid 
nitrogen (culture #2). After fresh preparation, cells attached in 85% (24/27) of the 
cases and after vital freezing before preparation, attachment of cells occurred in 78% 
(21/27). Vital cryo-storage had no significant influence on attachment (p=1.000). 
Establishment of stable outgrowing cell lines was successful in 63% (17/27) of freshly 
prepared material and in 59% (16/27) after transient cryo-conservation. Again, 
cryo-storage had no significant influence on outgrowth of cells (p=1.000). The 
comparison of fresh and vitally frozen material prior to preparation is summarized in 
Table 8. The six most rapidly and stable outgrowing pairs of cell cultures (could be 
passaged >40 times) were subsequently characterized in detail. Cell lines derived 
from fresh material were marked with the suffix #1 and cell lines from vitally frozen 
material with the suffix #2. 
Sample ID 
Outgrowth 
Sample ID 
outgrowth 
Sample ID 
outgrowth 
#1 #2 #1 #2 #1 #2 
HROG02   HROG15   HROG26   
HROG04   HROG16   HROG31   
HROG05   HROG17   HROG32   
HROG06   HROG19   HROG33   
HROG07   HROG21   HROG34   
HROG10   HROG22   HROG36   
HROG11   HROG23   HROG38   
HROG12   HROG24   HROG41   
HROG13   HROG25   HROG42   
 
Table 8: Outgrowth of in vitro models 
A comparative overview on the success of cell line establishment from the fresh and vitally frozen tumor material; 
successful cell line establishment is indicated by a check mark. 
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Morphology and growth kinetics 
In a first step, the cell lines were micro-photographed to compare the morphology of 
the cell line pairs. In Figure 8, the morphology of the newly established tumor cell 
lines is depicted, showing the pairs side by side for a direct comparison. 
Furthermore, doubling times of the cell lines were assessed and are presented 
pairwise in Figure 8. In all cases the pairs showed high similarity in regard to their 
morphology and doubling times but differences between the different cell lines were 
obvious. Morphologically all cell lines show a fibroblast-like phenotype, and no 
differences between cell lines established fresh and from previously frozen tumors 
became apparent. Doubling times ranged from 35/40 hours (#1/#2) for HROG36 to 
74/65 hours for HROG13. HROG17 having doubling times of 43/32 hours, followed 
by HROG02 with 36/54 hours, HROG05 with 48/44 and finally HROG06 with 59/57 
hours. 
38 (± 2.7) hours  48 (± 3.4) hours 48 (± 9.4) hours  44 (± 9.4) hours  
 
59 (± 14) hours 57 (± 5.6) hours  74 (± 2.7) hours  65 (± 4.3) hours  
 
43 (± 9.2) hours  32 (± 5.0) hours 35 (± 4.0) hours 40 (± 8.0) hours 
 
Figure 8: Cell line pair morphology and doubling time 
Phenotypes of the cell lines captured by micro-photography (100x enlarged) are displayed pairwise and doubling 
times (in hours) of the cell lines are given. 
 
 
 
HROG02#1 HROG02#2 HROG05#2 HROG05#1 
HROG06#1 
HROG17#1 
HROG06#2 
HROG17#2 
HROG13#1 
HROG36#1 
HROG13#1 
HROG36#1 
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Molecular data 
Molecular markers relevant for GBM such as the methylation status of the MGMT 
promoter, the amplification rate of EGFR, as well as mutation status of the genes 
IDH 1 and 2, TP53, K-Ras and B-Raf were assessed for the cell line pairs in 
comparison to the original tumor material (Table 9). The methylation status of the 
MGMT promoter was always consistent between original tumor and cell line pairs. 
The amplification rate of the EGFR differed in 4 (HROG02, HROG05, HROG06 and 
HROG17) out of 6 cases when comparing the status of the original tumor to the cell 
lines. No differences were, however, observed between the cell line pairs (Table 9).  
Of note, all mutations detected in the original tumors were maintained in the cell 
lines. HROG02 and HROG06 show a mutation in the TP53 gene and HROG05 has a 
mutation in the K-Ras gene. No mutations were detected in HROG13, HROG17 or 
HROG36 and similarly, we did not observe any hot spot mutations in the genes IDH1 
and 2 or B-Raf (see above Table 2). 
Sample ID 
MGMT promoter EGFR 
[x fold] PMR status 
HROG02 
tumor 25 
M 
3 
#1 39 1 
#2 47 2 
HROG05 
tumor 35 
M 
82 
#1 13 2 
#2 58 2 
HROG06 
tumor 0 
U 
82 
#1 0 3 
#2 0 2 
HROG13 
tumor 4 
M 
1 
#1 22 1 
#2 19 1 
HROG17 
tumor 13 
M 
4 
#1 6 1 
#2 4 1 
HROG36 
tumor 0 
U 
1 
#1 0 1 
#2 0 1 
 
Table 9: Molecular comparison 
This table summarizes molecular characteristics of tumors in comparison to the corresponding cell line pairs. 
Listed are the PMR values and thereby scored methylation status of the MGMT promoter (M = methylated; 
U = unmethylated) and the genomic amplification rate of the EGFR compared to the normal diploid status 
(1 = 2n). 
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Drug response 
For functional comparison of the cell line pairs, the sensitivity of each cell line (pair) 
towards a panel of therapeutic agents commonly used for GBM treatment was 
assessed (summarized in Table 10). As expected, the response to different drugs 
varied within a given cell line. Similarly, the response to one agent varied between 
the different cell lines. Notably, no severe differences in regard to sensitivity to one 
agent were observed when comparing the cell lines in matched pairs (TMZ p=0.551; 
BCNU p=0.431; Vincristine p=0.259; Imatinib p=0.247). There was only one 
exception from this rule. For HROG36 minor dissimilarities were observed with 
regard to the substance Vincristine (p=1.000). The IC50 values of HROG36#1 and 
HROG36#2 are 79nM and 42nM respectively; but HROG36#1 plateaus at about 50% 
of dead cells.  
Sample ID 
TMZ [µM] BCNU [µM] Vincristine [µM] Imatinib [µM] 
#1 #2 #1 #2 #1 #2 #1 #2 
HROG02 2,010 2,004 88 48 105 97 218 105 
HROG05 1,205 1,245 23 66 0.2 0.9 144 86 
HROG06 490 575 88 95 3 1 88 88 
HROG17 39 15 85 57 0.9 0.4 151 133 
HROG36 1,201 1,235 223 159 0.8 0.4 159 184 
 
Table 10: Comparison of drug responses 
This table summarizes calculated IC50 values (after three independent assessments in triplicates) for 144 hour 
incubation with the therapeutic agents for all cell lines. 
 
In summary, no obvious discrepancies in drug sensitivity of the cell line pairs were 
observed. Thus, functional drug response measurements of tumor samples obtained 
from individual GBM patients are not influenced by a transient cryo-preservation step 
before the start of culture; this may be of special interest for future clinical studies. 
 
4.4 Model application for translational Research 
Recent research in GBM focuses on novel targeted compounds, in addition to 
standard chemotherapy. One of the emerging compounds is CGT, which by binding 
to integrins (i.e. αvβ3 and αvβ5) may inhibit angiogenesis and also is directly 
cytotoxic to tumor cells by interfering with intracellular signaling pathways. At the 
present an interventional study on the combination of CGT and metronomic TMZ in 
children and adolescents with relapsed or refractory high grade gliomas or diffuse 
intrinsic pontine gliomas is recruiting patients (HGG-CilMetro; NTC01517776). The 
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Children´s Hospital of the University Medicine Rostock is part of this multicenter 
clinical trial, thus an accompanying laboratory investigation on the effects of a 
combination therapy was performed. 
 
Integrin expression 
The expression of integrins targeted by CGT was analyzed by flow cytometry. In all 
cell lines a high general expression of av integrins was detectable (Figure 9 and 
Table 11). The degree of avβ3 and avβ5 expression varied between the cell lines but 
was positive in all cases (Figure 9). Strong staining for avβ3 and avβ5 integrins was 
detected in the cell lines HROG02, HROG15 and HROG17. An intermediate staining 
was seen in HROG05, HROG10 and HROG36, followed by relatively weak staining 
in HROG04, HROG06, HROG13 and HROG38. 
Figure 9: Integrin expression 
The percentage of cell lines expressing pan-av, avβ3 and avβ5 integrins, as assessed by flow cytometry, is 
illustrated in a box plot diagram. The grey box represents middle 50% of values; the line in the box is the median 
expression; whiskers indicate the range of the data set; outliers are plotted as dots. 
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Determination of IC50 values for TMZ and CGT 
In a first step, response of the GBM cell lines to increasing doses of TMZ and CGT 
was assessed (IC50 values; Table 11). Response to TMZ correlated with the 
methylation status of the MGMT promoter and was significantly higher in 
hypermethylated cell lines (p=0.016). In addition, we observed strong responses to 
CGT; IC50 values did not exceed 20µM in any of the assays (Table 11), while plasma 
levels in patients receiving CGT peak at 40 – 50µM85. Responses to CGT also 
seemed to correlate with the methylation status of the MGMT promoter. Contrary to 
TMZ, cell lines with unmethylated promoter strongly tended to respond better to CGT 
(p=0.066). 
Sample ID 
IC50 values Integrin expression [% / MFI] 
CGT [µM] TMZ [mM] pan αv αvβ3 αvβ5 
HROG02 7.0 0.5  88.7 / 5.8  51.0 / 3.6  72.8 / 6.2 
HROG04 5.4 3.5  96.4 / 2.9  3.0 / 0.9  10.8 / 1.2 
HROG05 6.0 0.5  90.1 / 2.8  14.8 / 1.4  23.8 / 2.8 
HROG06 8.0 1.5  96.3 / 6.7  1.4 / 0.1  5.5 / 1.3 
HROG10 5.4 1.5  83.5 / 3.6  10.6 / 0.6  9.2 / 1.4 
HROG13 2.0 2.0  84.4 / 0.7  0.1 / 0.2  0.3 / 0.0 
HROG15 10.0 0.8  94.5 / 9.1  31.1 / 2.2  83.2 / 7.2 
HROG17 5.0 0.1  86.6 / 4.5  72.9 / 3.9  33.3 / 2.5 
HROG36 20.0 0.8  94.2 / 4.5  13.4 / 1.6  12.6 / 1.8 
HROG38 0.8 1.0  91.4 / 0.2  0.0 / 0.2  11.3 / 4.0 
 
Table 11: IC50 values and integrin expression 
Calculated IC50 values (mean of three independent assessments in triplicates) for TMZ and CGT are provided for 
the ten cell lines. The expression of integrins was assessed by flow cytometry and is given as % expressing cells 
and as MFI [= (fluorescence intensity of sample – fluorescence intensity of control) / fluorescence intensity of 
control]. 
 
Combination treatment 
Next, we studied potential additive or synergistic effects of combined CGT and TMZ 
treatment. A functional in vitro test regimen was performed by combining three CGT 
concentrations with three TMZ concentrations. We decided on the following three 
TMZ doses for subsequent analysis: a low concentration (5µM), comparable to that 
used in metronomic treatment148, an intermediate concentration (50µM) consistent 
with plasma levels in patients receiving standard treatment149; and a very high 
concentration (500µM) to study maximum effects. In case of CGT we also chose 
three doses: a low concentration (1.4µM), comparable to the IC50 value of the 
sensitive cell lines; an intermediate concentration (7µM), which is close to the IC50 
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value of the majority of tested cell lines; and a high concentration (10µM), 
representing the average IC90 value. 
In all cases CGT monotherapy was more effective than TMZ monotherapy. In cell 
lines harboring a methylated MGMT promoter addition of TMZ had a beneficial effect 
(Figures 10). The effects of the combined in vitro treatment regimen ranged from 
almost additive (HROG17 and HROG36) to synergistic (HROG02 and HROG15) 
(Figure 10). In the unmethylated promoter setting, CGT monotherapy had even 
greater effects on cell viability than in the methylated setting; but the addition of TMZ 
showed no further benefit (Figure 10). 
Figure 10: Combination treatment 
Viability of cells treated with decreasing amounts of CGT (10µM, 7µM and 1.4µM) alone and in combination with 
50µM TMZ is depicted. The fluorescence intensity is normalized (1 = untreated cells; 0 = alcohol treated/dead 
cells). On the left hand side (mMGMT) MGMT promoter hypermethylated cell lines, on the right hand side 
(uMGMT) MGMT promoter unmethylated cell lines. 
mMGMT uMGMT 
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5. Discussion 
Over a decade ago, Prof. Stefaan van Gool initiated the HGG-IMMUNO group and 
corresponding meeting with the aim of uniting forces of physicians and scientist, and 
promoting the idea and concepts of an autologous DC vaccine for patients with brain 
tumors. The ultimate goal remains providing all patients suffering from (GBM) tumors 
with access to such an immunotherapeutic intervention. Patients with relapsed GBM 
were first vaccinated in the university hospital in Leuven (UZ Leuven) in 200064. As 
source of antigens for presentation, the DC are loaded with tumor lysate and after 
repeated subcutaneous applications are capable of inducing a tumor specific immune 
reaction. The great success of this treatment strategy not only led to the extension of 
the Leuven treatment setting and research but also inspired many partners to follow 
their example. One of the limiting factors in this process is the amount of accessible 
tumor material; in fact “no tumor material” is an exclusion criterion. As part of the 
consortium, the AG Hirntumorvakzine supports the concept with basic and 
translational research. A simple yet elegant solution for the antigen source / tumor 
material may be the establishment of permanent cell lines out of a small piece of the 
resected tumor. Nearly unlimited amounts of tumor lysate could be produced in vitro. 
At the same time these cell lines would also provide an opportunity to address a 
multitude of questions concerning the biology, immunology and genetic composition 
of these tumors. Finally, individualized response prediction for other treatments in 
conjunction with DC could be ideally tested. 
 
In consequence, the aim of this work was to generate a collection of GBM models 
reflecting the entire clinical appearance of GBM grade IV cases. Successful and 
feasible protocols for model generation could be established. The clinical 
characteristics of the HROG patient cohort and thus of the analyzed cell line 
collection matched fairly well with published data of “typical” GBM patient cohorts. 
The median age at surgery in the Rostock patients was 62 years; when stratifying the 
patients by diagnosis with primary GBM tumors and secondary, 93% of the patients 
had been diagnosed with a primary and only 7% with a secondary GBM. Such a 
predominance of primary GBM (about 90%) versus secondary (about 10%) is well 
established in literature4. The median age for primary GBM was 63 years and 53 
years for secondary GBM. This correlates with data from the literature with 64 years 
in median for primary GBM and 45 years for secondary6,7. Since there were only 
 58 Discussion 
three secondary GBM tumors represented (age 44, 71 and 45 years) one outliner 
largely raised the median age. The overall male to female ratio was 1.3 to 1 and 1.1 
to 1 for the grade IV tumors. In literature preponderance for the male sex is described 
with male to female ratios ranging from 1.3 – 1.5 to 11,8. Survival of patients 
correlated with the WHO grading of the tumors (worst for patients with WHO grade IV 
tumors) and patients with newly diagnosed GBM survived significantly longer than 
those suffering of a relapse (p=0.029) as is described in literature150,151. Patients with 
a methylated MGMT promoter tended to survive longer than patients showing no 
such methylation, the correlation of MGMT promoter methylation and prolonged 
survival is common knowledge15. However, in the Rostock cohort, no significance 
was reached. This may be due to the still low number but should be followed in future 
clinical data analysis in order to exclude any therapeutic bias. 
The analyzed patients from Rostock reflected age and gender distribution fairly well 
and the cohort size seemed to be representative. 
The distribution of all patients between newly diagnosed and relapsed GBM were 
28/42 (67%) newly diagnosed tumors and 14/42 (33%) relapses. Of note, the 
distribution in the “cell line patients” was 8/12 (67%) newly diagnosed GBM and 4/12 
(33%) relapses, too. 
 
In vitro attachment rates to the culture dishes were above 85% when cells were 
prepared freshly directly after surgery. No differences were observed between 
attachment of newly diagnosed and relapsed GBM (p=1.000). These attached cells 
would already recommend themselves as a starting point for decision making in an 
individualized therapy manner (response prediction for single agent treatment or 
combinations) or at least for predicting development of resistance in a first simple 
screen. 
In vitro outgrowth of cells was successful in 60% (61% for newly diagnosed and 57% 
for relapsed GBM). Again no differences between newly diagnosed and relapsed 
GBM were observed (p=1.000). The HROG cell line establishment rates are for the 
most part superior to what is described in literature. Take rates range from 3% for 
pediatric brain tumors152 over 10%153 to 21%154 for adult GBM tumors. However, most 
authors do not comment on any statistics at all. The most stable outgrowing and 
subsequently characterized twelve cell lines included eight newly diagnosed and four 
relapsed tumors, meaning successful stable outgrowth in 29% of cases for both 
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newly diagnosed and relapsed tumors. Obviously, there was no difference between 
the two types (p=1.000). 
In contrast, in vivo engraftment of tumor pieces into immunodeficient mice led to 
outgrowth in 22% of tumors. Separating newly diagnosed tumors from relapses, the 
success was 16% and 36%, respectively. Take rates from the literature vary largely 
depend on sample size and mouse strains used as hosts for engraftment: for 
subcutaneous engraftment into the flanks of mice, about one third successful 
engraftment into Nude-Foxn1 nu mice136 is comparable to the observed rates for the 
HROG tumors. However, successful engraftment in half of cases into NMRI nu/nu 
mice154 and nearly 60% (but mouse strain not mentioned)119 are also described in the 
literature. Orthotopic implantation into the brain of NSG mice was successful in three 
quarters of cases137. 
Although differences observed between newly diagnosed and relapsed tumors were 
apparent, no level of significance was reached – most likely due to the limited sample 
size. The question whether vital cryo-storage of tumor pieces has an influence on 
outgrowth in immunodeficient mice or not is currently being addressed in a direct 
comparative study. Here, pieces of a tumor are engrafted immediately after surgery 
and after vital storage in nitrogen. This has not been performed so far and thus 
represents a valuable twist to xenografting, since it allows engraftment of many 
tumors at the same time and pre-selection according to pathological diagnosis and 
grading. 
 
Establishment of cell lines was more successful than in vivo engraftment. This is in 
sharp contrast to success rates for colorectal carcinomas in our group135 but very 
much in line with data from the literature on GBM114. Thus, any handling artifacts are 
very unlikely but it rather underlines differences between entities and modeling 
systems. However, success rates both in vitro and in vivo may be improved. 
Although the rate of in vitro attachment is satisfyingly high this may even be 
augmented further by applying different coating substances beside collagen, e.g. 
fibronectin or laminin125,155 and supplementing the media with further additives such as 
EGF, VEGF and bFGF125,156. Different cell culture options such as spheroid culture, 
stem cell conditions or different additives are possible and might have positive impact 
on success. In this manner success rates of nearly 100% are described125. Growth 
factor supplementation such as EGF and bFGF is thought to enhance stemness and 
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promote expansion of BTSC (-like) cell populations24,125,126. However, this is ongoing 
work and shall be analyzed in detail in the near future. 
For the in vivo system, different immunodeficient mouse strains are available as 
touched on above and may be associated with differences in engraftment rates. The 
NMRI nu/nu mice used in the HROG study have deficient T cells but fully functional 
B and NK cells. NOD SCID or SCID Beige mice may be more suitable, since these 
mouse strains have deficient T and B cells as well as impaired NK cells. NSG mice 
additionally lack functional NK cells and are considered best for achieving high 
engraftment rates (Dr. I. Fichtner, EPO GmbH, Berlin, personal communication). 
Implanting the tumor (pieces) in an orthotopic manner may further augment the 
success rate since GBM tumors are strongly dependent on the microenvironment157. 
Further means may include co-implanting matrigel (provides a matrix for cell 
attachment and contains growth factors) as well as tumor-supporting fibroblasts or 
even glia cells157. On the pro side of in vitro models are the fast and easily feasible 
method and high success rates114 thus cell cultures provide a good model for a first 
drug screen on response and resistance development. Subsequent testing and 
verification may then more selectively be performed using in vivo model(s) – 
preferably established in parallel to the cell lines. 
 
The morphology of the established HROG cell lines was a fibroblast-like appearance 
of the cells with some polygonal variations. The most common GBM cell morphology 
is a fibroblast-like or epithelial-like one [ATCC and DSMZ]. Cells rarely changed their 
morphology during the culturing process. 
The doubling times ranged from 35 to 89 hours, which is in accordance with what 
was described by others for GBM cell lines158,159. Of note, the doubling times for all 
cell lines were assessed for passage 20 and lower; the doubling time tends to 
increase with culturing time160,161. 
 
One major drawback of tumor models in general is a trend towards genetic drift (in 
comparison to the original tumor material)162. Thus, the GBM models generated in 
this work were compared to the primary GBM tumor tissue presented to the 
department of pathology for routine diagnosis. 
High preservation of the GBM tumor´s molecular features was achieved in the cell 
cultures. Particularly the methylation status of the MGMT promoter and mutations in 
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the genes TP53, K-Ras and B-Raf were maintained in the cell lines. There was one 
exception from this rule concerning the mutation status of the IDH 1 gene, which was 
not maintained in the in vitro model (HROG41). Another exception is the gradual loss 
of EGFR genomic amplification under standard in vitro culture conditions. However, 
this is no drawback of the present work since both phenomena are well described in 
literature118-121. 
More and more extensive molecular pathological analyses are being performed on 
GBM tumors. This is no longer restricted to immunohistochemistry (hematoxylin and 
eosin staining, Ki67, GFAP, Nestin) and methylation analyses (of the MGMT 
promoter) but meanwhile includes a broad spectrum of mutation and gene 
amplification analyses. An antibody directed against the most common mutation 
(R132H) of the IDH 1 gene is used to distinguish between primary and secondary 
GBM163 and has simplified the pathologist’s decision making in this regard 
substantially (personal information of Prof. Prall, Institute for Pathology, University 
Medicine Rostock). In rare cases, fluorescent in situ hybridization analyses may also 
be part of the repertoire, e.g. for EGFR amplification detection164.  
The extensive molecular pathological analyses are not only required for detailed 
diagnosis but also have clinical relevance. In breast carcinoma patients the human 
epidermal growth factor receptor 2 (HER2)/neu is relevant for therapy with the 
monoclonal antibody Trastuzumab; only patients with an amplification of the 
HER2/neu receptor profit of this therapy165. For GBM patients not responding to the 
first line therapy (radio-chemotherapy with TMZ) a variety of alternatives including 
targeted therapeutics are available. Patients with amplification of the EGFR may 
receive Cetuximab, a monoclonal antibody directed against this. Alternatively, 
Panitumumab, a further monoclonal antibody directed against EGFR might be 
used166. However, effectiveness of both antibodies seems to be restricted to the 
expression of the wild type form of the receptor167. Bevacizumab is an antibody 
directed against the growth factor VEGF and thus could inhibit tumor vascularization 
and (neo-) angiogenesis168. 
Many recent studies, i.e. clinical testing of targeted therapeutics, have not led to the 
expected results but rather fell short of the high expectations169. 
This is to a big part attributable to the fact that GBM consist of very heterogeneous 
tumors169 and thus comes as no big surprise. One line of argumentation is that given 
the great heterogeneity, and thus not adequately considering this fact when recruiting 
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for clinical studies, it may obscure beneficial effects for individual GBM sub-types. 
Taking this argumentation further one could even dare to state that this may imply 
that GBM is not one disease but rather a common heading of different glioma tumors. 
So these “individual” diseases should be treated as such and patient cohorts for 
clinical trials should be carefully defined. In line with this argumentation is the 
initiative to sub-classify GBM tumors into the categories, e.g. in proneural, neural, 
mesenchymal and classical by designating specific molecular characteristics to these 
sub-groups57. Duarte and coworkers used this approach for a correlation of GBM sub-
types and prognosis. They described a gene signature in the proneural subtype of 
GBM which may be responsible for the poor prognosis by chemotherapy and/or 
radiation resistance in those cells170. Their results might have strong implications both 
for better prediction models for survival and improved understanding of the 
underlying subtype-specific molecular mechanisms for GBM tumor progression and 
treatment response. 
 
A key feature of cancer development is the progressive accumulation of genomic 
changes resulting in the loss of tumor suppressor functions, the activation of 
oncogenes and/or the generation of fusion genes with oncogenic potential171. Such 
complex structural and numerical alterations in the genome leading to changes in the 
DNA copy number are characteristic also of GBM tumors172. 
In essence, amplifications recommend themselves as (proto-) oncogenes and 
deleted sequences as tumor suppressor candidates. An in-depth analysis of a large 
number of GBM samples and cell lines will provide the most accurate information on 
the amplifications and deletions most frequent in GBM. This might further advance 
sub-classification and shed light into this heterogeneous disease. 
In this regard, a genomic analysis with very high resolution taking advantage of the 
SNP Array 6.0 was performed. This technique allows comparative genomic analyses 
at a very high resolution173,174. The most frequent alteration was a complete or at least 
partial loss (minimum one allele) of chromosome 10. It was observed in 10/11 cell 
lines (91%) and this loss has been associated with a poor prognosis53. However, 
numerous more unique amplifications and deletions were present in all GBM cell 
lines. Some of these alternations serve as markers for a GBM sub-classification. 
Amplification of chromosome 7 and loss of chromosome 10 are common in the 
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classical, deletion of 17q11.2 in the mesenchymal and amplification of 4q12 in the 
proneural sub-type57. 
In the context of the present work, these data were not further analyzed concerning 
candidate tumor suppressor or oncogenes. A provisional analysis performed together 
with Dr. B. Schneider from the Institute of Pathology revealed a number of promising 
candidate genes which shall be validated in the near future. 
I would like to hint towards another point that can be brought forward in favor of cell 
lines: any contamination with normal cells can be excluded here and thus the data 
obtained from array CGH analyses are less likely to contain misleading results. 
However, even then, one cannot guarantee to see all differences which may be 
present in sub-clonal populations of these cell lines. 
 
The neuronal origin of the cell lines was proven by staining the cells with different 
neuronal and GBM (specific) markers and detection was performed by flow 
cytometry. As expected, all cell lines were of neuronal origin (highly positive for 
CD90). CD90 plays a primal role in BTSC formation and CD90+ cells localize around 
vascular structures175. The expression of CD90 is significantly higher in WHO grade 
III and IV tumors compared to grade I and II; thus CD90 is a marker for high grade 
gliomas175. Moreover, a higher expression is associated with an undifferentiated GBM 
cell type176. 
In contrast to CD90 the other markers (CD24, GFAP, Nestin and S-100) were 
expressed to a much lower and also more varying degree in the HROG cell lines. 
The two major intermediate filament proteins of astrocytes are Vimentin and GFAP. 
Early in development, radial glia and immature astrocytes express mainly Vimentin177. 
Expression of Vimentin in GBM cells is dependent on the density; in low density cell 
cultures the expression is highest178. The expression is associated with a more 
aggressive tumor behavior, with a metastatic phenotype and thus a poor prognosis179. 
Finally, Vimentin is also a marker for EMT179. 
Towards the end of gestation, a switch occurs whereby Vimentin is progressively 
replaced by GFAP in differentiated astroglial cells. GFAP has been widely recognized 
as an astrocyte differentiation marker177. In the adult stage, GFAP is induced upon 
brain damage, during CNS degradation and in the aged brain in general180. 
Decreased GFAP expression has been associated with glioma growth, especially in 
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high grade gliomas (grade III and IV)181. Lastly, GFAP has proven as a valuable 
diagnostic marker for GBM182. 
CD24 enhances metastatic potential of malignant cells by functioning as a ligand for 
P-selectin183. CD24 is overexpressed in GBM tumors; however a clear association 
with clinicopathological parameters has only recently been established by Deng and 
colleagues who could correlate CD24 overexpression with a poor prognosis in 
GBM184. 
The S-100 protein is specific for the nervous system and is expressed at high levels 
in the brain, primarily by astrocytes and astrocytic tumors185. Its expression increases 
with the level of malignancy186. Some S-100 proteins are associated with 
angiogenesis186. Thus, the S-100 protein is likely to be involved in the progression of 
GBM malignancy186. 
In contrast to CD90, the other markers (CD24, GFAP, Nestin and S-100) were 
expressed to a much lower and also more varying degree in the HROG cell lines.  
 
The CSC hypothesis was initiated in the 1990s by Dick and colleagues187. Their 
report on Leukemia initiating cells became the paradigm for later studies proposing 
CSC to be at the top of a hierarchical pyramid188. Since then a broad spectrum of 
tumor entities encompassing CSC populations have been described23,24,26-29. These 
CSC maintain hallmarks of normal stem cells such as the ability to self-renewal and 
to differentiate into all cell types of the tissue they originate from189. However, CSC 
are not only responsible for tumor maintenance but are also thought to be the key 
players in recurrence and therapy resistance3,20,22,30. 
The lack of robust markers allowing the identification of BTSC is an obstacle in the 
development of specific treatments. Nevertheless, frequently proposed cell surface 
markers (alone or in combination) are CD133, CD15, Nestin, CD34 and CD4422,30-32. 
Since BTSC seem to be a part of GBM development, maintenance and therapy 
resistance, the presence of BTSC-like populations was assessed in the HROG cell 
lines. The markers CD15, CD34, CD133 and Nestin were expressed in a percentage 
of cells in the range of what might be expected for CSC. However, CD44 was present 
on about 90% of cells in the cultures and thus highly improbable of representing only 
CSC. In fact, CD44 is a marker for EMT and thus also of the mesenchymal sub-type 
of GBM tumors190. Of note the mesenchymal sub-type is the most commonly 
represented in cell lines57. 
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A number of strategies have been developed and tested to treat GBM tumors by 
specifically targeting the BTSC or BTSC-like cells. Yang and coworkers used a CSC 
specific miRNA (miR145) to target CD133+ cells and showed that this approach 
significantly inhibited their tumorigenic and BTSC-like abilities and facilitated their 
differentiation into non-BTSC. Furthermore, the expression of drug-resistance and 
anti-apoptotic genes was suppressed and cells were rendered sensitive to radiation 
and TMZ treatment191. Wang et al. studied the efficacy of photothermolysis 
challenging cells with single-walled carbon nanotubes conjugated with an anti-CD133 
monoclonal antibody and then irradiated with near-infrared laser light. This resulted in 
an eradication of BTSC-like cells and blocked the tumorigenic and self-renewal 
capability192. Also immunological targeting of BTSC was tested. The group around Xu 
isolated BTSC from tumor specimen of GBM patients and lethally irradiated the cells 
to load autologous monocyte derived DC with the apoptotic BTSC. These loaded DC 
were capable of eliciting a “BTSC-specific” Th1 immune response. Finally, this DC 
vaccination achieved a robust antitumor T cell immunity and led to a significant 
survival benefit for rats challenged with BTSC neurospheres193. As a possible 
exploitation of the HROG cell line collection, it would be promising to validate this 
principle approach by isolating BTSC from HROG lines and testing their 
immunological potential in comparison to non-BTSC and untouched HROG cells. 
 
The brain is an immunologically privileged organ and under normal physiological 
conditions only minimal entry of immune cells takes place for purpose of immune 
surveillance194. The normal brain does not possess a lymphatic system and 
furthermore brain cells do not express HLA molecules which are necessary for the 
initiation of an immune response195. However, there is increased awareness of and 
appreciation for the complex interplay between the nervous system and the immune 
system in the setting of many disease states, including neoplasms196. 
Maintaining a healthy steady state is the role of the immune system. Tumor cell 
recognition and elimination by the immune system does not simply rely on the ability 
to differentiate between “host” and “non-host” cells but on a more subtle 
differentiation between “host” and “transformed”197. To fulfill this function the immune 
system must be in constant interaction with the cells in an immunosurveillance and 
immunoediting manner197. The immune system not only controls tumor quantity 
(tumor size) but also tumor quality (immunogenicity). In this regard three distinct 
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phases are important, which have magnificently been described by Schreiber and 
coworkers. (I) In the elimination phase the innate and adaptive immune system work 
together to detect and destroy transformed cells before a cancer becomes clinically 
apparent. (II) In the equilibrium phase transformed cells that survived elimination 
persist. The adoptive immune system however prevents tumor cell growth and thus 
sculpts the immunogenicity of these cells and residual tumor cells are maintained in a 
state of dormancy. (III) In the final escape phase tumor cells have acquired the ability 
to circumvent immune recognition and destruction and thus tumor progression and 
visible growth proceed198. 
So, differentiation between tumor cells and non-transformed counter parts is 
achieved by antigens expressed specifically by the tumor cells. These antigens 
include: (I) differentiation antigens (e.g. melanocyte differentiation antigens), (II) 
mutational antigens (e.g. mutated p53), (III) overexpressed cellular antigens (e.g. 
EGFR, HER2/neu), (IV) viral antigens (e.g. CMV) and (V) cancer/testis antigens, 
which are normally only expressed in germ cells of testis and ovary (e.g. 
NY-ESO-1)198. Based on these hypotheses different immunotherapeutic strategies 
have been developed and these are roughly divided into active (induction of host 
immune response) and passive (supporting the host immune response) as well as 
specific (tumor/antigen specific interventions) and unspecific (induction of a general 
immune response e.g. by microbes)197. 
In the process of malignant transformation, astrocytoma cells display a number of 
surface proteins not expressed by their normal adult counterparts. These include 
TAA as well as HLA class I and II. The concomitant expression of TAA and HLA 
molecules together with the disruption of the blood brain barrier often occurring in 
tumor patients may elicit an acquired (humoral or cell mediated) immune response195. 
TSA or TAA qualify as prime target structures for therapeutic interventions, since 
they are highly (and rather exquisitely) expressed on the tumor cells. The expression 
(level) of TAA and HLA molecules on GBM cells is thus of particular interest for 
immunotherapeutic interventions.  
The most frequent HLA-A allele is the *A2; 50% of people of the Caucasian race 
harbor this allele147. Most of the initial studies aiming at the identification or validation 
of novel T cell epitopes of TAA are thus designed in an HLA-A2 restricted manner. In 
this regard it is of special interest that ten out of the twelve HROG cell lines carry this 
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allele; they recommend themselves as tools for studying the immunogenicity of 
candidate TAA. 
HIP 1 is predominantly expressed in neuronal cells of the CNS199. In yeast the protein 
is involved in organization and polarization of the cytoskeleton199. Its oncogenic 
potential is ascribed to the fact that it is part of the oncogenic HIP 1/platelet-derived 
growth factor beta receptor (PDGFβR) fusion protein200. HIP 1 is overexpressed in 
cancers of the prostate, colon and breast as well as in primary brain tumors200. The 
oncogenic function may arise from an altered biology of brain cells by overexpression 
of the protein and thus inducing malignant transformation200. An interesting 
observation is that the overexpression of HIP 1 correlates with the overexpression of 
EGFR and PDGFβR in GBM tumors200. However, on the HROG cell lines it is 
expressed rather marginally. Shedding some doubt on the latter finding. 
The IL-13Rα, a cancer associated receptor for IL-13201, is a promising target for 
immunotherapy since it is abundantly expressed on GBM cells but not on host CNS 
cells202,203. IL-13 is a pro-inflammatory cytokine inducing apoptosis204,205. Despite the 
presence of high levels of IL-13 in GBM tumors, often only a low level of apoptosis is 
observed206. IL-13Rα may bind IL-13 with an extremely high affinity and is internalized 
as well but the signal is not transduced205. Thus, the IL-13Rα is termed a decoy 
receptor given its inability to mediate downstream signaling207,208 and thus may protect 
GBM cells of IL-13 induced apoptosis. The receptor was expressed in all HROG cell 
lines but as HIP 1 only with a low(er) intensity. 
Okano and coworkers could show that a novel epitope of IL-13Rα stimulates CD8+ 
T cells, which secreted interferon gamma (IFNγ) and were capable of lysing IL-13Rα-
expressing GBM cells in vitro. In line with the argumentation to the relevance of HLA-
A2, they showed this for the HLA-A2+ situation209. An in vivo targeting of IL-13Rα was 
performed by tagging IL-13 with a mutated form of the pseudomonas exotoxin202,205,210. 
The fusion protein (IL-13-PE38QQR), termed Cintredekin besudotox, injected 
intracranially led to both tumor regression and prolonged survival in an animal 
model211. 
While only few cells staining positive for the more GBM-specific antigens, all the 
HROG cell lines expressed the general TAA CEA; most HROG lines even high 
levels. CEA was first described by Gold and Freedman in 1965 in human colon 
cancer tissue212. Twenty years later, immunohistochemical evidence of CEA 
expression in GBM tumors was presented213. In the late 1970s and early 1980s CEA 
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became a favored target antigen214. Since then, numerous therapeutic strategies 
targeting CEA have been developed such as vaccines, antibodies and recombinant 
retroviruses215,216. Today, CEA is not only a therapeutic target but also an important 
diagnostic marker in a variety of tumor entities217-219. Analysis of the amino acid 
sequence of CEA and of the other members of the CEA family revealed that they 
belong to the immunoglobulin superfamily214. CEA plays a role in tumor 
progression220,221 and metastasis220,222. 
 
GBM tumors are said to be exquisitely good in surrounding themselves with an 
immunosuppressive environment; they secret cytokines – mostly IL-6 and IL-8, 
attract regulatory cells and regulate HLA expression as well as antigen 
presentation223,224. Thus, by rendering a very immunosuppressive milieu, 
immunological recognition through the patients´ immune system is prevented. A 
challenge to overcome in advancing GBM therapy is the complexity of the GBM 
microenvironment225. One of the emerging strategies to counteract GBM tumors is 
activating the immune system and thus overcoming this GBM-induced 
immunotolerance. Although lymphocyte infiltration into the tumor is observed in GBM 
tissue226 this is not sufficient to induce tumor rejection. The main players hereby are 
CD4+ CD56+ T cells226. It is becoming clearer that it is not sufficient to stimulate the 
immune system in order to elicit a (cytotoxic) immune response. Overcoming GBM 
resistance to traditional therapies requires consideration not only of the tumor cells 
intrinsic properties but also to analyze how these cells interact with neural precursor 
cells, vascular endothelial cells, stromal cells, astrocytes, microglia, lymphocytes, 
extracellular matrix proteins, and cytokines; in short the tumor micromilieu227. This 
dynamic interplay of diverse cell populations, cytokines, and extracellular matrix 
proteins is what enables GBM tumorigenesis, progression, and invasion. In essence, 
effective therapies not only have to be directly cytotoxic to a molecularly diverse 
population of tumor cells, but must also overcome the pro-tumorigenic properties of 
the microenvironment227. 
It is established that this hierarchy is also maintained by the cytokine milieu228. 
Immunosuppressive cytokines such as IL-10, TGF-β and prostaglandin E2, in the 
GBM microenvironment suppress the antitumor immune response in concert with 
other factors such as indoleamine-2,3-dioxygenase (IDO) and Galectin-1229-231. The 
sources of these molecules and the details of their interactions are yet to be fully 
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unraveled. Although the expression of IDO is associated with a poor prognosis and 
tends to predominate in high grade gliomas, it is essential whether IDO is 
tumor-derived (increased regulatory T cell (T reg) recruitment and decreased 
survival) or is peripheral (non-tumor derived IDO has no effect on T cells and overall 
survival of patients)230. Galectin-1 expression correlates with a high grade of 
malignancy in astrocytomas and poor overall survival. The immunosuppressive 
functions concern both arms of the immune system; it counteracts anti-tumor immune 
response of the innate arm by inducing tolerogenic DC and macrophages and 
induces accumulation of T reg cells and impairs T cell function in the adaptive arm231. 
Since GBM cell lines have long been known to secret high levels of 
immunosuppressive cytokines232, it is necessary to fully understand the relationship 
between distinct cytokines and the variety of cell populations composing the GBM 
microenvironment. In order to fully comprehend the interaction, a detailed 
sub-classification might be necessary227. 
Cytokines are factors known to regulate cell proliferation and differentiation. They can 
be divided into several groups such as growth factors, interleukins, interferons and 
tumor necrosis factors233. 
Physiologically, IL-6 is produced by T cells, involved in B cell maturation and 
secreted in acute chronic inflammation224. However, IL-6 release is commonly 
attributed to several tumor entities and especially to GBM cells234. High levels of the 
cytokine are thought to be involved in (tumor) cell growth and angiogenesis, e.g. by 
induction of VEGF235. GBM invasion and migration is promoted by IL-6 induced 
activation of signal transducer and activator of transcription 3236. It is a key player in 
immunosuppression by inhibiting DC differentiation235. IL-6 also plays a role in 
therapy resistance and it counteracts p53 induced apoptosis235,237-239. IL-6 is more 
frequently and to higher levels expressed in the most malignant gliomas (GBM) and 
inversely correlates with patient survival235. Thus, it comes as no surprise that more 
than half of the HROG cell lines secreted (high) levels of the cytokine. 
Under normal conditions IL-8 is undetectable in the brain but aberrant expression 
leads to pathogenesis240. The cytokine is highly secreted by GBM cell lines and stem 
cells234. The pathophysiological role is mainly that of an angiogenic factor241. IL-8 
secretion also correlates with increased proliferation, invasiveness and tumor 
growth36,242. These functions are mostly mediated by the two receptors chemokine 
(C-X-C motif) receptor 1 and chemokine (C-X-C motif) receptor 2241,243,244. Lastly, the 
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level of IL-8 correlates with the histopathological grade245. All but one HROG cell line 
(HROG38) secreted substantial amounts of the cytokine into the supernatant. 
Many different immune cells secrete TNFα, primarily monocytes, macrophages, 
activated natural killer cells and T cells246. In the normal, healthy brain TNFα is 
responsible for DC maturation246. But in a tumor environment the expression 
correlates positively with the tumor grade247. As a member of the Th1 
pro-inflammatory cytokines it can elicit cell mediated immune responses and thus 
exert anti-tumoral functions246,248. However, once produced by astrocytes and 
microglial cells, TNFα can induce the transcription of IL-6, IL-1 and IL-8241,249. These 
pleiotropic effects are dependent on the dosage and range from tumor suppression 
(high dosage) to promotion of tumorigenesis (low doses)224,250. On the side of the 
pro-tumorigenic capacity is the promotion of glioma formation and progression by 
angiogenesis251. Vascularization is promoted through IL-8 and VEGF induction251. 
However, none of the analyzed HROG cell lines produced detectable amounts of 
TNFα. 
Among the multiple pathways associated with GBM, the TGF-β pathway plays a very 
crucial role in regulating the behavior of the tumor cells252. So it comes as no surprise 
that TGF-β is one of the best characterized cytokines in GBM tumors224. At the 
cellular level TGF-β affects processes such as cell growth, cell survival, 
differentiation, migration and immune cell activation in a cell type-dependent manner 
and depending on the cellular context99. In the normal brain TGF-β is not produced: 
however, in GBM tumors it is often over-expressed224. In cancer it has a dual role and 
thus can exhibit both promoting and suppressive functions253,254 which depends on 
tumor stage and entity255,256. This phenomenon has been termed TGF-β paradox257,258. 
As a tumor suppressor it is a potent inhibitor of astrocytes, epithelial and immune 
cells. Some tumors can escape the TGF-β influence by acquiring mutations in the 
pathway; other tumors including GBM selectively abolish the capacity of TGF-β to 
inhibit proliferation while maintaining beneficial aspects (to the tumors) of the 
pathway259. In such tumors, TGF-β can activate proliferation, cell survival and 
maintain stemness, induce (neo-) angiogenesis, promote invasion and migration, 
boost therapy resistance, induce EMT and help create immune suppression99,100,260. 
Inspired by the preclinical data, it is clear that TGF-β-targeted therapy may be of 
great value for the treatment of gliomas. Therefore, a variety of therapeutics targeting 
TGF-β or the pathway has been or is currently being studied in GBM patients. This 
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encompasses a TGF-β specific antisense oligo-deoxynucleotide (Trabedersen), 
neutralizing antibodies, small molecule inhibitors and specific kinase inhibitors 
(NCT00761280; NCT01472731; NCT01220271)101,261. 
By regulating gene expression via transcription factors of the SMAD family 
pro-angiogenic factors such as VEGF are induced262, or molecules associated with 
invasion and migration (such as MMP) are up-regulated in GBM263. 
TGF-β also directly influences the immune system. As part of the Th3 immune 
response it exerts an exquisitely strong immunosuppressive function on tumor 
infiltrating lymphocytes248. Especially reduction of T, B and NK cell proliferation264,265, 
inhibition of T cell activation and suppression of NK cell activity as well as promotion 
of T reg activity232,266 lead to immunosuppression. But also interference with DC 
maturation267 and down regulation of HLA class II99. 
Irradiation leads to increased levels of TGF-β268,269. And finally elevated levels of 
TGF-β correlate with tumor grade, an advanced stage and poor prognosis100,252,270,271. 
Secretion of TGF-β was only detected in one cell line, HROG04, at high levels. The 
cell line was established of a patient with a relapsed GBM tumor. However, none of 
the other cell lines established from relapsed tumors secreted detectable levels of the 
cytokine. This may be explained – in addition to the lack of CEA secretion – by 
changes in immunological phenotype and cytokine secretion of GBM cells after 
in vitro passaging272. 
 
Beside defining and uncovering tumor initiating, propagating and metastasizing 
processes, and identifying new (molecular) target structures, high throughput 
screening of drugs is the main purpose of tumor models, especially in cell lines for 
the latter. Cell cultures are broadly used since cell lines are easy to handle, and 
manageable in high quantities; they represent a relatively low-cost approach and are 
ethically preferable to other methods; i.e. experimental animals273. Thus they have 
somewhat become the pharmaceutical industries favorite “pet”. One big obstacle 
remains. Cell lines established in the 1970s and 1980s when there was a big hype 
for GBM cell lines114, have been passaged uncountable many times and certainly 
have “acquired” culturing artifacts. Many changes over long term in vitro culturing are 
well described.  
Doubling time increases over culturing periods with the number of passages160,161 and 
this may have an influence on drug sensitivity, since many chemotherapeutic agents 
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aim at rapidly proliferating cells. Extensive in vitro passaging may lead to a 
hypermethylated phenotype. In this respect, Danam and colleagues demonstrated 
that with increasing cell culture passage, methylation progressively increased and 
revealed a concomitant trend to a completely MGMT-silenced phenotype274. In 
contrast, elimination or loss of amplification of the EGFR during GBM cell culturing is 
a well-known phenomenon yet causes remain enigmatic118-120. Also IDH mutations, 
present rather frequently in GBM tumors, are an obstacle to be maintained in 
culturing of GBM cells121. Acquisition of “new” mutations and chromosomal 
aberrations are further described for highly passaged cell lines114, also the above 
mentioned changes in immunological phenotype and cytokine secretion after 
passaging in vitro are possible272. These (very) long term cultures have little in 
common with the original situation in the patients and thus only have limited model 
capability and drug testing potential. 
The gold standard chemotherapeutic agent for GBM tumors is since 2005 TMZ14. All 
novel therapeutics must measure up to it and prove significant benefit for GBM 
patients or lower toxicity towards normal tissue, i.e. have fewer side effects. 
Responsiveness of the patient-derived low passage Rostock GBM cell line collection 
was assessed for conventional chemotherapeutic agents as the alkylating agents 
(BCNU, CCNU, TMZ and Procarbazine) and other conventional therapeutics 
(Cisplatin, Cytarabine, Irinotecan, Methotrexate, Topotecan and Vincristine). The 
sensitivity to CCNU, Cisplatin, Cytarabine and Topotecan correlated with the 
methylation status of the MGMT promoter or MGMT cDNA expression and was 
significantly higher in hypermethylated (cDNA expression <0.001) cell lines (p=0.033; 
p=0.002; p=0.016 and p=0.024 respectively). In contrast, no correlation of the 
methylation status of the MGMT promoter could be detected for the agents BCNU, 
TMZ and Procarbazine. This is somewhat in contrast to the positive correlation 
described for methylated MGMT promoter and response to alkylating agents275. 
However, the presence of MGMT cDNA tended to correlate with a better response in 
methylated cell lines; a final conclusion only would be possible when directly 
correlating the protein expression to drug response. Consequently, such a staining 
protocol will be established in the near future. This emphasizes the value of these 
patient-derived low passage cell lines since detailed characterization revealed for 
example a deletion of the entire MGMT sequence in HROG36 which was scored 
unmethylated but did not even harbor the sequence. Same holds true for HROG24 
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with only one copy of the MGMT gene. Methylation scoring for such cases may have 
to be reconsidered. 
Responses to Irinotecan and Topotecan strongly tended to be strongest for cell lines 
with mutated TP53. This finding goes well with the fact that GBM cells treated with 
the DNA topoisomerase inhibitor SN-38 only underwent cell cycle arrest and even 
re-proliferated after withdrawal of the inhibitor in an wild type p53 setting, whereas in 
cells with mutations in the tumor suppressor treatment caused apoptosis276. 
A general strong response to Vincristine was observed. In contrast, Methotrexate had 
no influence on cell viability in vitro. 
Further, in vitro response to several so called targeted therapeutics (Imatinib, 
Nilotinib, Bevacizumab, Cetuximab, Rapamycin, and Celecoxib) were assessed. The 
therapeutic antibodies Bevacizumab and Cetuximab had absolutely no influence on 
GBM cell viability; although binding of the antibody to the cell lines could be 
demonstrated by flow cytometry. A general response to the tyrosin kinase inhibitors 
could be observed with a strong tendency towards a better response to Imatinib 
compared to Nilotinib. Gleevec (Imatinib) failed in large scale studies to prove 
significant benefit for GBM patients277. However, repeating the trails or re-evaluation 
might produce sub-groups which might very well profit from the drug278.  
The cell lines most sensitive to Rapamycin (HROG17 and HROG24) did not express 
MGMT cDNA. In contrast, the least sensitive cell line HROG38 expressed MGMT 
cDNA, as did the three next most sensitive cell lines (HROG06, HROG07 and 
HROG10). Such a correlation has not been described so far and this finding should 
be evaluated in vivo using the xenografts models. The mTOR inhibitor Rapamycin 
not only has direct cytotoxic effects on the tumor cells but also modulates the 
immune response279.  
Cyclooxigenase inhibition had surprisingly strong effects on cell viability and all cell 
lines tested were rather sensitive to Celecoxib with a narrow range.  
Thalidomide, initially applied as a sedative, has proven anti-cancer efficacy280,281. 
Three cell lines: HROG05, HROG17 and HROG36 were highly responsive to the 
agent. Currently Lenalidomide (derived from Thalidomide; CC-5013) is under clinical 
investigation for treatment of advanced cancers and GBM in particular. Four clinical 
trials are listed currently on clinicaltrials.gov. Two, which have been completed: (1) 
Study of Lenalidomide and radiotherapy in patients with newly diagnosed GBM 
(NCT00165447) and (2) CC-5013 in treating patients with recurrent glioma 
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(NCT00036894), one active but not recruiting: Irinotecan plus Lenalidomide in adult 
patients with recurrent GBM (NCT00671801) and one currently recruiting: 
Lenalidomide in combination with Bevacizumab, Sorafenib, Temsirolimus, or 
5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) in patients with advanced cancers 
(NCT01183663). 
 
Current efforts of improving GBM treatment include the addition of novel targeted 
agents to the standard of care regimen. Thus, analyses regarding the addition of 
CGT to the standard chemotherapeutic agent TMZ were performed. Possible 
beneficial effects as published previously85,86 were assessed in vitro. Further, defining 
responses to CGT alone or in combination with TMZ in correlation with molecular 
characteristics of the tumor cells were of particular interest. Somewhat unexpected, 
the amount of surface integrin expression, by which CGT is thought to inhibit 
angiogenesis and induce cytotoxicity, did not correlate with the response to CGT. 
The observed strong in vitro reaction to CGT monotherapy is in accordance with the 
positive in vivo response of the randomized phase II study published by Reardon and 
colleagues94. Further, a positive correlation of MGMT promoter methylation with the 
response towards TMZ was observed as described earlier282,283. Contrary to that, a 
strong trend indicating a better response to CGT (monotherapy) in non-promoter-
methylated cells was found. This finding is somehow conflicting with data of Maurer 
et al. who demonstrated complete lack of influence of MGMT expression on 
response towards CGT284. However, this shall be clarified in the near future since 
several clinical studies are currently addressing this question, i.e. the CORE study 
only recruiting GBM patients with an unmethylated MGMT promoter (NCT00813943), 
the CENTRIC study, including exclusively patients with a methylated promoter 
(NCT00689221), and the pediatric HGG-CilMetro study (NCT01517776), including 
both. Recently, two studies revealed a significant benefit of a combination therapy 
with TMZ and CGT for patients with a methylated MGMT promoter85,86. I would like to 
stress the fact that this effect was also observed with the ultra-low passage HROG 
cell line collection. The response analysis on the ultra-low passage GBM cell lines to 
treatment with TMZ and CGT allows the following conclusions: (I) There is a clear 
positive correlation between the MGMT promoter methylation status and response to 
TMZ. (II) Addition of CGT resulted in an at least additive effect, suggesting that 
patients with MGMT promoter methylated GBM will most likely benefit from the 
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addition of CGT to the standard treatment with TMZ. (III) In contrast, patients 
suffering from GBM with unmethylated MGMT promoter may benefit most from CGT 
monotherapy. 
The results on drug response further strengthen the hypothesis that patient-derived 
(ultra-) low passage cell lines represent a model system with ideal features for 
response and resistance prediction and are a good step towards individualized 
therapy and screening in drug development, particularly when molecularly and 
clinically well characterized. 
 
Since the establishment of cell lines was crowned by such high success rates, further 
focus was laid on optimizing the methodology and improving the logistics. Therefore 
practicability of cryo-preservation prior to model establishment was assessed. Tumor 
tissue from GBM surgical resection specimens could be vitally stored and successful 
in vitro culture establishment remained feasible. As a technically very simple method, 
cryo-preservation of GBM tumor tissue prior to model establishment may be quite 
appealing to both clinical and basic researchers alike for the following reasons: 
(1) The methodology is easy and as successful as for the cell cultures established 
from fresh tumor material. Even though success rates tend to be lower after vital 
freezing than with tumor tissue fresh from surgery, this difference did not reach 
statistical significance (p=1.000). This finding is in line with similar analyses of 
gastrointestinal tumors135,285 as well as for established GBM xenografts and 
cancer-initiating cells286,287. In seven cases no successful tumor outgrowth was 
possible. In four of these cases, the tissue was captured from surgery for recurrent 
glioblastoma. Besides the comparable little tumor mass in these patients, the tumors 
were heavily pretreated according to standard therapy often causing necrotic tissue 
as previously described.  
(2) There were no clear-cut differences observed neither in morphology and growth 
kinetic nor in the sensitivity towards the tested drugs. Moreover, the mutational 
patterns of the original tumors were maintained in the cell line pairs. The latter may 
quite possibly not withstand whole genome sequence analysis. It is, however, very 
likely that slight differences will also be observed when analyzing several micro 
samples originating from the same GBM case as has been shown for methylation 
patterns and the levels of receptor amplification in different sub-clones288,289.  
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(3) Finally and most important, the cryo-method will allow pre-selection of interesting 
cases before model establishment according to molecular data of the original tumor, 
clinical course, therapy response or development of resistance. 
Taken together, the simple cryo-step does not interfere with successful establishment 
of ultra-low passage GBM cell lines or primary cultures. This comparison has been 
performed under the best possible conditions imaginable including an in-depth 
molecular characterization and functional tests. Ultra-low passage primary cell 
cultures are considered superior to continuous cell lines in brain tumor research152. 
However, their availability can be limiting to scientific progress. Thus, separating the 
pure collection of clinical GBM specimens from the more complex logistics of model 
establishment will simplify the successful generation of individual GBM models.  
Not only pre-selection of interesting cases prior to laborious cell line establishing 
processes is possible, but the technique also enables repetitive establishment 
procedures and therefore allows going “back” to primary cultures. Of course, this will 
depend on the amount of GBM tissue stored immediately after operation. One simple 
problem is the cost for generating many cryo-aliquots of a tissue sample. This 
problem is obvious for academics but most likely not so in the context of clinical 
studies. Also, the procedure does not necessarily interfere with pathological analysis 
of the operated GBM, since cryopreserved tissue pieces can be substitute of fresh 
material; at least for diagnostic pathological procedures.  
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5.1 Conclusion 
Patient derived individual model establishment is feasible and could be performed 
with very acceptable success rates (in especially for the in vitro system), even from 
vitally frozen material. Noteworthy, the latter has never been performed before; 
neither for cell culturing nor for xenografting. A large collection of patient-individual 
models could be established by these means. Subsequently, these models could be 
well characterized and preserved in the established biobank in (ultra-) low passages. 
Molecular analyses revealed that the cell lines exhibit only few alterations when 
compared to the original patients’ tumors. Finally, proof-of-concept studies allow the 
conclusion that these (ultra-) low passage patient-derived models can readily be 
applied for drug sensitivity testing. Thus, these cultures may very well be suitable for 
clinical response prediction and represent a valuable step towards true individualized 
therapy.  
 
5.2 Future perspectives 
The next steps for this research work beyond the analyses described here would be 
the testing of neurosphere cultures as well as stem cell conditions for the in vitro 
systems. Concerning the in vivo setting, establishing an orthotopic xenograft model 
will be the next step. 
The extensive molecular analyses, including the CGH array, should be further 
extended and candidate tumor suppressor genes can be functionally validated with 
the – ongoing – large model collection.  
From a more clinical aspect of view, the actual clinical outcome of the therapeutic 
intervention should be compared to in vitro drug sensitivity and validated starting in a 
retrospective manner but ultimately attempting prospective predictions. 
Finally, further functional and in especially immunological analyses will be performed 
by taking advantage of the biobanked patient material (lymphocytes and sera). 
 78 Summary 
6 Summary 
6.1 English 
The aim of this thesis on glioblastomas, the most common form of brain tumor with a 
devastating prognosis, was to establish individual patient-derived tumor models both 
in vitro (cell lines) and in vivo (xenografts). Generating models was successful from 
fresh and vitally frozen GBM patient material – the latter representing a completely 
novel technique. These models were subject to subsequent detailed characterization 
in direct comparison to the patients´ tumors. Generally, molecular characteristics 
such as mutations, gene amplifications and epigenetic alterations were maintained in 
the models. Immortality, neuronal origin and stem cell characteristics of the cell lines 
could be demonstrated. Extensive drug sensitivity screens were performed. These 
well-defined patient-individual models are ideal for establishment of individualized 
therapy approaches and enable testing of immunological strategies. 
 
6.2 German 
Ziel dieser Arbeit zu Glioblastomen, der häufigsten und aggressivsten Form von 
Hirntumoren, war die Etablierung von Patienten-individuellen Tumormodellen in vitro 
(Zelllinie) und in vivo (Xenograft). Eine neue Technik zur vitalen Kryo-Asservierung 
von Patientenmaterial konnte etabliert werden. Die Modelle wurden detailliert im 
Vergleich zu den Primärtumoren charakterisiert. Grundlegende molekulare 
Eigenschaften wie Mutationen, Amplifikationen und epigenetische Veränderungen 
blieben in der Regel in den Modellen erhalten. Der neuronale und maligne Ursprung 
der Zelllinien konnte nachgewiesen werden. Das Ansprechen der Zelllinien auf ein 
umfangreiches Panel an Therapeutika wurde getestet. Diese umfassend 
charakterisierten Modelle eignen sich hervorragend als Ausgangspunkt zur 
Etablierung individualisierter Therapieansätze und zur Testung immunologischer 
Strategien. 
 
 
 
 79 References 
7. References 
1.Louis, D. N. Molecular pathology of malignant gliomas. Annual review of pathology 1, 97-
117 (2006). 
2.Louis, D. N. et al. The 2007 WHO classification of tumours of the central nervous system. 
Acta neuropathologica 114, 97-109 (2007). 
3.Alves, T. R. et al. Glioblastoma cells: a heterogeneous and fatal tumor interacting with the 
parenchyma. Life sciences 89, 532-9 (2011). 
4.Ohgaki, H. & Kleihues, P. The definition of primary and secondary glioblastoma. Clinical 
cancer research : an official journal of the American Association for Cancer Research 19, 
764-72 (2013). 
5.Preusser, M. et al. Current concepts and management of glioblastoma. Annals of 
neurology 70, 9-21 (2011). 
6.Dolecek, T. A., Propp, J. M., Stroup, N. E. & Kruchko, C. CBTRUS statistical report: 
primary brain and central nervous system tumors diagnosed in the United States in 2005-
2009. Neuro-oncology 14 Suppl 5, v1-49 (2012). 
7.Ohgaki, H. et al. Genetic pathways to glioblastoma: a population-based study. Cancer 
research 64, 6892-9 (2004). 
8.Iacob, G. & Dinca, E. B. Current data and strategy in glioblastoma multiforme. Journal of 
medicine and life 2, 386-93 (2009). 
9.Ohgaki, H. & Kleihues, P. Epidemiology and etiology of gliomas. Acta neuropathologica 
109, 93-108 (2005). 
10.Wrensch, M. et al. Variants in the CDKN2B and RTEL1 regions are associated with high-
grade glioma susceptibility. Nature genetics 41, 905-8 (2009). 
11.Shete, S. et al. Genome-wide association study identifies five susceptibility loci for glioma. 
Nature genetics 41, 899-904 (2009). 
12.Inskip, P. D. et al. Cellular-telephone use and brain tumors. The New England journal of 
medicine 344, 79-86 (2001). 
13.Henriksson, R., Asklund, T. & Poulsen, H. S. Impact of therapy on quality of life, 
neurocognitive function and their correlates in glioblastoma multiforme: a review. Journal of 
neuro-oncology 104, 639-46 (2011). 
14.Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for 
glioblastoma. The New England journal of medicine 352, 987-96 (2005). 
15.Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. 
The New England journal of medicine 352, 997-1003 (2005). 
16.Muñoz, D. M. & Guha, A. Mouse models to interrogate the implications of the 
differentiation status in the ontogeny of gliomas. Oncotarget 2, 590-8 (2011). 
 80 References 
17.Rankin, S. L., Zhu, G. & Baker, S. J. Review: insights gained from modelling high-grade 
glioma in the mouse. Neuropathology and applied neurobiology 38, 254-70 (2012). 
18.Liu, C. et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. 
Cell 146, 209-21 (2011). 
19.Al-Hajj, M., Becker, M. W., Wicha, M., Weissman, I. & Clarke, M. F. Therapeutic 
implications of cancer stem cells. Current opinion in genetics & development 14, 43-7 (2004). 
20.Lima, F. R. et al. Glioblastoma: therapeutic challenges, what lies ahead. Biochimica et 
biophysica acta 1826, 338-49 (2012). 
21.Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-
74 (2011). 
22.Denysenko, T. et al. Glioblastoma cancer stem cells: heterogeneity, microenvironment 
and related therapeutic strategies. Cell biochemistry and function 28, 343-51 (2010). 
23.Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that 
originates from a primitive hematopoietic cell. Nature medicine 3, 730-7 (1997). 
24.Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396-
401 (2004). 
25.Fang, J. et al. [Isolation and identification of brain tumor stem cells from human brain 
neuroepithelial tumors]. Zhonghua yi xue za zhi 87, 298-303 (2007). 
26.Prince, M. E. et al. Identification of a subpopulation of cells with cancer stem cell 
properties in head and neck squamous cell carcinoma. Proceedings of the National Academy 
of Sciences of the United States of America 104, 973-8 (2007). 
27.Sadri-Ardekani, H. et al. Propagation of human spermatogonial stem cells in vitro. JAMA : 
the journal of the American Medical Association 302, 2127-34 (2009). 
28.Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. 
Nature 445, 111-5 (2007). 
29.Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. 
Prospective identification of tumorigenic breast cancer cells. Proceedings of the National 
Academy of Sciences of the United States of America 100, 3983-8 (2003). 
30.Dimov, I., Tasić-Dimov, D., Conić, I. & Stefanovic, V. Glioblastoma multiforme stem cells. 
TheScientificWorldJournal 11, 930-58 (2011). 
31.Brescia, P., Richichi, C. & Pelicci, G. Current strategies for identification of glioma stem 
cells: adequate or unsatisfactory? Journal of oncology 2012, 376894 (2012). 
32.Gilbert, C. A. & Ross, A. H. Cancer stem cells: cell culture, markers, and targets for new 
therapies. Journal of cellular biochemistry 108, 1031-8 (2009). 
33.Brat, D. J. & van Meir, E. G. Vaso-occlusive and prothrombotic mechanisms associated 
with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Laboratory 
investigation; a journal of technical methods and pathology 84, 397-405 (2004). 
 81 References 
34.Furnari, F. B. et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. 
Genes & development 21, 2683-710 (2007). 
35.Jensen, R. L. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, 
pseudoprogression, and as a therapeutic target. Journal of neuro-oncology 92, 317-35 
(2009). 
36.Bonavia, R., Inda, M., Cavenee, W. K. & Furnari, F. B. Heterogeneity maintenance in 
glioblastoma: a social network. Cancer research 71, 4055-60 (2011). 
37.Armstrong, T. S. et al. A case of soft tissue metastasis from glioblastoma and review of 
the literature. Journal of neuro-oncology 103, 167-72 (2011). 
38.Kraus, J. A., Felsberg, J., Tonn, J. C., Reifenberger, G. & Pietsch, T. Molecular genetic 
analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in 
supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. 
Neuropathology and applied neurobiology 28, 325-33 (2002). 
39.Masui, K., Cloughesy, T. F. & Mischel, P. S. Review: molecular pathology in adult high-
grade gliomas: from molecular diagnostics to target therapies. Neuropathology and applied 
neurobiology 38, 271-91 (2012). 
40.Dunn, G. P. et al. Emerging insights into the molecular and cellular basis of glioblastoma. 
Genes & development 26, 756-84 (2012). 
41.Belden, C. J. et al. Genetics of glioblastoma: a window into its imaging and 
histopathologic variability. Radiographics : a review publication of the Radiological Society of 
North America, Inc 31, 1717-40 (2011). 
42.Chow, L. M. & Baker, S. J. Capturing the molecular and biological diversity of high-grade 
astrocytoma in genetically engineered mouse models. Oncotarget 3, 67-77 (2012). 
43.Bleeker, F. E., Molenaar, R. J. & Leenstra, S. Recent advances in the molecular 
understanding of glioblastoma. Journal of neuro-oncology 108, 11-27 (2012). 
44.Nagane, M., Lin, H., Cavenee, W. K. & Huang, H. J. Aberrant receptor signaling in human 
malignant gliomas: mechanisms and therapeutic implications. Cancer letters 162 Suppl, 
S17-S21 (2001). 
45.Hatanpaa, K. J., Burma, S., Zhao, D. & Habib, A. A. Epidermal growth factor receptor in 
glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia (New 
York, N.Y.) 12, 675-84 (2010). 
46.Gan, H. K., Kaye, A. H. & Luwor, R. B. The EGFRvIII variant in glioblastoma multiforme. 
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 
16, 748-54 (2009). 
47.Montano, N. et al. Expression of EGFRvIII in glioblastoma: prognostic significance 
revisited. Neoplasia (New York, N.Y.) 13, 1113-21 (2011). 
48.Bakhoum, S. F. & Compton, D. A. Chromosomal instability and cancer: a complex 
relationship with therapeutic potential. The Journal of clinical investigation 122, 1138-43 
(2012). 
 82 References 
49.Martinez, R. et al. Molecular mechanisms associated with chromosomal and microsatellite 
instability in sporadic glioblastoma multiforme. Oncology 66, 395-403 (2004). 
50.Martinez, R. et al. Low-level microsatellite instability phenotype in sporadic glioblastoma 
multiforme. Journal of cancer research and clinical oncology 131, 87-93 (2005). 
51.Vaish, M. & Mittal, B. DNA mismatch repair, microsatellite instability and cancer. Indian 
journal of experimental biology 40, 989-94 (2002). 
52.Zheng, S., Chheda, M. G. & Verhaak, R. G. Studying a complex tumor: potential and 
pitfalls. Cancer journal (Sudbury, Mass.) 18, 107-14 (2012). 
53.Hill, C., Hunter, S. B. & Brat, D. J. Genetic markers in glioblastoma: prognostic 
significance and future therapeutic implications. Advances in anatomic pathology 10, 212-7 
(2003). 
54.Martinez, R. et al. A microarray-based DNA methylation study of glioblastoma multiforme. 
Epigenetics : official journal of the DNA Methylation Society 4, 255-64 (2009). 
55.Laffaire, J. et al. Methylation profiling identifies 2 groups of gliomas according to their 
tumorigenesis. Neuro-oncology 13, 84-98 (2011). 
56.Shinawi, T. et al. DNA methylation profiles of long- and short-term glioblastoma survivors. 
Epigenetics : official journal of the DNA Methylation Society 8, (2013). 
57.Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of 
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 
17, 98-110 (2010). 
58.Paccapelo, A. et al. A retrospective pooled analysis of response patterns and risk factors 
in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy. Journal 
of translational medicine 10, 90 (2012). 
59.Scoccianti, S. et al. Second-line chemotherapy with fotemustine in temozolomide-
pretreated patients with relapsing glioblastoma: a single institution experience. Anti-cancer 
drugs 19, 613-20 (2008). 
60.Glas, M. et al. Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma. 
Oncology 76, 184-9 (2009). 
61.Schreiber, R. D. Cancer vaccines 2004 opening address: the molecular and cellular basis 
of cancer immunosurveillance and immunoediting. Cancer immunity 5 Suppl 1, 1 (2005). 
62.Gilboa, E. DC-based cancer vaccines. The Journal of clinical investigation 117, 1195-203 
(2007). 
63.Ardon, H. et al. Integration of autologous dendritic cell-based immunotherapy in the 
standard of care treatment for patients with newly diagnosed glioblastoma: results of the 
HGG-2006 phase I/II trial. Cancer immunology, immunotherapy : CII 61, 2033-44 (2012). 
64.de Vleeschouwer, S. et al. Postoperative adjuvant dendritic cell-based immunotherapy in 
patients with relapsed glioblastoma multiforme. Clinical cancer research : an official journal of 
the American Association for Cancer Research 14, 3098-104 (2008). 
 83 References 
65.Fadul, C. E. et al. Immune response in patients with newly diagnosed glioblastoma 
multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after 
radiation chemotherapy. Journal of immunotherapy (Hagerstown, Md. : 1997) 34, 382-9 
(2011). 
66.Caruso, D. A. et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells 
pulsed with tumor RNA in children and young adults with brain cancer. Neuro-oncology 6, 
236-46 (2004). 
67.Wu, A. et al. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for 
dendritic cell based immunotherapy of gliomas. Journal of neuro-oncology 76, 23-30 (2006). 
68.Phuphanich, S. et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for 
patients with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 62, 
125-35 (2013). 
69.Söderberg-Nauclér, C. & Johnsen, J. I. Cytomegalovirus infection in brain tumors: A 
potential new target for therapy? Oncoimmunology 1, 739-740 (2012). 
70.Dziurzynski, K. et al. Glioma-associated cytomegalovirus mediates subversion of the 
monocyte lineage to a tumor propagating phenotype. Clinical cancer research : an official 
journal of the American Association for Cancer Research 17, 4642-9 (2011). 
71.Ghazi, A. et al. Generation of polyclonal CMV-specific T cells for the adoptive 
immunotherapy of glioblastoma. Journal of immunotherapy (Hagerstown, Md. : 1997) 35, 
159-68 (2012). 
72.Crough, T. et al. Ex vivo functional analysis, expansion and adoptive transfer of 
cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunology and 
cell biology 90, 872-80 (2012). 
73.Harris, M. Monoclonal antibodies as therapeutic agents for cancer. The lancet oncology 5, 
292-302 (2004). 
74.Bulgaru, A. M., Mani, S., Goel, S. & Perez-Soler, R. Erlotinib (Tarceva): a promising drug 
targeting epidermal growth factor receptor tyrosine kinase. Expert review of anticancer 
therapy 3, 269-79 (2003). 
75.Culy, C. R. & Faulds, D. Gefitinib. Drugs 62, 2237-48; discussion 2249-50 (2002). 
76.Sahade, M., Caparelli, F. & Hoff, P. M. Cediranib: a VEGF receptor tyrosine kinase 
inhibitor. Future oncology (London, England) 8, 775-81 (2012). 
77.Reardon, D. A. et al. Phase I pharmacokinetic study of the vascular endothelial growth 
factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for 
malignant glioma. Cancer 115, 2188-98 (2009). 
78.Reardon, D. A. et al. Phase I study of sunitinib and irinotecan for patients with recurrent 
malignant glioma. Journal of neuro-oncology 105, 621-7 (2011). 
79.Ma, S. & Rosen, S. T. Enzastaurin. Current opinion in oncology 19, 590-5 (2007). 
 84 References 
80.van Maanen, J. M., Retèl, J., de Vries, J. & Pinedo, H. M. Mechanism of action of 
antitumor drug etoposide: a review. Journal of the National Cancer Institute 80, 1526-33 
(1988). 
81.Seeliger, H., Guba, M., Kleespies, A., Jauch, K. & Bruns, C. J. Role of mTOR in solid 
tumor systems: a therapeutical target against primary tumor growth, metastases, and 
angiogenesis. Cancer metastasis reviews 26, 611-21 (2007). 
82.Kang, K. B. et al. Enhancement of glioblastoma radioresponse by a selective COX-2 
inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. 
International journal of radiation oncology, biology, physics 67, 888-96 (2007). 
83.Mikkelsen, T. et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated 
schedule-dependency. International journal of cancer. Journal international du cancer 124, 
2719-27 (2009). 
84.Nabors, L. B. et al. Phase I and correlative biology study of cilengitide in patients with 
recurrent malignant glioma. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology 25, 1651-7 (2007). 
85.Stupp, R. et al. Phase I/IIa study of cilengitide and temozolomide with concomitant 
radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with 
newly diagnosed glioblastoma. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology 28, 2712-8 (2010). 
86.Nabors, L. B. et al. A safety run-in and randomized phase 2 study of cilengitide combined 
with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 118, 5601-7 
(2012). 
87.Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-87 
(2002). 
88.Humphries, J. D., Byron, A. & Humphries, M. J. Integrin ligands at a glance. Journal of 
cell science 119, 3901-3 (2006). 
89.Jin, H. & Varner, J. Integrins: roles in cancer development and as treatment targets. 
British journal of cancer 90, 561-5 (2004). 
90.Weis, S. M. & Cheresh, D. A. αv Integrins in Angiogenesis and Cancer. Cold Spring 
Harbor perspectives in medicine 1, a006478 (2011). 
91.Dechantsreiter, M. A. et al. N-Methylated cyclic RGD peptides as highly active and 
selective alpha(V)beta(3) integrin antagonists. Journal of medicinal chemistry 42, 3033-40 
(1999). 
92.Nisato, R. E., Tille, J., Jonczyk, A., Goodman, S. L. & Pepper, M. S. alphav beta 3 and 
alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 6, 105-19 
(2003). 
93.MacDonald, T. J. et al. Preferential susceptibility of brain tumors to the antiangiogenic 
effects of an alpha(v) integrin antagonist. Neurosurgery 48, 151-7 (2001). 
 85 References 
94.Reardon, D. A. et al. Randomized phase II study of cilengitide, an integrin-targeting 
arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology 26, 5610-7 (2008). 
95.Westphal, M. et al. A phase 3 trial of local chemotherapy with biodegradable carmustine 
(BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 5, 
79-88 (2003). 
96.Puduvalli, V. K. et al. Phase II trial of irinotecan and thalidomide in adults with recurrent 
glioblastoma multiforme. Neuro-oncology 10, 216-22 (2008). 
97.Triscott, J. et al. Disulfiram, a drug widely used to control alcoholism, suppresses the self-
renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget 3, 1112-23 
(2012). 
98.Ikushima, H. et al. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-
initiating cells through Sry-related HMG-box factors. Cell stem cell 5, 504-14 (2009). 
99.Joseph, J. V., Balasubramaniyan, V., Walenkamp, A. & Kruyt, F. A. TGF-β as a 
therapeutic target in high grade gliomas - Promises and challenges. Biochemical 
pharmacology 85, 478-85 (2013). 
100.Platten, M. et al. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits 
transforming growth factor-beta relesase and reduces migration and invasiveness of human 
malignant glioma cells. International journal of cancer. Journal international du cancer 93, 53-
61 (2001). 
101.Bogdahn, U. et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor 
trabedersen: results of a randomized and controlled phase IIb study. Neuro-oncology 13, 
132-42 (2011). 
102.Haseley, A., Alvarez-Breckenridge, C., Chaudhury, A. R. & Kaur, B. Advances in 
oncolytic virus therapy for glioma. Recent patents on CNS drug discovery 4, 1-13 (2009). 
103.Fulci, G. & Chiocca, E. A. Oncolytic viruses for the therapy of brain tumors and other 
solid malignancies: a review. Frontiers in bioscience : a journal and virtual library 8, e346-60 
(2003). 
104.Geletneky, K. et al. Phase I/IIa study of intratumoral/intracerebral or 
intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with 
progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC cancer 
12, 99 (2012). 
105.Gilbert, M. R. Recurrent glioblastoma: a fresh look at current therapies and emerging 
novel approaches. Seminars in oncology 38 Suppl 4, S21-33 (2011). 
106.Bai, R., Staedtke, V. & Riggins, G. J. Molecular targeting of glioblastoma: Drug discovery 
and therapies. Trends in molecular medicine 17, 301-12 (2011). 
107.Farias-Eisner, G. et al. Glioblastoma biomarkers from bench to bedside: advances and 
challenges. British journal of neurosurgery 26, 189-94 (2012). 
 86 References 
108.Schuster, J. M., Friedman, H. S. & Bigner, D. D. Therapeutic analysis of in vitro and in 
vivo brain tumor models. Neurologic clinics 9, 375-82 (1991). 
109.Garson, K., Shaw, T. J., Clark, K. V., Yao, D. & Vanderhyden, B. C. Models of ovarian 
cancer--are we there yet? Molecular and cellular endocrinology 239, 15-26 (2005). 
110.Reyes, G. et al. Orthotopic xenografts of human pancreatic carcinomas acquire genetic 
aberrations during dissemination in nude mice. Cancer research 56, 5713-9 (1996). 
111.Vogel, C. L., Reddy, J. C. & Reyno, L. M. Efficacy of trastuzumab. Cancer research 65, 
2044 (2005). 
112.Voskoglou-Nomikos, T., Pater, J. L. & Seymour, L. Clinical predictive value of the in vitro 
cell line, human xenograft, and mouse allograft preclinical cancer models. Clinical cancer 
research : an official journal of the American Association for Cancer Research 9, 4227-39 
(2003). 
113.Fiebig, H. H., Maier, A. & Burger, A. M. Clonogenic assay with established human 
tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug 
discovery. European journal of cancer (Oxford, England : 1990) 40, 802-20 (2004). 
114.Huszthy, P. C. et al. In vivo models of primary brain tumors: pitfalls and perspectives. 
Neuro-oncology 14, 979-93 (2012). 
115.Fischer, H., Schwechheimer, K., Heider, M., Bernhardt, S. & Zang, K. D. Establishment 
and characterization of a human glioblastoma cell line with a stable karyotype and nullisomy 
13. Cancer genetics and cytogenetics 17, 257-68 (1985). 
116.Bakir, A. et al. Establishment and characterization of a human glioblastoma multiforme 
cell line. Cancer genetics and cytogenetics 103, 46-51 (1998). 
117.Romaguera-Ros, M. et al. Cancer-initiating enriched cell lines from human glioblastoma: 
preparing for drug discovery assays. Stem cell reviews 8, 288-98 (2012). 
118.Bigner, S. H. et al. Characterization of the epidermal growth factor receptor in human 
glioma cell lines and xenografts. Cancer research 50, 8017-22 (1990). 
119.Pandita, A., Aldape, K. D., Zadeh, G., Guha, A. & James, C. D. Contrasting in vivo and 
in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes, chromosomes 
& cancer 39, 29-36 (2004). 
120.Witusik-Perkowska, M. et al. Glioblastoma-derived spheroid cultures as an experimental 
model for analysis of EGFR anomalies. Journal of neuro-oncology 102, 395-407 (2011). 
121.Piaskowski, S. et al. Glioma cells showing IDH1 mutation cannot be propagated in 
standard cell culture conditions. British journal of cancer 104, 968-70 (2011). 
122.Brewer, G. J. & Torricelli, J. R. Isolation and culture of adult neurons and neurospheres. 
Nature protocols 2, 1490-8 (2007). 
123.Janka, M. et al. Comparative amplification analysis of human glioma tissue and glioma 
derived fragment spheroids using reverse chromosome painting (RCP). Anticancer research 
16, 2601-6 (1996). 
 87 References 
124.Ignatova, T. N. et al. Human cortical glial tumors contain neural stem-like cells 
expressing astroglial and neuronal markers in vitro. Glia 39, 193-206 (2002). 
125.Pollard, S. M. et al. Glioma stem cell lines expanded in adherent culture have tumor-
specific phenotypes and are suitable for chemical and genetic screens. Cell stem cell 4, 568-
80 (2009). 
126.Galli, R. et al. Isolation and characterization of tumorigenic, stem-like neural precursors 
from human glioblastoma. Cancer research 64, 7011-21 (2004). 
127.Mohr, U. et al. Pathology of tumours in laboratory animals. Tumours of the lower 
respiratory tract and pleura in the rat. IARC scientific publications 275-99 (1990).at 
<http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=2093651&retmode
=ref&cmd=prlinks> 
128.Schmidek, H. H., Nielsen, S. L., Schiller, A. L. & Messer, J. Morphological studies of rat 
brain tumors induced by N-nitrosomethylurea. Journal of neurosurgery 34, 335-40 (1971). 
129.DRUCKREY, H., IVANKOVIC, S. & PREUSSMANN, R. [SELECTIVE INDUCTION OF 
MALIGNANT TUMORS IN THE BRAIN AND SPINAL CORD OF RATS BY N-METHYL-N-
NITROSOUREA]. Zeitschrift für Krebsforschung 66, 389-408 (1965). 
130.Macleod, K. F. & Jacks, T. Insights into cancer from transgenic mouse models. The 
Journal of pathology 187, 43-60 (1999). 
131.Talmadge, J. E., Donkor, M. & Scholar, E. Inflammatory cell infiltration of tumors: Jekyll 
or Hyde. Cancer metastasis reviews 26, 373-400 (2007). 
132.Talmadge, J. E. Pathways mediating the expansion and immunosuppressive activity of 
myeloid-derived suppressor cells and their relevance to cancer therapy. Clinical cancer 
research : an official journal of the American Association for Cancer Research 13, 5243-8 
(2007). 
133.Woolfenden, S., Zhu, H. & Charest, al A Cre/LoxP conditional luciferase reporter 
transgenic mouse for bioluminescence monitoring of tumorigenesis. Genesis (New York, 
N.Y. : 2000) 47, 659-66 (2009). 
134.Senner, V., Sturm, A., Hoess, N., Wassmann, H. & Paulus, W. In vivo glioma model 
enabling regulated gene expression. Acta neuropathologica 99, 603-8 (2000). 
135.Linnebacher, M. et al. Cryopreservation of human colorectal carcinomas prior to 
xenografting. BMC cancer 10, 362 (2010). 
136.Carlson, B. L., Pokorny, J. L., Schroeder, M. A. & Sarkaria, J. N. Establishment, 
maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme 
(GBM) xenograft models for translational biology studies and drug discovery. Current 
protocols in pharmacology / editorial board, S.J. Enna (editor-in-chief) ... [et al.] Chapter 14, 
Unit 14.16 (2011). 
137.Joo, K. M. et al. Patient-specific orthotopic glioblastoma xenograft models recapitulate 
the histopathology and biology of human glioblastomas in situ. Cell reports 3, 260-73 (2013). 
 88 References 
138.Ogino, S. et al. Epigenetic profiling of synchronous colorectal neoplasias by quantitative 
DNA methylation analysis. Modern pathology : an official journal of the United States and 
Canadian Academy of Pathology, Inc 19, 1083-90 (2006). 
139.Hayflick, L. Recent advances in the cell biology of aging. Mechanisms of ageing and 
development 14, 59-79 (1980). 
140.Chakravarti, A., Chakladar, A., Delaney, M. A., Latham, D. E. & Loeffler, J. S. The 
epidermal growth factor receptor pathway mediates resistance to sequential administration of 
radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent 
manner. Cancer research 62, 4307-15 (2002). 
141.Mazzoleni, S. et al. Epidermal growth factor receptor expression identifies functionally 
and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is 
required for gliomagenesis. Cancer research 70, 7500-13 (2010). 
142.Hobbs, J. et al. Paradoxical relationship between the degree of EGFR amplification and 
outcome in glioblastomas. The American journal of surgical pathology 36, 1186-93 (2012). 
143.Gambichler, T., Grothe, S., Rotterdam, S., Altmeyer, P. & Kreuter, A. Protein expression 
of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic 
skin lesions. American journal of clinical pathology 131, 782-7 (2009). 
144.Dango, S. et al. Elevated expression of carcinoembryonic antigen-related cell adhesion 
molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell 
lung cancer. Lung cancer (Amsterdam, Netherlands) 60, 426-33 (2008). 
145.Ieda, J. et al. Re-expression of CEACAM1 long cytoplasmic domain isoform is 
associated with invasion and migration of colorectal cancer. International journal of cancer. 
Journal international du cancer 129, 1351-61 (2011). 
146.Zhou, C. et al. The different expression of carcinoembryonic antigen-related cell 
adhesion molecule 1 (CEACAM1) and possible roles in gastric carcinomas. Pathology, 
research and practice 205, 483-9 (2009). 
147.Ellis, J. M. et al. Frequencies of HLA-A2 alleles in five U.S. population groups. 
Predominance Of A*02011 and identification of HLA-A*0231. Human immunology 61, 334-40 
(2000). 
148.Kurzen, H., Schmitt, S., Näher, H. & Möhler, T. Inhibition of angiogenesis by non-toxic 
doses of temozolomide. Anti-cancer drugs 14, 515-22 (2003). 
149.Agarwala, S. S. & Kirkwood, J. M. Temozolomide, a novel alkylating agent with activity in 
the central nervous system, may improve the treatment of advanced metastatic melanoma. 
The oncologist 5, 144-51 (2000). 
150.Nieder, C., Grosu, A. L. & Molls, M. A comparison of treatment results for recurrent 
malignant gliomas. Cancer treatment reviews 26, 397-409 (2000). 
151.Brada, M. et al. Multicenter phase II trial of temozolomide in patients with glioblastoma 
multiforme at first relapse. Annals of oncology : official journal of the European Society for 
Medical Oncology / ESMO 12, 259-66 (2001). 
 89 References 
152.Xu, J. et al. Novel cell lines established from pediatric brain tumors. Journal of neuro-
oncology 107, 269-80 (2012). 
153.Maunoury, R. Establishment and characterization of 5 human cell lines derived from a 
series of 50 primary intracranial tumors. Acta neuropathologica 39, 33-41 (1977). 
154.Stockhausen, M. et al. Maintenance of EGFR and EGFRvIII expressions in an in vivo 
and in vitro model of human glioblastoma multiforme. Experimental cell research 317, 1513-
26 (2011). 
155.Lathia, J. D. et al. Laminin alpha 2 enables glioblastoma stem cell growth. Annals of 
neurology 72, 766-78 (2012). 
156.Ferla, R., Bonomi, M., Otvos, L., Jr & Surmacz, E. Glioblastoma-derived leptin induces 
tube formation and growth of endothelial cells: comparison with VEGF effects. BMC cancer 
11, 303 (2011). 
157.Gilbertson, R. J. & Rich, J. N. Making a tumour's bed: glioblastoma stem cells and the 
vascular niche. Nature reviews. Cancer 7, 733-6 (2007). 
158.Ishiwata, I. et al. Establishment and characterization of human glioblastoma cell line 
(HUBT-n). Human cell 18, 59-65 (2005). 
159.Wang, J. et al. Establishment of a new human glioblastoma multiforme cell line (WJ1) 
and its partial characterization. Cellular and molecular neurobiology 27, 831-43 (2007). 
160.Bin Park, Y. et al. Alterations of proliferative and differentiation potentials of human 
embryonic stem cells during long-term culture. Experimental & molecular medicine 40, 98-
108 (2008). 
161.Chang-Liu, C. M. & Woloschak, G. E. Effect of passage number on cellular response to 
DNA-damaging agents: cell survival and gene expression. Cancer letters 113, 77-86 (1997). 
162.Capes-Davis, A. et al. Match criteria for human cell line authentication: Where do we 
draw the line? International journal of cancer. Journal international du cancer 
(2012).doi:10.1002/ijc.27931 
163.Joseph, N. M. et al. Diagnostic implications of IDH1-R132H and OLIG2 expression 
patterns in rare and challenging glioblastoma variants. Modern pathology : an official journal 
of the United States and Canadian Academy of Pathology, Inc 
(2012).doi:10.1038/modpathol.2012.173 
164.Kim, B. et al. The clinicopathologic values of the molecules associated with the main 
pathogenesis of the glioblastoma. Journal of the neurological sciences 294, 112-8 (2010). 
165.Montserrat, M., Leveque, D., Barthelemy, P. & Bergerat, J. P. Duration of adjuvant 
trastuzumab treatment in routine practice. Anticancer research 32, 4585-8 (2012). 
166.Berezowska, S. & Schlegel, J. Targeting ErbB receptors in high-grade glioma. Current 
pharmaceutical design 17, 2468-87 (2011). 
167.Gajadhar, A. S., Bogdanovic, E., Muñoz, D. M. & Guha, A. In situ analysis of mutant 
EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and 
 90 References 
differential response to anti-EGFR targeted therapy. Molecular cancer research : MCR 10, 
428-40 (2012). 
168.Laviolette, P. S. et al. Vascular change measured with independent component analysis 
of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. 
Neuro-oncology (2013).doi:10.1093/neuonc/nos323 
169.Wang, Y. & Jiang, T. Understanding high grade glioma: Molecular mechanism, therapy 
and comprehensive management. Cancer letters (2013).doi:10.1016/j.canlet.2012.12.024 
170.Duarte, C. W. et al. Expression signature of IFN/STAT1 signaling genes predicts poor 
survival outcome in glioblastoma multiforme in a subtype-specific manner. PloS one 7, 
e29653 (2012). 
171.Forment, J. V., Kaidi, A. & Jackson, S. P. Chromothripsis and cancer: causes and 
consequences of chromosome shattering. Nature reviews. Cancer 12, 663-70 (2012). 
172.Ruano, Y. et al. Identification of survival-related genes of the phosphatidylinositol 3'-
kinase signaling pathway in glioblastoma multiforme. Cancer 112, 1575-84 (2008). 
173.Maletzki, C. et al. Establishment, characterization and chemosensitivity of three 
mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas. PloS 
one 7, e52485 (2012). 
174.Linnebacher, M. et al. Single nucleotide polymorphism array analysis of microsatellite-
stable, diploid/near-diploid colorectal carcinomas without the CpG island methylator 
phenotype. Oncology letters 5, 173-178 (2013). 
175.He, J. et al. CD90 is identified as a candidate marker for cancer stem cells in primary 
high-grade gliomas using tissue microarrays. Molecular & cellular proteomics : MCP 11, 
M111.010744 (2012). 
176.Parry, P. V. & Engh, J. A. CD90 is identified as a marker for cancer stem cells in high-
grade gliomas using tissue microarrays. Neurosurgery 70, N23-4 (2012). 
177.Bramanti, V., Tomassoni, D., Avitabile, M., Amenta, F. & Avola, R. Biomarkers of glial 
cell proliferation and differentiation in culture. Frontiers in bioscience (Scholar edition) 2, 558-
70 (2010). 
178.Trog, D., Yeghiazaryan, K., Schild, H. H. & Golubnitschaja, O. Up-regulation of vimentin 
expression in low-density malignant glioma cells as immediate and late effects under 
irradiation and temozolomide treatment. Amino acids 34, 539-45 (2008). 
179.Satelli, A. & Li, S. Vimentin in cancer and its potential as a molecular target for cancer 
therapy. Cellular and molecular life sciences : CMLS 68, 3033-46 (2011). 
180.Middeldorp, J. & Hol, E. M. GFAP in health and disease. Progress in neurobiology 93, 
421-43 (2011). 
181.Chumbalkar, V. C. et al. Differential protein expression in human gliomas and molecular 
insights. Proteomics 5, 1167-77 (2005). 
 91 References 
182.Jung, C. S. et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 
: a journal of neurology 130, 3336-41 (2007). 
183.Taniuchi, K., Nishimori, I. & Hollingsworth, M. A. Intracellular CD24 inhibits cell invasion 
by posttranscriptional regulation of BART through interaction with G3BP. Cancer research 
71, 895-905 (2011). 
184.Deng, J. et al. CD24 expression as a marker for predicting clinical outcome in human 
gliomas. Journal of biomedicine & biotechnology 2012, 517172 (2012). 
185.Reeves, R. H. et al. Astrocytosis and axonal proliferation in the hippocampus of S100b 
transgenic mice. Proceedings of the National Academy of Sciences of the United States of 
America 91, 5359-63 (1994). 
186.Camby, I. et al. Differential expression of S100 calcium-binding proteins characterizes 
distinct clinical entities in both WHO grade II and III astrocytic tumours. Neuropathology and 
applied neurobiology 26, 76-90 (2000). 
187.Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation 
into SCID mice. Nature 367, 645-8 (1994). 
188.Rosen, J. M. & Jordan, C. T. The increasing complexity of the cancer stem cell 
paradigm. Science (New York, N.Y.) 324, 1670-3 (2009). 
189.Tan, C. & Scotting, P. J. Stem cell research points the way to the cell of origin for 
intracranial germ cell tumours. The Journal of pathology 229, 4-11 (2013). 
190.Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nature reviews. 
Cancer 2, 442-54 (2002). 
191.Yang, Y. et al. Inhibition of cancer stem cell-like properties and reduced 
chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short 
branch PEI. Biomaterials 33, 1462-76 (2012). 
192.Wang, C. et al. Photothermolysis of glioblastoma stem-like cells targeted by carbon 
nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine : nanotechnology, 
biology, and medicine 7, 69-79 (2011). 
193.Xu, Q. et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer 
stem-like cell-associated antigens. Stem cells (Dayton, Ohio) 27, 1734-40 (2009). 
194.Prendergast, C. T. & Anderton, S. M. Immune cell entry to central nervous system--
current understanding and prospective therapeutic targets. Endocrine, metabolic & immune 
disorders drug targets 9, 315-27 (2009). 
195.Sawamura, Y. & de Tribolet, N. Immunotherapy of brain tumors. Journal of neurosurgical 
sciences 34, 265-78 (1990). 
196.Sunit, das, Srikanth, M. & Kessler, J. A. Cancer stem cells and glioma. Nature clinical 
practice. Neurology 4, 427-35 (2008). 
197.Halama, N., Zoernig, I. & Jäger, D. [Immunotherapy for cancer--modern immunologic 
strategies in oncology]. Deutsche medizinische Wochenschrift (1946) 133, 2105-8 (2008). 
 92 References 
198.Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's 
roles in cancer suppression and promotion. Science (New York, N.Y.) 331, 1565-70 (2011). 
199.Hackam, A. S. et al. Huntingtin interacting protein 1 induces apoptosis via a novel 
caspase-dependent death effector domain. The Journal of biological chemistry 275, 41299-
308 (2000). 
200.Bradley, S. V. et al. Huntingtin interacting protein 1 is a novel brain tumor marker that 
associates with epidermal growth factor receptor. Cancer research 67, 3609-15 (2007). 
201.Wykosky, J., Gibo, D. M., Stanton, C. & Debinski, W. Interleukin-13 receptor alpha 2, 
EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas 
and specific targets for combinatorial therapy. Clinical cancer research : an official journal of 
the American Association for Cancer Research 14, 199-208 (2008). 
202.Debinski, W., Gibo, D. M., Slagle, B., Powers, S. K. & Gillespie, G. Y. Receptor for 
interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma 
multiforme. International journal of oncology 15, 481-6 (1999). 
203.Debinski, W., Slagle, B., Gibo, D. M., Powers, S. K. & Gillespie, G. Y. Expression of a 
restrictive receptor for interleukin 13 is associated with glial transformation. Journal of neuro-
oncology 48, 103-11 (2000). 
204.Nishimura, Y., Nitto, T., Inoue, T. & Node, K. STAT6 mediates apoptosis of human 
coronary arterial endothelial cells by interleukin-13. Hypertension research : official journal of 
the Japanese Society of Hypertension 31, 535-41 (2008). 
205.Kawakami, M., Leland, P., Kawakami, K. & Puri, R. K. Mutation and functional analysis 
of IL-13 receptors in human malignant glioma cells. Oncology research 12, 459-67 (2001). 
206.Hsi, L. C. et al. Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous 
signaling. Molecular cancer therapeutics 10, 1149-60 (2011). 
207.Rahaman, S. O. et al. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of 
IL-4-dependent signal transduction in glioblastoma cells. Cancer research 62, 1103-9 (2002). 
208.Chiaramonte, M. G. et al. Regulation and function of the interleukin 13 receptor alpha 2 
during a T helper cell type 2-dominant immune response. The Journal of experimental 
medicine 197, 687-701 (2003). 
209.Okano, F., Storkus, W. J., Chambers, W. H., Pollack, I. F. & Okada, H. Identification of a 
novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated 
antigen, interleukin 13 receptor alpha2 chain. Clinical cancer research : an official journal of 
the American Association for Cancer Research 8, 2851-5 (2002). 
210.Husain, S. R., Joshi, B. H. & Puri, R. K. Interleukin-13 receptor as a unique target for 
anti-glioblastoma therapy. International journal of cancer. Journal international du cancer 92, 
168-75 (2001). 
211.Kawakami, K., Kioi, M., Liu, Q., Kawakami, M. & Puri, R. K. Evidence that IL-13R alpha2 
chain in human glioma cells is responsible for the antitumor activity mediated by receptor-
directed cytotoxin therapy. Journal of immunotherapy (Hagerstown, Md. : 1997) 28, 193-202 
(2005). 
 93 References 
212.Gold, P. & Freedman, S. O. Specific carcinoembryonic antigens of the human digestive 
system. The Journal of experimental medicine 122, 467-81 (1965). 
213.d'Aquino, S. et al. [Immunohistochemical study on the presence of CEA in primary brain 
tumors. Preliminary note]. Minerva medica 76, 1587-91 (1985). 
214.Hammarström, S. The carcinoembryonic antigen (CEA) family: structures, suggested 
functions and expression in normal and malignant tissues. Seminars in cancer biology 9, 67-
81 (1999). 
215.Turriziani, M. et al. Carcinoembryonic antigen (CEA)-based cancer vaccines: recent 
patents and antitumor effects from experimental models to clinical trials. Recent patents on 
anti-cancer drug discovery 7, 265-96 (2012). 
216.Chester, K. A. et al. Recombinant anti-carcinoembryonic antigen antibodies for targeting 
cancer. Cancer chemotherapy and pharmacology 46 Suppl, S8-12 (2000). 
217.Bolocan, A., Ion, D., Ciocan, D. N. & Paduraru, D. N. Prognostic and predictive factors in 
colorectal cancer. Chirurgia (Bucharest, Romania : 1990) 107, 555-63 (2012). 
218.Garud, S. S. & Willingham, F. F. Molecular analysis of cyst fluid aspiration in the 
diagnosis and risk assessment of cystic lesions of the pancreas. Clinical and translational 
science 5, 102-7 (2012). 
219.Tamura, K. [Tumor markers for thyroid malignant disease]. Nihon rinsho. Japanese 
journal of clinical medicine 69 Suppl 2, 298-303 (2011). 
220.Fiori, V., Magnani, M. & Cianfriglia, M. The expression and modulation of CEACAM1 and 
tumor cell transformation. Annali dell'Istituto superiore di sanità 48, 161-71 (2012). 
221.Nouvion, A. & Beauchemin, N. [CEACAM1 as a central modulator of metabolism, tumor 
progression, angiogenesis and immunity]. Médecine sciences : M/S 25, 247-52 (2009). 
222.Thomas, P., Forse, R. A. & Bajenova, O. Carcinoembryonic antigen (CEA) and its 
receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver. 
Clinical & experimental metastasis 28, 923-32 (2011). 
223.Pellegatta, S., Cuppini, L. & Finocchiaro, G. Brain cancer immunoediting: novel 
examples provided by immunotherapy of malignant gliomas. Expert review of anticancer 
therapy 11, 1759-74 (2011). 
224.Zhu, V. F., Yang, J., Lebrun, D. G. & Li, M. Understanding the role of cytokines in 
Glioblastoma Multiforme pathogenesis. Cancer letters 316, 139-50 (2012). 
225.Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R. & Kettenmann, H. The brain 
tumor microenvironment. Glia 59, 1169-80 (2011). 
226.Waziri, A. et al. Preferential in situ CD4+CD56+ T cell activation and expansion within 
human glioblastoma. Journal of immunology (Baltimore, Md. : 1950) 180, 7673-80 (2008). 
227.Jackson, A. The changing face of brain tumours. Preface. The British journal of radiology 
84 Spec No 2, S79-81 (2011). 
 94 References 
228.Harling-Berg, C. J., Park, T. J. & Knopf, P. M. Role of the cervical lymphatics in the Th2-
type hierarchy of CNS immune regulation. Journal of neuroimmunology 101, 111-27 (1999). 
229.Rodrigues, J. C. et al. Normal human monocytes exposed to glioma cells acquire 
myeloid-derived suppressor cell-like properties. Neuro-oncology 12, 351-65 (2010). 
230.Wainwright, D. A. et al. IDO expression in brain tumors increases the recruitment of 
regulatory T cells and negatively impacts survival. Clinical cancer research : an official 
journal of the American Association for Cancer Research 18, 6110-21 (2012). 
231.Verschuere, T., de Vleeschouwer, S., Lefranc, F., Kiss, R. & van Gool, S. W. Galectin-1 
and immunotherapy for brain cancer. Expert review of neurotherapeutics 11, 533-43 (2011). 
232.Wrann, M. et al. T cell suppressor factor from human glioblastoma cells is a 12.5-kd 
protein closely related to transforming growth factor-beta. The EMBO journal 6, 1633-6 
(1987). 
233.Veldhuis, G. J., Willemse, P. H., Mulder, N. H., Limburg, P. C. & de Vries, E. G. Potential 
use of recombinant human interleukin-6 in clinical oncology. Leukemia & lymphoma 20, 373-
9 (1996). 
234.Yeung, Y., McDonald, K., Grewal, T. & Munoz, L. Interleukins in glioblastoma 
pathophysiology: implications for therapy. British journal of pharmacology 168, 591-606 
(2013). 
235.Rolhion, C. et al. Interleukin-6 overexpression as a marker of malignancy in human 
gliomas. Journal of neurosurgery 94, 97-101 (2001). 
236.Liu, Q. et al. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and 
T98G cell lines. Journal of neuro-oncology 100, 165-76 (2010). 
237.Weissenberger, J. et al. IL-6 is required for glioma development in a mouse model. 
Oncogene 23, 3308-16 (2004). 
238.Saidi, A. et al. Combined targeting of interleukin-6 and vascular endothelial growth factor 
potently inhibits glioma growth and invasiveness. International journal of cancer. Journal 
international du cancer 125, 1054-64 (2009). 
239.Goswami, S., Gupta, A. & Sharma, S. K. Interleukin-6-mediated autocrine growth 
promotion in human glioblastoma multiforme cell line U87MG. Journal of neurochemistry 71, 
1837-45 (1998). 
240.Xie, K. Interleukin-8 and human cancer biology. Cytokine & growth factor reviews 12, 
375-91 (2001). 
241.Brat, D. J., Bellail, A. C. & van Meir, E. G. The role of interleukin-8 and its receptors in 
gliomagenesis and tumoral angiogenesis. Neuro-oncology 7, 122-33 (2005). 
242.La Iglesia, de, N. et al. Deregulation of a STAT3-interleukin 8 signaling pathway 
promotes human glioblastoma cell proliferation and invasiveness. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 28, 5870-8 (2008). 
 95 References 
243.Holmes, W. E., Lee, J., Kuang, W. J., Rice, G. C. & Wood, W. I. Structure and functional 
expression of a human interleukin-8 receptor. Science (New York, N.Y.) 253, 1278-80 
(1991). 
244.Murphy, P. M. & Tiffany, H. L. Cloning of complementary DNA encoding a functional 
human interleukin-8 receptor. Science (New York, N.Y.) 253, 1280-3 (1991). 
245.Carlsson, A. et al. Plasma proteome profiling reveals biomarker patterns associated with 
prognosis and therapy selection in glioblastoma multiforme patients. Proteomics. Clinical 
applications 4, 591-602 (2010). 
246.Morse, M. A. et al. Immunotherapy of surgical malignancies. Current problems in surgery 
41, 15-132 (2004). 
247.Maruno, M., Kovach, J. S., Kelly, P. J. & Yanagihara, T. Distribution of endogenous 
tumour necrosis factor alpha in gliomas. Journal of clinical pathology 50, 559-62 (1997). 
248.Hao, C. et al. Cytokine and cytokine receptor mRNA expression in human glioblastomas: 
evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta neuropathologica 103, 171-8 
(2002). 
249.Hong, J. et al. Suppressing IL-32 in monocytes impairs the induction of the 
proinflammatory cytokines TNFalpha and IL-1beta. Cytokine 49, 171-6 (2010). 
250.Fajardo, L. F., Kwan, H. H., Kowalski, J., Prionas, S. D. & Allison, A. C. Dual role of 
tumor necrosis factor-alpha in angiogenesis. The American journal of pathology 140, 539-44 
(1992). 
251.Yoshida, S. et al. Involvement of interleukin-8, vascular endothelial growth factor, and 
basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. 
Molecular and cellular biology 17, 4015-23 (1997). 
252.Rich, J. N. The role of transforming growth factor-beta in primary brain tumors. Frontiers 
in bioscience : a journal and virtual library 8, e245-60 (2003). 
253.Curtin, J. F. et al. Combining cytotoxic and immune-mediated gene therapy to treat brain 
tumors. Current topics in medicinal chemistry 5, 1151-70 (2005). 
254.Rolle, C. E., Sengupta, S. & Lesniak, M. S. Challenges in clinical design of 
immunotherapy trials for malignant glioma. Neurosurgery clinics of North America 21, 201-14 
(2010). 
255.Derynck, R., Akhurst, R. J. & Balmain, A. TGF-beta signaling in tumor suppression and 
cancer progression. Nature genetics 29, 117-29 (2001). 
256.Siegel, P. M. & Massagué, J. Cytostatic and apoptotic actions of TGF-beta in 
homeostasis and cancer. Nature reviews. Cancer 3, 807-21 (2003). 
257.Rahimi, R. A. & Leof, E. B. TGF-beta signaling: a tale of two responses. Journal of 
cellular biochemistry 102, 593-608 (2007). 
258.Massagué, J. & Gomis, R. R. The logic of TGFbeta signaling. FEBS letters 580, 2811-20 
(2006). 
 96 References 
259.Seoane, J. Escaping from the TGFbeta anti-proliferative control. Carcinogenesis 27, 
2148-56 (2006). 
260.Peñuelas, S. et al. TGF-beta increases glioma-initiating cell self-renewal through the 
induction of LIF in human glioblastoma. Cancer cell 15, 315-27 (2009). 
261.Hau, P. et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from 
preclinical to phase I/II studies. Oligonucleotides 17, 201-12 (2007). 
262.Di Chunhui, Mattox, A. K., Harward, S. & Adamson, C. Emerging therapeutic targets and 
agents for glioblastoma migrating cells. Anti-cancer agents in medicinal chemistry 10, 543-55 
(2010). 
263.Li, A., Dubey, S., Varney, M. L., Dave, B. J. & Singh, R. K. IL-8 directly enhanced 
endothelial cell survival, proliferation, and matrix metalloproteinases production and 
regulated angiogenesis. Journal of immunology (Baltimore, Md. : 1950) 170, 3369-76 (2003). 
264.Llopiz, D. et al. Peptide inhibitors of transforming growth factor-beta enhance the 
efficacy of antitumor immunotherapy. International journal of cancer. Journal international du 
cancer 125, 2614-23 (2009). 
265.Okada, H. et al. Immunotherapeutic approaches for glioma. Critical reviews in 
immunology 29, 1-42 (2009). 
266.de Martin, R. et al. Complementary DNA for human glioblastoma-derived T cell 
suppressor factor, a novel member of the transforming growth factor-beta gene family. The 
EMBO journal 6, 3673-7 (1987). 
267.Grauer, O., Pöschl, P., Lohmeier, A., Adema, G. J. & Bogdahn, U. Toll-like receptor 
triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell 
inhibition by glioma-associated TGF-beta2. Journal of neuro-oncology 82, 151-61 (2007). 
268.Tabatabai, G., Frank, B., Möhle, R., Weller, M. & Wick, W. Irradiation and hypoxia 
promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent 
HIF-1alpha-mediated induction of CXCL12. Brain : a journal of neurology 129, 2426-35 
(2006). 
269.Ehrhart, E. J., Segarini, P., Tsang, M. L., Carroll, A. G. & Barcellos-Hoff, M. H. Latent 
transforming growth factor beta1 activation in situ: quantitative and functional evidence after 
low-dose gamma-irradiation. FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology 11, 991-1002 (1997). 
270.Sasaki, A. et al. Secretion of transforming growth factor-beta 1 and -beta 2 by malignant 
glioma cells. Neurologia medico-chirurgica 35, 423-30 (1995). 
271.Gold, L. I. The role for transforming growth factor-beta (TGF-beta) in human cancer. 
Critical reviews in oncogenesis 10, 303-60 (1999). 
272.Anderson, R. C. et al. Changes in the immunologic phenotype of human malignant 
glioma cells after passaging in vitro. Clinical immunology (Orlando, Fla.) 102, 84-95 (2002). 
273.Matarese, G., Cava, A. L. & Horvath, T. L. In vivo veritas, in vitro artificia. Trends in 
molecular medicine 18, 439-42 (2012). 
 97 References 
274.Danam, R. P., Howell, S. R., Remack, J. S. & Brent, T. P. Heterogeneous methylation of 
the O(6)-methylguanine-DNA methyltransferase promoter in immortalized IMR90 cell lines. 
International journal of oncology 18, 1187-93 (2001). 
275.Zhang, K., Wang, X., Bin Zhou & Zhang, L. The prognostic value of MGMT promoter 
methylation in Glioblastoma multiforme: a meta-analysis. Familial cancer 
(2013).doi:10.1007/s10689-013-9607-1 
276.Wang, Y., Zhu, S., Cloughesy, T. F., Liau, L. M. & Mischel, P. S. p53 disruption 
profoundly alters the response of human glioblastoma cells to DNA topoisomerase I 
inhibition. Oncogene 23, 1283-90 (2004). 
277.Wen, P. Y. et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: 
North American Brain Tumor Consortium Study 99-08. Clinical cancer research : an official 
journal of the American Association for Cancer Research 12, 4899-907 (2006). 
278.Desjardins, A. et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent 
grade III malignant gliomas. Journal of neuro-oncology 83, 53-60 (2007). 
279.Li, J. et al. [Inhibitory effects of rapamycin on proliferation of chronic myelogenous 
leukemia cells and its mechanism]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 
33, 843-6 (2012). 
280.Kumar, S., Witzig, T. E. & Rajkumar, S. V. Thalidomide as an anti-cancer agent. Journal 
of cellular and molecular medicine 6, 160-74 (2002). 
281.Thomas, D. A. & Kantarjian, H. M. Current role of thalidomide in cancer treatment. 
Current opinion in oncology 12, 564-73 (2000). 
282.Martinez, R. & Esteller, M. The DNA methylome of glioblastoma multiforme. 
Neurobiology of disease 39, 40-6 (2010). 
283.Palanichamy, K., Erkkinen, M. & Chakravarti, A. Predictive and prognostic markers in 
human glioblastomas. Current treatment options in oncology 7, 490-504 (2006). 
284.Maurer, G. D. et al. Cilengitide modulates attachment and viability of human glioma 
cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro-oncology 11, 747-56 
(2009). 
285.Sorio, C. et al. Successful xenografting of cryopreserved primary pancreatic cancers. 
Virchows Archiv : an international journal of pathology 438, 154-8 (2001). 
286.Goike, H. M. et al. Cryopreservation of viable human glioblastoma xenografts. 
Neuropathology and applied neurobiology 26, 172-6 (2000). 
287.Foong, C. S. et al. Cryopreservation of cancer-initiating cells derived from glioblastoma. 
Frontiers in bioscience (Scholar edition) 3, 698-708 (2011). 
288.Szerlip, N. J. et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and 
PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor 
response. Proceedings of the National Academy of Sciences of the United States of America 
109, 3041-6 (2012). 
 98 References 
289.Hamilton, M. G. et al. Determination of the methylation status of MGMT in different 
regions within glioblastoma multiforme. Journal of neuro-oncology 102, 255-60 (2011). 
 
 99 Supplementary Material 
8. Supplementary Material 
CGH array data: Pseudo-karyograms of the HROG cell lines obtained from the 
Affymetrix Genotyping Console 4.1.2 software generated from hybridizations of 
cell lines gDNA on Affymetrix SNP 6.0 chips. Given is the cell line name followed 
by the karyogram. Blue indicates genomic gains (i.e. amplifications), whereas red 
indicates genomic losses (i.e. deletions) in comparison to a reference genome 
(human reference 103 from Axiom). Detailed information on how this technology is 
to be used is available at: www.affymetrix.com. 
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